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Abstract 
 
Streptococcus pneumoniae is a major human pathogen and causes a significant 
burden of disease in both developed and developing countries.  Currently, two 
pneumococcal vaccines are available, a polysaccharide conjugate vaccine for 
children <2 years of age and an adult polysaccharide vaccine for ‘at risk’ groups 
such as the elderly and immunocompromised.  Unfortunately, due to the vast 
variation and highly recombinant nature of the pneumococcus vaccine escape 
through serotype replacement is significantly decreasing the efficacy of 
pneumococcal vaccines globally.  New cost-effective and protective 
pneumococcal vaccines are urgently required. 
 
Pneumolysin (PLY) is a 53Kd cholesterol-dependent cytolysin that is largely 
conserved in all strains of Streptococcus pneumoniae, making it an ideal 
candidate for inclusion in a broad spectrum vaccine.  It has been shown that PLY 
is not only a protective immunogen but also has potent adjuvant properties and 
stimulates both IgG and IgA antibody responses to antigens genetically coupled 
to the toxin (Douce et al., 2010).  Both systemic and mucosal responses are 
induced when PLY is used as an adjuvant which may prevent colonization and 
therefore provide non-serotype specific herd immunity to Streptococcus 
pneumoniae.   The cytolytic activity of PLY prevents its inclusion in a human 
vaccine; a non-lytic deletion mutant @6PLY was created for this purpose which 
retains adjuvanticity, albeit slightly reduced.  These properties of PLY formed 
the basis of this PhD project; the aim of this study was to elucidate the 
mechanism(s) of PLY/Δ6PLY adjuvanticity, it will be essential to have a basic 
model of adjuvant activity before PLY-based vaccines can be advanced to human 
clinical trials.  
 
This project used a combination of high-throughput methods such as protein 
pull-downs and gene expression profiling to examine the abilities of PLY, @6PLY 
and the truncation mutants D123PLY and D4PLY to bind to and be internalized by 
host cells and to differentially regulate gene expression.  These studies 
highlighted specific and direct interactions between PLY variants and the host 
cytoskeleton that could mediate antigen/PLY uptake; they also revealed a 
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pattern of gene expression that is similar to those of other adjuvants and could 
provide the basis for a model of adjuvanticity. 
Finally, through the use of reporter cell lines and transgenic TLR4-/- BMDM, the 
relationship between PLY and TLR4 has been further defined.  A novel method 
for preparing vehicle controls provided evidence that the ligation of TLR4 in this 
system is PLY-dependent and is not an artefact caused by contaminating TLR 
ligands such as LPS.  Once this was established it was possible to further 
investigate the role of TLR4 in the adjuvant activity of PLY, in particular the 
PLY-dependent production of IL-1β.  Through these studies a surprising role for 
TLR4 in in vitro PLY-dependent cytokine production was discovered.  
Additionally, it was found that complement has an essential role in the PLY-
dependent production of IL-1β.  The role(s) of complement and IL-1β in the 
adjuvant activity were further investigated using an in vivo immunization model 
and the biological basis for the difference in adjuvant activity of PLY and @6PLY 
was defined. 
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1. Introduction 
Streptococcus pneumoniae is an important human pathogen, it causes a range of 
diseases but the most common are otitis media, pneumonia, septicaemia and 
meningitis.  Pneumococcal disease burden is a concern in both developed and 
developing countries, particularly in children under the age of 5 and adults over 
the age of 60 and as such vaccination is recommended for individuals in these 
higher risk categories.  Currently used vaccines include the single dose 23-valent 
polysaccharide vaccine which confers protection against the most prevalent of 
the 90 different serotypes.  However, this vaccine is ineffective in children 
under the age of 2 (who cannot produce strong T-cell-independent responses) 
(Pollard et al., 2009).  To combat this, a pneumococcal conjugate vaccine is 
available for all children aged 2-23 months, this vaccine is given in 4 doses and 
confers strong protection against the most invasive serotypes, however it does 
not give a broad spectrum of protection. The available pneumococcal vaccines 
have limited effectiveness, they are not effective on a global scale due to 
varying serotype prevalence and they may promote serotype replacement.   
Modern vaccine research to prevent and control S. pneumoniae infections aims 
to address the limitations of both vaccines by providing species wide protection 
through conserved pneumococcal virulence factors; ideally this vaccine would 
also prevent nasopharyngeal colonization so as to confer non-serotype specific 
herd immunity to a sufficiently immunized population.  The work presented in 
this thesis aimed to elucidate the mechanism of action of one such novel 
pneumococcal vaccine, designed and constructed within the Mitchell group.  The 
basis for this vaccine is pneumolysin (PLY), a cholesterol-dependent cytolysin 
(CDC) and highly conserved pneumococcal virulence factor.  It was found that 
PLY is both an immunogen and adjuvant in its own right and that genetic fusion 
of other conserved pneumococcal virulence factors to the toxin created an 
effective and protective pneumococcal vaccine.  This was also true where a non-
lytic deletion mutant of PLY (Δ6PLY) was used as the protein carrier and 
adjuvant.  A particular aim of this study was to discover the mechanisms of 
adjuvant activity that were dependent/independent of pore formation. 
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1.1 Streptococcus pneumoniae background 
Streptococcus pneumoniae, first discovered in 1881, is a gram positive 
facultative anaerobe; it is coccoid in shape and typically grows in pairs or chains 
resulting in its original name “the diplococcus” (Pasteur, 1881; Sternberg, 1881).   
It is both a commensal organism of the human nasopharynx (it is conservatively 
estimated that 20-40% of healthy children and 5-10% of healthy adults are 
carriers) and an opportunistic pathogen.  Armed with a number of virulence 
factors, the most widely studied and targeted for immunization is the capsule; 
there are over 90 known capsular serotypes of S. pneumoniae, the Danish 
nomenclature system which classifies serotypes according to their structural and 
antigenic characteristics is the adopted standard.  Although there are virulent 
unencapsulated variants of S. pneumoniae these are less commonly isolated and 
are associated with specialized disease e.g. conjunctivitis (Marimon et al., 
2013), encapsulated pneumococci are far more frequently identified in both 
disease and carriage and in animal models tend to be more virulent than isogenic 
unencapsulated pneumococci.  The pneumococcal capsule promotes survival of 
the bacterium in multiple ways; firstly, the capsule helps to prevent mechanical 
removal by mucus (Nelson et al., 2007), it also confers resistance to antibody 
deposition and complement mediated lysis and inhibits phagocytosis by host cells 
(Hyams et al., 2010).  There is a relationship between capsular thickness and 
survival in certain anatomical location e.g. blood.  The pneumococcus has a 
variety of other surface associated virulence factors involved in adhesion, 
complement resistance and scavenging (AlonsoDeVelasco et al., 1995;  Mitchell 
& Mitchell, 2010), the virulence factors PspA, PspC, PsaA, PhtD and PLY which 
were chosen as novel antigenic targets are described further in chapter 6 and 
sections 1.3 and 1.6. 
There is vast genetic variation within the species, in addition to the 90 known 
capsular types over 4000 multi-locus sequence types (MLST) have been identified 
(spneumoniae.mlst.net).  In addition, S. pneumoniae is naturally recombinant 
and able to acquire additional virulence factors and indeed swap capsules-types 
during mixed colonization.  This is a particularly relevant characteristic when 
constructing new pneumococcal vaccines, as antigenic targets should be highly 
conserved indicating their importance in pneumococcal survival and/or spread. 
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1.2 Pneumococcal Disease Burden: Prevention and 
Treatment 
As mentioned previously  S. pneumoniae is capable of causing otitis media, 
pneumoniae, septicaemia and meningitis, it can also cause conjunctivitis, 
empyema, endocarditis and others (though more rarely) (Carvalho et al., 2003; 
Facklam et al., 2003; Musher et al., 1992).  Pneumococcal disease is not usually 
associated with sustained carriage, it is thought to arise when the host is 
colonized by a new serotype by transmission via respiratory droplets (Gray et 
al., 1980).  Aside from the ‘at risk’ age groups previously mentioned other risk 
factors for pneumococcal disease include HIV, asplenia, complement deficiency 
and smoking (active or passive) (Ram et al., 2010).  Increased susceptibility to 
pneumococcal disease is also associated with ethnicity, among other races 
Alaskan Inuit and Australian aborigines are at risk with a specific predisposition 
to severe otitis media (Wenger et al., 2010).  Otitis media in Australian 
aboriginal children is unusual as it can often be asymptomatic and is 
subsequently not diagnosed until tympanic rupture occurs (Mackenzie et al., 
2009) 
 
1.2.1 Disease burden 
All cause pneumonia (of which the pneumococcus is the greatest contributor) 
currently kills more children under the age of 5 than measles, malaria and HIV 
combined, the World Health Organization’s latest figures state that in 2000 
there were approximately 14.5 million cases of serious pneumococcal disease, 
resulting in the deaths of approximately 826,000 children under the age of 5.  
The highest burden of disease is found in Africa and Southeast Asia, areas where 
there are not efficient or affordable vaccination programmes (O’Brien et al., 
2009; Scott, 2007). There is also the consideration of cost and mortality, for 
instance, pneumococcal meningitis is rare but has a high mortality rate (~37%) 
(Gouveia et al., 2011) whereas pneumococcal otitis media has a very low 
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mortality rate but is common in children under the age of 2 and puts 
considerable financial burden on healthcare systems. 
 
1.2.2 Treatment of pneumococcal disease and antibiotic 
resistance 
As with many other bacterial pathogens there is increasing incidence of 
antibiotic–resistant pneumococci.  Particularly, there is increasing resistance 
(and in some cases multi-resistance) to β-lactams, macrolides and 
fluoroquinolones such as penicillin, erythromycin and ciprofloxacin (Doern, 
2001).  This is a global issue and although the introduction of pneumococcal 
vaccines and regulation of antibiotic prescription have reduced the incidence of 
new resistant strains (Liñare et al., 2010) it is imperative that new 
antimicrobials are developed in conjunction with sensible prescription policies; a 
non-serotype specific vaccine that provides broad protection against all 
pneumococcal strains would also be an effective intervention.  It has been 
suggested that antibodies to pneumococcal capsular polysaccharide that are 
non-opsonic can increase genetic exchange (Yano et al., 2011), it could be 
important to consider this when designing future pneumococcal polysaccharide 
vaccines as a means of reducing capsule switching and antibiotic resistance.  
 
1.2.3 Pneumococcal vaccines: Coverage, effectiveness and 
limitations 
Currently used vaccines target pneumococcal capsular polysaccharide and 
include the single dose 23-valent polysaccharide vaccine Pneumovax 23 (PPV-23) 
which confers protection against the most prevalent of the 90 different 
serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 
19A, 20, 22F, 23F and 33F.); however this vaccine is ineffective in children under 
the age of 2 (who cannot produce strong T-cell independent responses).  To 
combat this, a pneumococcal conjugate vaccine PCV13 is available for all 
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children aged 2-23 months, this vaccine is given in 4 doses and confers strong 
protection against 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F and 23F).  Both vaccines have been shown to provide effective 
protection against invasive pneumococcal disease. 
Considering there are over 90 known serotypes of S. pneumoniae it is obvious 
that the current vaccines do not give a broad spectrum of protection.  Serotypes 
associated with disease tend to vary geographically; therefore the serotypes 
included within these vaccines may not be appropriate in some countries.  The 
phenomenon of serotype replacement describes the increasing incidence of 
disease caused by serotypes not included in either pneumococcal vaccine 
following their introduction (Weinberger et al., 2011; Hicks et al., 2007).  This 
phenomenon is now widely recognised and effects virtually all populations 
immunized against S. pneumoniae; in one case serotype replacement has made 
immunization with the current vaccines completely ineffective at controlling 
pneumococcal infections within the population (Wenger et al., 2010).  The 
available pneumococcal vaccines have limited efficacy in preventing pneumonia 
and otitis media (Huss et al., 2009), in addition, the initial reductions seen in 
incidence of pneumococcal pneumonia following introduction of either vaccine 
quickly begin to diminish; this is likely due to serotypes not included in the 
vaccines.  
Aside from serotype replacement there are conflicting reports of the efficacy of 
pneumococcal conjugate vaccines.  The majority of analyses focus on PCV-7 
since PCV-13 has not yet been introduced into all vaccine schedules and has only 
been available for 3 years. Colonization in children immunized with PCV-7 is not 
completely controlled; children immunized with PCV-7 are less likely to be 
colonized with vaccine serotypes but are more likely to be colonized by non-
vaccine serotypes (O’Brien et al., 2007).  A meta-analysis of clinical trial data 
has shown that PCV-7 has 55-57% efficacy in preventing acute otitis media and 
89% efficacy in preventing invasive disease, yet efficacy for preventing clinical 
and radiograph-confirmed pneumonia was only 5-7% and 29-32%, respectively 
(Pavia et al., 2009).   
 
Pneumovax, the 23-valent pneumococcal polysaccharide vaccine is considered 
effective in preventing IPD, however, a meta-analysis of immunized over 65 year 
olds demonstrated that Pneumovax is ineffective at preventing pneumococcal 
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pneumonia (Huss et al., 2009).  In 2011 the Joint Council on Vaccines and 
Immunization (JCVI) concluded that there was insufficient evidence to suggest 
that Pneumovax had any effect in preventing IPD in the over 65 group (in 
England) and the continuation of the immunization programme is under review 
(JCVI, 2011).  It was suggested that any perceived protection in this group is 
likely due to immunization of children with PCV-7/-13 preventing transmission.  
In addition, within this age group pneumococcal pneumonia is often secondary to 
Influenza infection, therefore high uptake and efficacy of the Influenza 
immunization programme could also protect against pneumococcal disease (Mina 
et al., 2013). 
Purification and/or conjugation of capsular polysaccharides is a lengthy and 
expensive process; a typical dose of PCV-13 costs around $5, while this may be 
cost-effective in high-income countries the cost of four doses for each child 
makes immunization difficult in lower income countries, particularly where 
there is no state help.   The GAVI alliance in combination with the Bill and 
Melinda Gates foundation are providing pneumococcal vaccines and financial aid 
in 25 eligible countries to reduce the inequality of pneumococcal disease 
prevention. 
 
1.3 Immunity to Streptococcus pneumoniae 
Novel pneumococcal vaccine research seeks to provide non-serotype specific 
immunity to avoid the increasingly recognised issue of serotype replacement.  
Additionally, a better understanding of the immune phenotype that is required 
to effectively clear pneumococcal infection allows vaccines to be chosen that 
induce this type of response.  
 
1.3.1 Innate Immunity to the pneumococcus 
Early innate immune responses to the pneumococcus involve the influx of 
inflammatory leukocytes such as neutrophils and macrophages, this is an 
essential protective response (Herbold et al., 2010; Sun et al., 2011).  In 
addition the pneumococcus is thought to interact with a number of pattern 
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recognition receptors (PRR), particularly TLR2 and the intracellular receptor 
NOD2, recognition by both of these receptors induces the production of TNFα, 
IL-6, CCL2 and IL-1β (Opitz et al., 2004; Paterson & Mitchell, 2006).  In addition 
a type-I IFN response is induced by the pneumococcus, the role of IFN in 
pneumococcal infection has not yet been fully elucidated, neither has the 
mechanism of induction of this response (Koppe et al., 2011).  Finally, TLR4 has 
been shown to be protective during pneumococcal infection, furthermore its role 
is PLY-dependent (Malley et al., 2003).  A clear binding mechanism has not yet 
been identified, neither has a role for TLR4 in the humoral or cell-mediated 
immune responses to PLY.  This role/mechanism was a particular focus of the 
work presented in this thesis. 
 
1.3.2 Humoral immunity to the pneumococcus 
Currently, the efficacy of pneumococcal vaccines is predicted and quality 
controlled by assessing the opsonic activity of antibodies generated in mouse 
models of immunization.  Typically, an opsonic titre of 1:8 is considered the 
minimum activity permitted and equates to an efficacious IgG concentration of 
0.2 to 0.35μg/ml in immunized infants.  A standard assessment of 
opsonophagocytic activity between diagnostic centres exists, the Romero-Steiner 
assay is considered the ‘Gold standard’ opsonophagocytosis assay (OPA) (Fleck & 
Nahm, 2005; Romero-Steiner et al., 1997; Romero-Steiner et al., 2006).  
Therefore, it is clear that anti-pneumococcal antibodies are considered vital for 
protection against the pneumococcus.   
S. pneumoniae is resistant to phagocytosis unless opsonised by complement, this 
can be achieved either through the alternative complement pathway, or, by 
targeted activation of the classical complement pathway by specific anti-
pneumococcal antibodies.  It is through this mechanism that anti-pneumococcal 
antibodies mediate protection, in particular IgG subsets IgG2a and IgG2b confer 
the highest phagocytic activity (Lefeber et al., 2003).  As detailed in section 
1.2.3, non-opsonising antibodies are inefficient at conferring protection against 
S. pneumoniae and can have negative effects, increasing recombination events 
(Yano et al., 2011). 
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Humoral immunity is a particularly relevant topic with respect to children; 
typically children are incapable of producing T-cell independent antibody 
responses until between 2 and 5 years of age (necessitating conjugate vaccines) 
(Lane, 1996).  Children have high rates of carriage and although infection is 
more common than in healthy adults some level of protection is afforded 
through both maternal antibodies and generation of antibodies to pneumococcal 
proteins.  Understanding the dynamics of colonization, passive immunity and 
maturation of active immune responses may help identify more suitable antigens 
for non-serotype specific vaccines.  One longitudinal study correlated levels of 
IgM, IgG and IgA against 17 pneumococcal vaccine antigen candidates 
simultaneously with nasopharyngeal colonization in infants from 1.5 to 24 
months of age (Lebon et al., 2011).  This study was performed before the 
introduction of PCV-7 and also monitored incidence of respiratory tract infection 
(RTI) in subjects, it was found that maternal antibodies did not prevent 
colonization, in fact higher maternal anti-pneumococcal antibody levels 
correlated with higher levels of colonization.  Colonization itself induced 
protective antibodies against some virulence factors, levels of IgG increased over 
time as expected but while this increase in specific antibody was associated with 
decreased RTI it did not prevent colonization.  It is well known that colonization 
of adults can stimulate production of anti-capsular antibodies (Musher et al., 
1997). In a longitudinal study of unvaccinated adults nasopharyngeal carriage 
was associated with serotype specific antibody production; however, this did not 
prevent further colonization, similarly antibodies generated toward PLY and 
PsaA were modestly increased following carriage but did not prevent future 
colonization against any serotype (Goldblatt et al., 2005).  Protection against 
disease was not measured.  These studies raise interesting questions about the 
goals of current immunization strategies where prevention of colonization is 
central to perceived efficacy; this study demonstrates that invasive disease can 
be prevented while allowing colonization, however, this would not provide herd 
immunity. A vaccine that mimics natural immunity and allows colonization while 
preventing invasive disease would also eliminate concerns about potentially 
harmful colonizers that would fill the niche left by S. pneumoniae should a non-
serotype specific vaccine that prevents colonization be introduced.   
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Natural antibodies exist in the naive host and typically have an IgM isotype 
(Baumgarth et al., 2005).  The role of natural antibodies in preventing and 
clearing pneumococcal infections is of important consideration as it may give 
insight into the most desirable antibody response following immunization.  These 
antibodies form part of the host’s innate defence and are produced by B-1 cells.  
B-1 cells are an unconventional B cell subset in that they can produce specific 
antibody in a T-cell-independent manner.  B-1 cells are further subdivided into 
B-1a and B-1b cells according to their expression of the surface marker CD5 
(positive and negative, respectively).  The role of these unusual B cells in 
immunity to the pneumococcus has been investigated in mice genetically lacking 
either subset (Haas et al., 2005); it has been shown that natural antibodies 
against pneumococcal polysaccharide (PPS) are produced by the B-1a subset, B-
1b cells produce antibodies directed against PPS following immunization.  Mice 
lacking B-1b cell but retaining B-1a cells have no increased susceptibility to 
infection but immune memory to PPS following immunization is short-lived.  In 
contrast mice lacking B-1a cells but retaining B-1b are more susceptible to 
infection but have more efficient and long-lasting humoral immunity. 
 
1.3.3 Cell mediated immunity to the pneumococcus  
Several studies have demonstrated the importance of CD4+ T cell in mediating 
protection from and clearance of the pneumococcus, specifically Th17 cells.  In 
a CD4+ T cell deficient model, mice were significantly more susceptible to 
pneumococcal pneumonia and bacteraemia than those with intact T cell 
responses (Kadioglu et al., 2004).  Furthermore, CD4+ T cells have also been 
shown to be involved in acquired immune responses to pneumococci that 
prevent colonization and can be elicited by intranasal immunization with 
pneumococcal proteins (Basset et al., 2007) or capsular polysaccharide (Malley 
et al., 2006) in immunoglobulin deficient mouse models.  The protective T-cell 
subset identified in response to pneumococcal infection or immunization is Th17, 
a phenotype recognized as protective against extracellular bacterial or fungal 
infections.  The cytokine IL-17A is signature cytokine of the Th17 T cell 
phenotype and has been shown to have an essential role in clearing 
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pneumococcal colonization ( Lu et al., 2008; Malley et al., 2006).  The 
production of IL-17A by Th17 cells is thought to enhance pneumococcal 
clearance via the recruitment of inflammatory leukocytes such as 
monocytes/macrophages and neutrophils which have roles in both early and late 
responses, respectively (Zhang et al., 2009).  Interestingly, neutrophils are also 
producers of IL-17; although there is huge early neutrophil migration into the 
pneumococcal lung this does not seem to be effective until later stages of 
infection.  It may be that infiltrating neutrophils do not act in a classical manner 
during early infection and instead the lesser recognised functions of neutrophils 
such as antigen presentation are utilized (Culshaw et al., 2008; Matthias et al., 
2013).  The production of IL-17 by recruited neutrophils may also serve to 
enhance the influx of other inflammatory leukocytes, creating a positive 
feedback-loop.  The discovery that Th17-mediated responses are essential in 
preventing pneumococcal colonization led to high-throughput identification 
studies to find Th17 inducing pneumococcal antigens for novel pneumococcal 
vaccines (Moffitt et al., 2012).   
 
1.3.4 Mucosal immunization 
Mucosal immunization has many advantages over traditional subcutaneous and 
intramuscular immunization, it requires no needles and therefore is cheaper to 
administer as well as safer (reduced risk of needle being re-used and therefore 
risk of associated infections such as HIV).  The primary aim/advantage in 
mucosal immunization is to induce protective immunity against pathogens that 
enter the body at these sites, specifically through the induction of IgA (Neutra & 
Kozlowski, 2006).  In addition, the phenomenon of ‘common mucosal immunity’ 
results in immunity at all mucosal sites following immunization at one e.g. 
intranasal immunization would also induce immunity at peripheral sites such as 
the gut and genital mucosa (McDermott & Bienenstock, 1979). However, there 
have been difficulties in perfecting this mode of immunization, mainly the 
difficulty of inducing protective immune responses and avoiding tolerance 
induction (Neutra & Kozlowski, 2006).  Interestingly this has been less of an issue 
with intranasal pneumococcal vaccines, several novel intranasal pneumococcal 
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vaccines have been developed using murine models and are well tolerated and 
induce protective immunity, some of which are discussed in section 1.3.5.  It is 
important to note the anatomical difference between humans and mice which 
may cause difficulty in translating experimental intranasal vaccines into real 
human interventions, while the nasal-associated lymphoid tissue (NALT) of mice 
is a disorganised structure on the soft palate, humans have Waldeyer’s ring -  an 
organised collection of lymphoid tissues (the palatine, lingual and 
nasopharyngeal tonsils).  
 
1.3.5 Novel pneumococcal vaccines/ PATH project 
In the quest for more effective pneumococcal vaccines a number of different 
approaches have been taken to create novel pneumococcal vaccines.  Novel 
pneumococcal vaccines can be roughly split into three categories – vaccines 
based on conserved pneumococcal surface proteins, conjugate vaccines using 
pneumococcal polysaccharide conjugated to a pneumococcal protein carrier and 
vaccines that use novel adjuvants.   In some cases all three approaches have 
been combined, a selection of these is summarized in table 1-1.  One such 
approach carried out by the Mitchell group was funded by the Programme for 
Appropriate Technology in Health (PATH), referred to as ‘the PATH project’ 
throughout this thesis. 
 
 
 
 
 
 
 30 
 
 
Table 1-1 Novel Pneumococcal Vaccines: Composition and Efficacy 
Antigenic 
composition of 
vaccine 
Adjuvant Protection? Reference 
Carriage Disease 
eGFP or PsaA 
genetically 
conjugated to 
PLY or Δ6PLY 
PLY/Δ6PLY Yes No (Douce et al., 
2010) 
PlyD1 
(toxoided 
version of PLY) 
Alhydrogel N/A N/A (Kamtchoua et 
al., 2013) 
PdB (toxoided 
version of PLY) 
Aluminium 
phosphate 
N/A Yes (Alexander et 
al., 1994) 
PspA, PspC, 
PdT (toxoided 
version of PLY) 
Cholera toxin 
(CT) 
Yes N/A (Basset et al., 
2007) 
PspA, PspC none N/A Yes (Ferreira et al., 
2009) 
PspA, PdT 
(toxoided 
version of PLY) 
Aluminium 
hydroxide 
N/A Yes (Goulart et al., 
2013) 
PsaA, PdT, 
pneumococcal 
cell wall 
polysaccharide 
Aluminium 
hydroxide 
 
No 
 
 
Yes 
 
 
(Lu et al., 
2009) 
PcsB, StkP, 
PsaA, PspA 
IC31 (novel 
adjuvant and 
TLR9 ligand) 
N/A 
 
Yes 
 
(Olafsdottir et 
al., 2012) 
PspA Flt3 ligand 
(novel 
adjuvant) 
N/A 
 
Yes 
 
(Kataoka et al., 
2011) 
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The study published by Douce et al., 2010 describes some of the initial results 
from the PATH project; although this example does not show protection against 
disease other formulations from the PATH project did show protection 
(unpublished data).  The study published by Douce et al. also demonstrated that 
PLY and the non-pore forming mutant delta 6 PLY (Δ6PLY) possess adjuvant 
activity as antibodies were raised against both PspA and the model adjuvant 
eGFP when genetically conjugated to PLY/Δ6PLY in the absence of an additional 
adjuvant.    
 The PATH vaccines are based on highly conserved pneumococcal protein 
antigens PsaA, PspA, PspC and PhtD genetically conjugated to either PLY or 
Δ6PLY and administered either intranasally or subcutaneously.  This resulted in 
10 PATH experiments, where odd numbers indicate immunization via the 
intranasal route and even numbers the subcutaneous route (figure 1-1). 
 
 Figure 1-1 Schematic of PATH experimental procedure. 
 
The PATH project consisted of the experimental adjuvant PLY/
to PsaA (PATH 1/2), PspA (PATH 3/4), PspC (PATH 5/6), PhtD (PATH 7/8) and a mix of all 4 
Δ6PLY conjugates given at a higher dose (10X) (PATH 9/10).  The vaccines were 
administered either intranasally (odd numbers) or subcutaneously (even numbers) following 
the schedule detailed in table 2
also investigated (Douce et al., 2010)
 
The pneumococcal antigens for the PATH project w
highly conserved and are important pneumococcal virulence factors. 
sub-capsular lipoprotein and forms part of a Mn
(Johnston et al., 2004)
survival and growth and is particularly important in pneumococcal resistance to 
oxidative stress (Tseng et al.
shown to confer protective immunity in a fusion vaccine consisting of PsaA, 
pneumococcal cell wall polysaccharide and a non
et al., 2009).  PspA is a protein exposed on the surface of the pneumococcus, its 
primary function is to inhibit
 
Δ6PLY genetically conjugated 
-13.  A control vaccine using the model antigen eGFP was
. 
ere chosen because they 
+ transporter of 
, it is an adhesin and has an vital role in pneumococcal 
, 2002).  PsaA is highly conserved and has been 
-toxic PLY derivative (
 the activation of host complement by binding and 
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are 
 PsaA is a 
S. pneumoniae 
PdT) (Lu 
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thereby inhibiting the action of Factor B, pneumococcal strains lacking PspA are 
rapidly cleared from blood in murine challenge experiments (Tu et al., 1999).  
Monoclonal antibodies directed against PspA are highly efficient in preventing 
fatal pneumococcal infection in mice (McDaniel et al., 1991), fusion vaccines 
based on PspA coupled to the non-toxic PLY derivatives PdT and PdB were found 
to confer similarly protective immune responses in immunized mice (Goulart et 
al., 2013).  PspC (also called choline-binding protein A, CbpA) is another 
important surface protein of S. pneumoniae.  PspC contains proline-rich and 
choline-binding domains that are identical to those of PspA and as such there is 
significant cross-reactivity in antibodies to these proteins (Brooks-Walter et al., 
1999).  Like PspA, PspC acts as a virulence factor by protecting the 
pneumococcus from the host complement system, it does so by binding 
complement Factor H conferring resistance to complement-mediated 
opsonophagocytosis (Dave et al., 2004; Kerr et al., 2006). The contribution of 
PspC to pneumococcal virulence has been shown to be strain-dependent (Kerr et 
al., 2006) and previous PspC-based vaccines have failed to protect mice against 
invasive disease (Ferreira et al., 2009).  However, PspC is highly conserved 
within the species (75%) (Dave et al., 2001) and its cross-reactivity with PspA 
makes it a useful candidate in broad spectrum vaccines that hope to limit 
vaccine escape.  PhtD is a member of the polyhistidine triad (Pht) family of 
proteins; it is associated with the surface of the pneumococcus and is an 
important virulence factor, aiding adherence to the surface of host cells and 
scavenging zinc ions (Khan & Pichichero, 2012; Plumptre et al., 2013).  Anti-PhtD 
antibodies present in healthy human serum have been shown to decrease 
pneumococcal adherence to host cells suggesting PhtD is a good vaccine 
candidate (Khan & Pichichero, 2012).   
Serum samples taken from each PATH experiment were available as research 
materials and were used by the author to determine the influence of conjugate 
antigens on the IgG subclass of raised specific antibodies, presented in chapter 
6. 
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1.3.6 The future of pneumococcal vaccination 
Pneumococcal clearance and survival has been demonstrated to require both 
antibody and cell-mediated immunity, specifically, antibody mediated 
complement opsonisation and a Th17 response.  It would seem that Th17 is 
important in preventing/clearing colonization and early lung infection whereas 
antibody mediated protection is essential in protection from invasive disease 
such as bacteraemia (Cohen et al., 2011; Mccool & Weiser, 2004).  Any effective 
future vaccine(s) should elicit both humoral and cell-mediated protection.  In 
the case of either mode of immunity, choice of antigen is critical in determining 
success. 
Modern vaccine research into S. pneumoniae aims to address the limitations of 
both vaccines by providing species wide protection through conserved 
constituents of the pneumococcal cell wall; ideally this vaccine would also 
prevent nasopharyngeal colonization so as to confer non-serotype specific herd 
immunity to a sufficiently immunized population. 
 
1.4 Pneumolysin as a Virulence Factor and Vaccine 
Antigen 
Pneumolysin is a member of the cholesterol-dependent cytolysin (CDC) family of 
virulence factors that bind to and form pores in cholesterol-containing 
membranes. This family is characterized by a conserved amino acid sequence  
(ECTGLAWEWWR) termed the undecapeptide that is located in the C-terminal 
domain 4 and is critical for the structural changes that occur during pore 
formation (Dowd & Tweten, 2012). The cholesterol recognition/binding motif 
(CRM) is located near this conserved sequence and consists of two amino acids 
(threonine and leucine) that are conserved in all CDCs (Farrand et al., 2010).  
Cholesterol-dependent cytolysins are possessed by over 20 genera of gram 
positive bacteria including Listeria, Bacillus, Clostridium and Streptococcus. 
There are 14 known PLY alleles (Jefferies et al., 2007) and PLY is unique in being 
the only CDC lacking a secretion signal sequence (all other CDC depend on type II 
secretion systems) (Price et al., 2012).  CDCs act as virulence factors by causing 
 cytolysis in host cells through
forming large oligomers and inserting into the host cell resul
of pores (Tweten, 2005a)
a series of pro-inflammatory responses by the host, these are detailed with 
reference to PLY later in this section.
In the absence of reliable crystallography data for PLY a putative structure has 
been suggested based on a best fit model using perfringolysin (PFO) as a 
template (Tilley et al.
reality PLY consists of two separable domains as the polypeptide backbone 
weaves in and out of dom
The proposed structure of PLY is shown in figure 1
 
Figure 1-2 Domain structure of pneumolysin
 This worm and tube model shows the proposed structure of pneumolysin (not solved) 
based on the crystal structure of perfringolysin O (PFO).  Structural data was retrieved from 
NCBI’s Entrez structure database.
visualisation programme for biomolecular structures; Cn3D 
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 40Å.  The collapse of the pore complex drives the β
three into the membrane, piercing it to form a strikingly large pore.  The pores 
formed can be up to 350Å in diameter with each pore containing as many as 50 
PLY monomers (Nöllmann et al.
 
Figure 1-3 Process of 
 The worm and tube model
structure of perfringolysin O (PFO).  Structural data was retrieved from NCBI’s Entrez 
structure database.  Secondary structure 
blue) using NCBI’s visualisation programme for biomolecular structures; Cn3D 
2000). The process of pore formation is descri
 
The formation of pores by pneumolysin frequently results in host cell death as 
membrane integrity is destroyed.
virulence factor are a combination of direct cytotoxicity through pore for
subsequent disruption of cell structure and function, enhancement of 
proinflammatory mediator production and recruitment of leukocytes that further 
exacerbate inflammatory conditions.  The induction of a proinflammatory 
response may seem counterint
-hairpins formed 
, 2004).  This process is summarised in figure 1
pore formation. 
s of PLY monomers, prepore and pore are 
highlighted (helix = green
bed in section 1.4. 
  The properties of PLY that allow it to act as a 
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between inducing inflammation that aids bacterial spread by subverting the 
immune response and eliciting host immunity that is detrimental to bacterial 
survival (Marriott et al. 2008); although the exact mechanism of PLY release is a 
contentious issue it is known to occur following autolysis of the pneumococcus; 
this may result in PLY release at sites where the pneumococcal population is 
contracting thereby directing immune responses away from the active infection.  
Additionally, as will be discussed in the final chapters of this thesis, the 
adjuvant activity of PLY is unusual in that it preferentially directs immune 
responses against antigens other than itself. 
 
Pneumolysin facilitates the direct extension of the pneumococcus from the 
nasopharynx to the eyes, ears and lungs and subsequent spread to the blood and 
brain.  Although inflammation caused by the proinflammatory reaction to PLY 
may cause loss of integrity and barrier function in epithelial and endothelial 
layers, PLY itself can directly disrupt barrier function by causing gross changes in 
the ultrastructure of epithelial and endothelial barriers.  Damage to endothelial 
cells in a model of pneumococcal infection has been shown to precede the 
infiltration of leukocytes in a PLY-dependent manner (Rubins et al., 1992).    In a 
model of the human respiratory mucosa, isogenic PLY positive and negative 
pneumococci rapidly adhere to mucus and both caused significant damage to the 
ultrastructure of the epithelium over 48hrs; damage includes extrusion of cells 
and cells debris.  Pneumococci did not adhere directly to ciliated cells, however, 
PLY positive pneumococci caused significant damaged to the ciliated epithelium; 
reduced ciliary beat or ciliary stasis and disorganization of cilia was observed 
(Rayner et al., 1995). These cellular changes could allow a model of bacterial 
spread where pneumococci travel from the nasopharynx into the lungs 
unimpeded by the mucocilliary elevator due to reduced function of the cilliated 
epithelium.  The damage to ciliated cells during infection not only aids the 
spread of infection but can cause permanent damage to the host; an example of 
such damage is the sensorineural hearing loss that can sometimes accompany 
pneumococcal otitis media.  PLY is responsible for loss of hearing due to damage 
caused to cochlear hair cells, the damage can be severe ranging from stereocilia 
disorganization as seen on ciliated epithelial cells, to total cell loss mediated by 
calcium influx.  In addition, PLY can induce the separation of epithelial tight 
junctions and increased pneumococcal adherence is seen on the edges of 
 38 
 
separated cells (Rayner et al., 1995).  Once in the lungs reduced membrane 
integrity could allow extravasation from the lungs into the blood and from there 
to other to other anatomical sites such as the blood brain barrier (BBB). In a 
model of the blood brain barrier using Human Brain Microvascular Endothelial 
Cells (HBMEC), rapid PLY-dependent rounding and detachment of HBMEC was 
observed (Zysk et al., 2001).  This is a similar cellular response to that seen in 
the model of respiratory endothelium and suggests pneumococci cross the 
respiratory endothelium and blood brain barrier using a similar mechanism that 
is at least partially PLY-dependent.  As seen in other ciliated cells PLY has the 
ability to slow ciliary beat in ependymal cells of the rat brain, this was shown 
with both purified PLY and penicillin-lysed pneumococci (Hirst et al., 2004).  In 
addition ciliary sloughing and cytoplasmic extrusions were noted following PLY 
treatment of ciliated ependymal cells, these effects of PLY could be blocked 
with anti-PLY antibodies (Hirst et al., 2004).  The proinflammatory responses 
induced by PLY will be further discussed in the context of PLY as an adjuvant in 
section 1.6. 
 
As discussed previously, incorporating PLY into pneumococcal vaccines has 
shown to it to be a protective antigen (table 1-1).  Anti-PLY antibodies are 
produced in response to carriage, however, their role in natural immunity is 
questionable as anti-capsular antibody is a more effective indicator of protection 
(Goldblatt et al., 2005).  Although anti-PLY responses following infection may 
not be strong or protective this does not preclude the efficacy of PLY as a 
vaccine antigen, for instance, the DTaP vaccine induces highly effective 
protection against the effects of Diphtheria and Tetanus toxins even though 
infection with Corynebacterium diptheriae or Clostridium tetani does not induce 
antibody responses against these toxins (Casadevall & Pirofski, 2003).  In 
addition to being an adjuvant and immunogen PLY is an ideal conjugate as it 
replaces current protein carriers and avoids the issue of anti-carrier antibodies 
within the current vaccine schedule. 
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1.5 Vaccine Adjuvants and their Mode(s) of Action 
It is well known that in the case of subunit vaccines increasing purity results in 
decreasing immunogenicity, it therefore necessary to use an adjuvant.  An 
adjuvant is defined as a substance which acts non-specifically to enhance the 
specific immune response to the target antigen(s).  This definition may be 
outdated in that it is now widely accepted that initial interactions between 
pathogen and/or adjuvant and the host’s innate immune system shape the final 
outcome of the immune response in a very specific manner (Iwasaki & 
Medzhitov, 2010).  Historically, the field of adjuvant design has been empirical 
rather than rational; modern adjuvant design aims to produce adjuvants which 
are specifically tailored to elicit the most appropriate immune response to the 
target pathogen.  However, given that that mechanism of adjuvanticity for Alum 
(the most widely used adjuvant) is still poorly understood this is fraught with 
difficulties.  In addition, in all adjuvants there is a delicate balance between 
adjuvanticity and toxicity, and while many substances have adjuvant activity 
from mineral oils, mineral compounds and LPS to tapioca and breadcrumbs this 
does not translate to many adjuvants that are safe and sensible for inclusion in 
human vaccines (Gupta et al., 1993; Vogel et al., 1926). 
 
Until recently the only adjuvants licensed for use in human vaccines were 
aluminium salts; however, they are known to induce Th2 type responses and are 
incapable of stimulating cytotoxic T cells making them unsuitable for many 
vaccines, there are now several new adjuvants available for use.  Alum has been 
in use for around 80 years as a vaccine adjuvant and is included in the current 
DTaP (diptheria, tetanus and acellular pertussis), pneumococcal conjugate, and 
hepatitis A and B vaccines to name a few.  However, its mode of action is still 
not completely understood.  Until very recently it was thought that alum-
adsorption created an antigen depot, leading to slow release of antigen and 
allowing time for strong immune responses to develop, however it has recently 
been shown by removal of the injection site that this is not true (Hutchison et 
al., 2012).  Additionally, the ability of Alum to activate the NLRP3 
inflammasome and induce IL-1β has been widely studied and attributed to 
phagosomal destabilization (Kuroda et al., 2011), it was thought that alum could 
somehow synergize with TLR agonists to induce pro-IL-1β production (De 
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Gregorio et al., 2008).  However, in some studies it has been shown that NLRP3 
activation and IL-1β production not an essential feature of alum adjuvanticity 
(Franchi & Núñez, 2008).  There are still other biological activities of alum that 
could lead to a definitive mechanism, for example its ability to activate 
complement (Güven et al., 2013). 
MF59 is an emulsion based vaccine adjuvant used in the Influenza vaccine 
Fluad®, it is remarkably potent and safe adjuvant.  MF59 does not create a 
depot effect, however, similarly to alum it increases recruitment of 
inflammatory leukocytes such as monocytes and neutrophils to the injection site 
and causes enhanced antigen uptake (O’Hagan et al., 2012).  In both cases this is 
thought to be due to induced secretion of the chemokines CCL2, CCL3, CCL4 and 
CXCL8. 
AS03 and AS04 (Adjuvant System) were both created by GlaxoSmithKline and are 
currently in use in GSK vaccines Pandemrix (A/H5N1 Influenza) and Cervarix 
(Human Papilloma virus).  AS03 is Squalene based and AS04 is a mix of aluminium 
hydroxide and monophosphoryl lipid A (MPL).  AS04 is thought to induce a 
transient local immune response consisting of upregulation of IL-6, TNFα, CCL2 
and CCL3 and influx of monocytes causing increased antigen presentation.  It is 
thought some of these responses may be mediated by MPL binding to TLR4 
(Didierlaurent et al., 2009).  The mechanism of action for AS03 is still poorly 
understood, however, both AS03 and AS04 are capable of inducing cellular 
immunity which may lead to effective vaccines against intracellular infections 
such as malaria, HIV and tuberculosis (Baldwin et al., 2012) 
A comparison of gene regulation in response to modern adjuvants demonstrated 
a shared pattern of gene regulation and could be a step towards understanding 
key features of adjuvanticity (Awate et al., 2012). 
1.6 Pneumolysin as a Novel Vaccine Adjuvant 
The mechanism(s) of action of currently licensed adjuvants are still not 
completely understood, however, through compare and contrast analysis of the 
adjuvants available certain patterns of activation are becoming discernible; for 
instance the upregulation of chemokines such as CCL2, CCL3, CCL4 and IL-8, 
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cytokines such as IL-6, IL-1β, TNFα and IFN and complement activation.  
Although there are specific nuances to the response profile each adjuvant 
produces (leading to differences in the final immune phenotype), generally 
speaking adjuvants function by increasing influx and activation of 
proinflammatory leukocytes, increasing antigen uptake and presentation in the 
context of MHC while simultaneously upregulating costimulatory molecules 
(CD80 and CD86).  The ‘nuances’ of each adjuvant response profile influence the 
phenotype of the subsequent adaptive immune response.  PLY is a pleiotropic 
protein and the interactions with/responses of the immune system to PLY 
detailed below are a selection of responses that could potentially be involved in 
its mechanism of adjuvant activity.  These have primarily been investigated in 
the context of infection biology, it is the aim of this project to determine which 
if any of these features of PLY toxicity are involved in adjuvant activity. 
 
1.6.1 Interaction with Pattern Recognition Receptors (PRR) 
Since pneumolysin is a cytolytic toxin it can be reasonably assumed that it will 
interact with host intracellular receptors. The Nod (nucleotide-oligomerization 
domain) like receptors (NLR) are a family of intracellular pattern recognition 
receptors (PRR), they are composed of a central NACHT domain which undergoes 
conformational change during PAMP (pathogen associated molecular pattern) 
recognition, a leucine rich repeat at the C-terminal and a protein-protein 
interaction domain at the N-terminal which is required to amplify the signal.  
The family consists of around 20 members not all of which have a defined ligand.  
It has been shown that the NLR Nod2 which recognises muramyl dipeptide plays 
a role in defence against S. pneumoniae, however there does not seem to be any 
NLR that can directly recognize pneumolysin.  It is more likely that pneumolysin 
activates intracellular receptors by the endogenous danger signals it produces 
such as calcium influx and potassium efflux.  During the course of this project 
several papers have been published establishing the activation of the NLRP3 
inflammasome by PLY and investigating its role in the immune response to PLY.  
NLRP3 is able to sense potassium efflux and uric acid, it then forms the NLRP3 
inflammasome by binding to two adaptor proteins ASC and CARDINAL, these 
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adaptor proteins are each capable of binding caspase-1.  After the assembly of 
the NLRP3 inflammasome caspase-1 is activated and is able to cleave pro-IL-1β 
into its active form. NLRP3 is also thought to promote the differentiation of Th17 
cells through the induction of IL-23 production. IL-1β has a variety of cellular 
functions including the induction of inflammation and fever, cellular 
proliferation and differentiation.  The activation of NLRP3 is considered the 
second signal in the pathway towards IL-1β secretion, the first signal is 
considered to be TLR4 stimulation which results in the upregulation of pro-IL-1β 
via the NFκB pathway.  TLR4 has been shown to be protective if not essential in 
protection from and clearance of pneumococcal disease, and PLY has been 
demonstrated to be a TLR4 ligand, however, this is a contentious issue as a 
mechanism (or PLY domain/amino acid sequence) for PLY binding to TLR4 has 
not been established any many in the field believe that contaminating LPS may 
be the source of this relationship.  Lipopolysaccharide (LPS) is the most 
extensively studied ligand of TLR4, a toll-like receptor family member capable 
of forming homodimers, TLR4 cannot bind LPS directly, it relies on MD-2 to bind 
to a complex of LPS, lipopolysaccharide binding protein (LBP) and CD14 (a 
coreceptor that transfers LPS:LBP to the TLR4/MD-2 complex) (figure 1-4) (Lu et 
al., 2008).  Malley et al. have shown that a TLR4 mutant lacking MD-2 (C3H/HEJ 
mouse strain)  which cannot recognize LPS is still involved in the production of 
inflammatory cytokines in response to pneumolysin (Malley et al., 2003). 
Macrophages from the C3H/HEJ strain treated with PLY are hyporesponsive and 
produce less TNFα and IL-6 compared to macrophages from the control mouse 
strain (C3H/HeOuJ).  To rule out contaminating LPS macrophages were also 
treated with heat treated PLY; as LPS is heat-stable it would be unaffected by 
this treatment and any LPS-dependent cytokine production would remain.  It was 
also found in this study that C3H/HEJ mice are more susceptible to colonisation 
with the bioluminescent S. pneumoniae strain A66.1 Xen 10, indicating a 
protective role for TLR4 in pneumococcal colonisation.  This study did not 
include challenge with a PLY negative isogenic strain, this would have given 
stronger evidence of the role of PLY interactions with TLR4 and protection from 
colonisation.  In a study of PLY-mediated apoptosis TLR4 was shown to be 
involved (Srivastava et al., 2005), RAW264.7 macrophages treated with PLY and 
a TLR4 inhibitor (B1287) were less susceptible to apoptosis as were macrophages 
derived from  C3H/HEJ mice, conversely HEK293 cells transfected to express 
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TLR4 had increased apoptosis in response to PLY.  In addition, an ELISA based 
solid phase binding assay was used to demonstrate that PLY can bind directly to 
purified TLR4 (but not TLR2), heat treatment of PLY abrogated this property.   If 
it is the case that pneumolysin is capable of interactions with TLR4 then it could 
provide the first signal required for IL-1β production.  Although the role of TLR4 
in the pneumolysin response is still poorly defined a synergistic relationship 
between pneumolysin and other TLR ligands has been demonstrated in DCs 
(McNeela et al., 2010). This study also used the C3H/HEJ mouse strain to 
demonstrate that PLY could induce production of IL-5, IL-10, IL-17 and IFNγ in 
splenocytes independently of TLR4.  It was shown that production of IL-1α and 
IL-1β by DC in response to TLR ligands Pam3Cysk4 (TLR1/2), LPS (TLR4), Zymosan 
(TLR2), Muramyldipeptide (TLR2) and CpG (TLR9) was significantly increased in 
the presence of PLY indicating a synergistic response.   Interestingly, TLR4 
binding has also been described in other CDCs.  In a study of the apoptotic 
response to Bacillus anthracis apoptosis was found to be TLR4-dependent, 
further analysis of B. anthracis culture supernatants found the CDC anthrolysin O 
(ALO) to be responsible (Park et al., 2004).  Further study using recombinant 
ALO to treat BMDM from C3H/HEJ mice demonstrated that in the absence of 
functional TLR4 the TNFα and IL-6 gene expression response was abrogated.  The 
same response was found using the CDCs listeriolysin (LLO), perfringolysin O 
(PFO) and suiolysin (SLO) and could indicate that TLR4 binding is another 
conserved function of cholesterol-dependent cytolysins.  The primary criticism 
of these studies is the widespread use of the C3H/HEJ mouse strain as it relies 
on the assumption that if PLY is a TLR4 ligand it will bind by the same 
mechanism as LPS, using MD2 as a coreceptor.  While the direct binding assay 
(Srivastava et al., 2005) provides strong evidence of TLR4 binding, evidence of 
function (such as cytokine production) in a true model of TLR4 absence (such as 
the tlr4-/- mouse strain used in this study) would provide stronger evidence of 
TLR4 binding. 
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Figure 1-4 Diagram of LPS/TLR4 complex .  
 This diagram was reproduced from ( Lu et al. 2008). 
 
1.6.2 Activation of the classical complement pathway 
The classical complement pathway is usually activated by the aggregation of 
antibodies on a target pathogen; it results in specific targeting of complement 
components to the pathogen surface resulting in opsonisation or the formation of 
the membrane attack complex (MAC) which results in cytolysis of the target.  
Streptococcus pneumonia is resistant to the formation of membrane attack 
complexes (MAC) by complement, also, C3b deposition is inhibited by the 
pneumococcal polysaccharide capsule which provides some protection against 
phagocytosis (Jarva, 2003).  However, activation of both the classical and 
alternative complement pathways is essential for pneumococcal clearance, it is 
thought these pathways initiate and determine the magnitude of C3b deposition, 
respectively (Yuste et al., 2005). In addition complement activation is thought to 
impede bacterial spread and is vital in preventing septicaemia by controlling 
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spread of the pneumococcus from the lungs into the bloodstream (Kerr et al., 
2005; Yuste et al., 2005). Pneumolysin plays a central role in protecting the 
pneumococcus from complement attack and aiding its spread to other 
tissues/organs.  PLY has been shown to activate the classical complement 
pathway, this occurs even in the absence of anti-PLY antibodies (Mitchell et al., 
1991). During active pneumococcal infection patients often exhibit reduced 
serum complement levels, it is thought that this is caused by activation of 
complement by PLY resulting in depletion of complement components.  PLY-
treated serum has reduced opsonic activity, indicating exhaustion of 
complement components, this mechanism could aid bacterial survival and spread 
by reducing phagocytosis of bacteria (Alcantara et al., 2001; Giebink et al., 
1980). 
 
The complement activating ability of pneumolysin was previously thought to be 
due to sequence homology in the fourth domain to human CRP (C-reactive 
protein) but it is now known to be due to structural homology to the Fc region of 
IgG.   The complement activating ability of pneumolysin has been shown to be 
dependent on amino acids Tyr384 and Asp385, amino acid substitutions at these 
positions through site-directed mutagenesis causes significant reduction or 
abolishment of complement activation, respectively (Mitchell et al., 1991).  In 
both of these mutants the ability to bind the Fc portion of IgG was almost 
absent, suggesting that PLY activates complement through the non-specific 
aggregation of IgG. 
 
1.6.3 Upregulation of genes 
Only one study has investigated PLY-dependent gene regulation, this study 
examined differential gene regulation in the THP-1 cell line treated with 
isogenic PLY positive and negative pneumococci (strain D39) (Rogers et al., 
2003).  148 genes were found to be differentially regulated in the presence of 
PLY, of interest were the caspases 4 and 6 (involved in apoptosis), MIP-1β 
(monocyte chemoattractant), IL-8 (neutrophils chemoattractant), IL-2Rβ and 
CD68 (expressed on monocytes/macrophages with a role in phagocytosis).  The 
aim of this study was to understand PLY-dependent gene regulation in the 
context of infection; this is reflected in the lists of genes differentially regulated 
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in this publication.  It is of particular interest to study PLY-dependent gene 
regulation and interpret the results with focus on adjuvanticity. 
1.6.4 Known cytokine and chemokine responses to PLY 
The production of cytokines and chemokines in response to PLY has been 
extensively studied, particularly with reference to leukocyte chemotaxis.  When 
PLY is used to intranasally inoculate mice IL-6, macrophage inflammatory 
protein (MIP)-2 and KC (the murine IL-8 homologue) are found in bronchiolar 
lavage fluid (BALF) and are responsible for the recruitment of 
polymorphonuclear leukocytes (PMNL) to the lungs (Rijneveld et al., 2002).  PLY 
has been shown to upregulate transcription of a number of chemokines in an 
NFκB, MAPK-dependent  manner such as CCL2, CCL4, CCL5, CCL8, CXCL8 and 
CXCL10 (Bernatoniene et al., 2008; Dogan et al., 2011).  Other in vitro models 
have also shown PLY-dependent production of TNFα and IL-1α/β in a capase-1, 
NLRP3-depedendent manner (Houldsworth et al., 1994; Shoma et al., 2008).  
Pneumolysin has also been shown to enhance the production of IL-12, IL-23, IL-6, 
IL-1α and IL-1β, TNFα, IL-17A and IFNγ in response to various TLR ligands 
(McNeela et al., 2010).  Production of nitric oxide in macrophages is induced by 
TNF-α, IL-1β and LPS in synergy with IFN-γ, PLY has been shown to induce these 
cytokines and to induce nitric oxide in production in macrophages in an IFN-γ-
dependent manner (Braun et al., 1999). 
 
1.6.5 Interaction with the cell cytoskeleton, a mechanism for 
antigen uptake? 
An interesting feature of PLY adjuvanticity is that antibody responses will not be 
generated towards the target antigen unless it is physically coupled to the toxin 
i.e. there is no by-stander effect.  In the PATH project this was achieved 
genetically by creating fusion proteins of PLY/Δ6PLY and target antigens.  The 
absence of a by-stander effect indicates that PLY mediates antigen uptake 
through direct contact with the cell, and that genetically coupled antigens are 
pulled into the cell, processed and presented along with PLY, whereas non-
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coupled antigens are not taken up by the cell.  The mechanism of PLY 
uptake/internalization is not well understood, it is unclear whether PLY is 
actively taken into the cell or whether the formation of pores allows PLY to pass 
through the membrane.  However, increased endocytic activity and presence of 
cytoplasmic vacuoles had been observed in response to PLY treatment (Hirst et 
al., 2002). Additionally, there is strong evidence that PLY can interact directly 
with the cell cytoskeleton, further investigation of this interaction could lead to 
discovery of an uptake mechanism. 
The changes in cell morphology have been attributed to PLY-induced changes to 
the actin cytoskeleton.  At sublytic concentrations rearrangement of the actin 
cytoskeleton and microtubule stabilization (as indicated by increased acetylation 
and bundling) can be observed in astrocytes (Förtsch et al., 2011; Iliev et al., 
2009).  Although these effects were seen in the absence of observable pores, 
pore forming competency was required and non-lytic mutants did not induce 
these cytoskeletal changes.  Cholesterol was also required for microtubule 
stabilization as these effects were abolished in cholesterol-depleted cells and 
when using cholesterol-treated PLY.  This suggested that PLY must be bound to 
the cell surface in order to induce these effects.  Recently, the mechanism of 
PLY-dependent cytoskeletal remodelling has been further elucidated, it has been 
shown that PLY has the ability to directly bind actin in vitro.  Domains 123 and 
full length PLY bind strongly to actin, the non-lytic deletion mutant ∆6PLY has 
comparatively reduced binding activity suggesting that the refolding and/or 
conformational changes that occur in D123 during pore formation are required 
for actin binding (Hupp et al., 2013).   
 
1.6.6 The neutrophil response to pneumolysin 
Rapid neutrophil infiltration occurs during bacterial pneumonia, this is both 
essential for protection and implicated in its pathogenesis (Craig et al., 2009). 
The chemotaxis and transendothelial migration of neutrophils during 
pneumococcal pneumonia is dependent on PLY (Moreland & Bailey, 2006) as are 
many of the subsequent inflammatory responses of recruited neutrophils.  The 
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neutrophil response to PLY is well documented and various proinflammatory 
factors are induced or upregulated.   
 
PLY induces activation of NFκB and subsequent synthesis and release of IL-8 in a 
Ca2+-dependent manner (Cockeran et al., 2002; Fickl et al., 2005), thus creating 
a positive feedback loop for additional neutrophils recruitment.  Neutrophils are 
exquisitely sensitive to PLY and calcium flux occurs even at apparently sublytic 
(≤100ng/ml) concentrations of PLY, calcium flux does not occur in neutrophils 
treated with the non-lytic deletion mutant Δ6PLY.  The flux of Ca2+ is a 
prerequisite for most neutrophil responses to PLY which include production of 
the anti-microbial peptides prostaglandin E2, Leukotriene B4 and phospholipase 
A2 (Cockeran et al., 2001).  PLY also induces increased superoxide production 
and release of elastase in neutrophils activated with the chemotactic tripeptide 
FMLP (N-formyl-methionine-leucine-phenylalanine) (Cockeran et al., 2001).  PLY 
is known to strongly induce production of neutrophil chemoattractants KC and 
IL-8, interestingly there is thought to be a positive feedback loop/crosstalk 
between Th17 cells and neutrophils, where each cell type is capable of 
recruitment and/or activation of the other (Pelletier et al., 2010).  Given the 
cytokine profile induced by PLY, the essential role of Th17 cells in preventing 
pneumococcal colonization and the role of neutrophils in pneumococcal 
infection, it could be possible that PLY induces Th17 cellular immunity and the 
production of neutrophil chemoattractants such as KC in response to PLY 
deserves further investigation. 
 
1.7 Aims of this study 
Pneumolysin stimulates a vast range of responses from host cells, this is further 
complicated in that these responses are also influenced by the lytic action of 
PLY, sub-lytic or non-lytic doses provoke different responses.  It would not have 
been possible to investigate all of the biological responses mentioned here and 
relate them to adjuvant activity in the time-frame allowed.  Therefore, 
combinations of high-throughput and specific investigations were used to try and 
elucidate the role(s) of a few key features of pneumolysin’s interactions with 
the host.  Throughout this project comparisons were drawn between lytic, non-
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lytic and truncated versions of PLY in an attempt to assign function to different 
regions of the toxin and to pore-forming capability.   
The supposed interaction of PLY with TLR4 was a particular focus of this project; 
the aim was to confirm an interaction between PLY and TLR4 and to determine 
what effect (if any) this had on the cytokines/chemokines selected for analysis.  
The primary hypothesis of this project was that the increased potency of PLY 
based vaccines compared to Δ6PLY based vaccines (in terms of antibody titres) 
was due to PLY-dependent IL-1β production.  It was hypothesised that PLY 
binding to TLR4 would result in upregulation of pro-IL-1β and that subsequent 
activation of NLRP3 by pore formation would cleave pro-IL-1β into its active 
form.  This highly inflammatory cytokine could then result in increased 
magnitude of response compared to the non-lytic Δ6PLY (which cannot form 
pores and therefore should not activate NLRP3). 
As target antigens must be genetically coupled to PLY/Δ6PLY it was hypothesised 
that a specific uptake mechanism such as receptor mediated endocytosis was 
involved in vaccine uptake and processing and that this could be elucidated 
using a high-throughput pull-down method.  Direct binding and internalization of 
PLY and its derivatives was assessed by fluorescence microscopy to try and 
assign binding and internalisation to a specific region (domains 1-3 or domain 4) 
of the toxin.  
Initial studies into PLY-dependent gene expression were performed to give a 
comprehensive view of the immune mediators potentially upregulated by PLY 
(appendix 5).  The potential role in adjuvant activity of differentially regulated 
genes was inferred and comparisons were drawn between PLY-dependent gene 
expression patterns and those of currently licensed adjuvants.  Finally, an in 
vivo immunization model was used to translate the in vitro findings into a model 
for adjuvant activity of PLY. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
Unless otherwise stated the chemicals used throughout this project were 
purchased from Sigma-Aldrich, Gillingham UK, Fisher Scientific, Loughborough 
UK or Melford, Suffolk UK. 
 
2.1.2 Enzymes 
All restriction enzymes and DNA polymerases used in this study were purchased 
from Promega, Southampton UK. 
2.1.3 Protein purification supplies 
Pre-packed HisTrap™ HP and HiTrap™ Capto™ Q affinity columns for the 
purification of His6 tagged recombinant proteins by nickel-affinity 
chromatography (NAC) and anion-exchange chromatography (AEC), respectively, 
were purchased from GE Healthcare, Buckinghamshire UK.  Pureproteome™ 
nickel magnetic beads for the separation of purified His6 tagged recombinant 
proteins from their solvents were purchased from Millipore, Watford UK.  Halo-
link™ resin for the purification of Halo™ tagged recombinant proteins was 
purchased from Promega UK, Southampton UK. 
2.1.4 Antibiotics 
The antibiotics described in table 2-1 were used for the selection of positive 
clones following bacterial transformation as well as routinely to maintain 
plasmid presence in transformed strains.  The antibiotics described in table 2-2 
were used routinely to prevent microbial contamination of cultured mammalian 
cells as well as for plasmid maintenance in stable mammalian reporter cell lines.  
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Table 2-1 List of antibiotics, preparation guidelines and storage conditions. 
Antibiotic Stock Conc. Working Conc. Solvent Storage 
Ampicillin 100mg/ml 100μg/ml dH2O -20°C 
Erythromycin 100mg/ml 1mg/ml EtOH -20°C 
Kanamycin 50mg/ml 50μg/ml dH2O +4°C to -20°C 
 
Table 2-2 List of antibiotics for tissue culture, preparation guidelines and storage 
conditions. 
Antibiotic Stock Conc. Working Conc. Solvent Storage 
Blastocidin 10mg/ml 10μg/ml dH2O -20°C 
Geneticin/G418 500mg/ml 500μg/ml dH2O -20°C 
Penicillin 5000U/ml 50U/ml PBS -20°C 
Puromycin 10mg/ml 5μg/ml dH2O -20°C 
Streptomycin 5mg/ml 50μg/ml PBS -20°C 
Zeocin 100mg/ml 200μg/ml dH2O -20°C 
 
 
2.2 Bacterial strains and vectors 
2.2.1 Storage and growth conditions 
E. coli strains were streaked onto Luria Bertani (LB) agar supplemented with the 
appropriate antibiotic to confirm purity before culturing O/N in LB broth at 37°C 
with shaking at 220rpm.  Frozen stocks of strains were prepared in 1ml aliquots 
of appropriate growth media supplemented with 15% vol/vol sterile glycerol and 
stored at -80°C. 
 
 52 
 
2.2.2 Bacterial strains 
Table 2-3 summarizes the bacterial strains used in this project.  Escherichia coli 
strains XL-1 blue and BL21 (DE3) were used for the propagation and storage of 
plasmid vectors and protein purification respectively. 
 
Table 2-3 Bacterial strain information. 
Species Strain Genotype Description Antibiotic 
Resistance 
E. coli XL-1 blue recA1 endA1 
gyrA96 thi-1 
hsdR17 supE44 
relA1 lac [F2 
proAB 
lacIqZ⊗M15 
Tn10 (Tetr)] 
Ideal host for 
long-term 
storage and 
propagation of 
plasmid 
vectors. 
None 
E. coli BL21 (DE3) E. coli B F- 
ompT hsdSB(rB
-
mB
-) gal dcm 
λ(DE3) 
General protein 
expression 
host. 
Expression 
controlled by 
lac promoter. 
None 
 
2.2.3 Vectors 
2.2.3.1 pET33b 
pET33b is a commercially available plasmid vector (Novagen, UK) and was used 
for the expression and purification of recombinant His6 tagged proteins.  This 
vector contains His6 sequences adjacent to the multiple cloning site allowing 
proteins to be tagged at either the N- or C-terminus.  Pneumolysin is not 
amenable to fusion at the C-terminus and so all PLY-fusions were made at the N-
terminus.  Protein expression is under the control of an inducible T7lac RNA 
polymerase promoter, expression is induced by IPTG.   
2.2.3.2 pFN18A HaloTag® Flexi® Vector 
pFN18A is part of the Flexi® Vector range (Promega, UK).  pFN18A encodes the 
HaloTag® such that it is appended to the N-terminus of the desired protein.  The 
 HaloTag system allows multiple downstream applications such as protein 
purification, fluorescence microscopy and pull
creating a single construct. The HaloTag itself is a 33kDa haloalkane 
dehalogenase derived from a prokaryotic hydrolase 
2008). Promega have engineered a vari
bind covalently to the HaloTag; for example a wide range of fluorochrome
tagged microscopy ligands exist and allow flexibility in protocols for cell 
localization and interaction studies. 
figure 2-1. All Flexi
sites SgfI and PmeI, this allows easy interchange of a desired insert from one 
Flexi® Vector to another.  A lethal Barnase gene within the cloning site and an 
ampicillin resistance selection marker allow positive selection of clones.  This is 
designed as a shuttle vector and allows the expression of the desired protein in 
both E. coli and mammalian cells under the control of a T7 RNA polymerase 
promoter. 
Figure 2-1 Diagram of pFN18A cloning site.  
 
 
2.2.4 Electrocompetent cells
Electrocompetent cells were generated in
and BL21 as follows.
Under sterile conditions, 500ml of LB was inoc
culture.  Cultures were incubated at 37°C, 200rpm until OD600nm 0.6 was 
reached. Culture flasks were rapidly chilled on ice
5000rpm for ten minutes at 4°C.  The resulting pellet was washed four times
ice-cold sterile dH2
-downs to be performed after 
(Feature, 2006; Los et al., 
ety of choroalkane-based ligands that 
The cloning site of pFN18A is s
® Vectors have a cloning site flanked by the rare restriction 
 
 
-house for the E. coli 
 
ulated with 5ml of an overnight 
 before centrifugation at 
O by repeated resuspension and centrifugation.  Finally, the 
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pellet was resuspended in 1-2ml of ice-cold sterile dH2O containing 10% glycerol.  
The competent cells were aliquoted in 60μl volumes, snap frozen in liquid 
nitrogen and stored at -80°C until required.  
 
2.3 Molecular cloning 
2.3.1 Oligonucleotides 
Oligonucleotide primers were purchased from either Sigma Aldrich (UK) or 
Eurofins MWG Operon (Germany).  Oligonucleotides were supplied lyophilized 
and were reconstituted to 100μM stock concentration in molecular biology grade 
dH2O.  Oligonucleotides were stored at -20°C until required. 
Table 2-4 Oligonucleotide primers. 
Name Description Sequence 
9Y Forward sequence of pneumolysin in pET 
33b(+) [i.e. start of Ply in pET] 
 
CGG GAT CCG GCA AAT 
AAA GCA GTA AAT GAC TTT 
 
9Z Reverse sequence of pneumolysin in pET 
33b(+) [i.e. end of Ply in pET] 
 
GAC GGA GCT CGA CTA 
GTC ATT TTC TAC CTT ATC 
 
20G Amplification of GFP for cloning into pET 33b in 
frame with the ATG and HisTag. Contains Nhe 1 
site and deletes ATG 
 
GTC AGG CTA GCA TGA 
GTA AAG GAG AAG AAC 
 
20H Amplification of GFP for cloning into pET33b. 
Contains Bgl 11 site (compatible with Bam HI). 
Also in frame with HisTag (c-term) and stop 
 
CCA CGC AGA TCT TTG TAT 
AGT TCA TCC 
 
23B Binds to bases 415-466 of Ply gene Introduces 
DA146R147 within Ply gene 
 
GGT CAA TAA TGT CCC AAT 
GCA GTA TGA AAA AAT AAC 
GGC TC 
 
23C Reverse and compliment of LK6 (forward) 
 
GAG CCG TTA TTT TTT CAT 
ACT GCA TTG GGA CAT TAT 
TGA CC 
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Table 2-4 continued 
48I Amplification of PLY domains 1-3  for cloning 
into pET33b - ends at VTAYRN then adds a stop 
codon. SacI site 
 
GACGGAGCTCGACTAGTTT
CTGTAAGCTGTAAC 
 
52Q From: Suzuki et al. 2005. Discrimination of 
Streptococcus pneumoniae from Viridans Group 
Streptococci by Genomic Subtractive 
Hybridization. J. Clin. Microbiol. 43: 4528-4534. 
 
ATTTCTGTAACAGCTACCAA
CGA 
 
52R From: Suzuki et al. 2005. Discrimination of 
Streptococcus pneumoniae from Viridans Group 
Streptococci by Genomic Subtractive 
Hybridization. J. Clin. Microbiol. 43: 4528-4534. 
 
GAATTCCCTGTCTTTTCAAA
GTC 
 
62P Halo seq for CCTGCCTAACTGCAAGGCTG 
62Q Halo seq rev CAGCAGCCAACTCAGCTTCC 
62R Halo ply for TAACGCGATCGCCATGGCAAAT
AAAGCAGTAAATGAC 
62S Halo ply rev TTCGTTTAAACCTAGTCATTTT
CTACCTTATCC 
62T Halo d123 rev stop ATTCGTTTAAACCTATCTGTAA
GCTGTAACCTTA 
62U Halo D4 for TAACGCGATCGCCTACAGAAAC
GGAGATTTACTGCT 
62V Halo egfp for GTCGCGATCGCCATGAGTAAAG
GAGAAGAACTTTTC 
62W Halo egfp rev GTTTAAACGACGGATCTTTGTA
TAGTTCATCC 
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2.3.2 Polymerase chain reaction (PCR) 
In this study PCR was used for the amplification or mutagenesis of target genes 
for molecular cloning as well as for screening subsequent bacterial colonies 
following transformation.  The proof-reading enzyme PfuUltra II fusion high 
fidelity polymerase (Stratagene, Cheshire UK) was used to amplify targets for 
molecular cloning and to perform Site-directed Mutagenesis.  Bacterial colony 
screening by PCR was performed using GoTaq DNA polymerase (Promega, 
Southampton UK).  Reactions were performed according to the manufacturer’s 
instructions; typical PCR conditions are detailed below. 
2.3.2.1 Typical PCR conditions using GoTaq standard fidelity DNA 
polymerase 
Table 2-5 GoTaq PCR mix 
Reaction 
Component 
Volume 
Required 
DNAse/RNase 
free dH2O 
up to 50μl 
5 x GoTaq green 
reaction buffer 
10μl 
dNTPs (10mM) 1μl 
for primer 
(10μM) 
1μl 
rev primer 
(10μM) 
1μl 
DNA template  <0.5μg 
total/xμl 
GoTaq DNA 
polymerase 
0.5μl 
Total reaction 
volume 
50μl 
 
Table 2-6 GoTaq PCR cycling conditions 
Step Temperature Time No. of 
Cycles 
Initial 
denaturation 
95°C 2 minutes 1x 
Melting 95°C 30 
seconds 
 
Annealing 42-65°C 30 
seconds 
 
30x 
Extension 72°C 1 
minute/kb 
 
Final 
Extension 
72°C 5 minutes 1x 
Soak 4°C Indefinite 1x 
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2.3.2.2 Typical PCR conditions using PfuUltra II fusion HS high fidelity DNA 
polymerase 
Table 2-7 PfuUltra II PCR mix 
Reaction 
Component 
Volume 
Required 
DNAse/RNase 
free dH2O 
up to 50μl 
5 x GoTaq green 
reaction buffer 
10μl 
dNTPs (10mM) 1μl 
for primer 
(10μM) 
1μl 
rev primer 
(10μM) 
1μl 
DNA template  <0.5μg 
total/xμl 
GoTaq DNA 
polymerase 
0.5μl 
Total reaction 
volume 
50μl 
 
Table 2-8 PfuUltra II PCR cycling conditions 
Step Temperature Time No. of 
Cycles 
Initial 
denaturation 
95°C 2 minutes 1x 
Melting 95°C 30 
seconds 
 
Annealing 42-65°C 30 
seconds 
 
30x 
Extension 72°C 1 
minute/kb 
 
Final 
Extension 
72°C 5 minutes 1x 
Soak 4°C Indefinite 1x 
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2.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to visualise PCR products and separate 
products from restriction digests for further purification.  Typically, 0.3μg of 
1kbp+ DNA standard (Invitrogen, Paisley UK) and 10μl of PCR product or 50μl of a 
restriction digest reaction were run on a 0.8% w/v agarose gel in 1x Tris-Acetate-
EDTA (TAE) buffer at 100 V for 20 minutes.  The UVPro Gold gel-documentation 
system (UV Tech) was used to visualise and image gels. 
2.3.4 Plasmid purification 
The QIAspin miniprep kit (Qiagen) was used according to the manufacturer’s 
instructions to purify plasmid DNA from O/N cultures of transformed bacteria.  
2.3.5 Restriction digest 
The conditions of restriction digests varied throughout this project and are 
described in more detail in section 2.4. 
2.3.6 Gel extraction and PCR product purification 
Following restriction digest the resulting DNA segments were separated by 
agarose gel electrophoresis and extracted from the gel using the Qiagen 
QIAquick gel extraction kit.  PCR products to be used in downstream reactions 
were purified from their PCR mix using the SV Wizard PCR purification kit 
(Promega, UK).  Where possible, gel extraction was avoided to reduce loss of 
digest products; digestion of pET33b constructs with NheI and BglII results in 6 
undesirable base pairs, these can be separated from the desired product using a 
PCR clean-up protocol resulting in increased yield compared to gel extraction. 
2.3.7 Ligation 
T4 DNA ligase (Promega, UK) was used to ligate DNA fragments for ligation 
dependent cloning.  The molecular ratio of vector to insert was 1:3 for cloning 
with “sticky ends” or 1:10 for blunt end cloning. Typically, 2μl of T4 DNA ligase 
and 2μl of 10X DNA ligase buffer were added to a reaction with a 20μl final 
volume.  Reactions were incubated at room temperature for 4hrs before heat 
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inactivation at 65°C for 10min. 5μl of the ligation reaction was used for 
transformation into electrocompetent XL-1 blue E. coli.  
2.3.8 Bacterial transformation 
Electrocompetent E. coli were transformed with plasmid DNA using the Bio-rad 
gene pulser electroporation system.  Briefly, 100μl of electrocompetent cells 
were allowed to thaw on ice, 5μl of salt-free plasmid DNA was added to the cells 
and incubated on ice for 20min.  The mix was transferred to a pre-chilled 0.2cm 
gap electroporation cuvette and pulsed at 2.5kV.  Following electroporation 
200μl of SOC medium was quickly added to the cuvette and the mixture was 
transferred to a 1.5ml microcentrifuge tube.  The transformed cells were 
incubated at 37°C at 220rpm for 1hr then plated onto selective LB.  The plates 
were incubated overnight at 37°C. 
2.4 Construction of plasmids 
2.4.1 pET33bPLY: PLY derivatives and eGFP. 
At the beginning of this work multiple PLY mutants had been constructed by 
previous researchers in the Mitchell group (see table 2-9).  Figure 2-2 describes 
the regions of the toxin that are amplified for cloning and the region containing 
the delta 6 mutation.  These mutants will allow the biological properties of PLY 
to be assigned to different regions of the toxin as well as differentiating 
between pore-dependent and independent interactions with the host.  For the 
majority of PLY mutants fusion proteins also existed, where eGFP was fused to 
PLY and its derivatives; eGFP serves as both a model antigen and tool to 
examine PLY localisation and interactions with the host.  In these studies PLY 
and PLY mutants were purified from existing constructs and several new 
constructs were created in the pET33b expression system, these are all listed in 
table 2-9. 
 
 
 Figure 2-2 Mutation and truncation of 
As previously mentioned domain 1 (residues 6
(residues 22-57, 343-359) and domain 3 (residues 148
inseparable. The delta 6 mutation which r
residues 146 and 147 within domain 1 (directly before a stretch of domain 3
(residues 360-469) can be purified separately from the other domains.
 
 
 
 
 
 
 
 
 
 
 
pneumolysin.  
-21, 58-147, 198-243, 319
-197, 244-318) are physically 
enders PLY non-toxic is achieved by deleting 
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-342), domain 2 
). Domain 4 
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Table 2-9 pET33b constructs available for use 
Name of construct Origin Description 
pET33b-PLY Graeme Cowan His6 tagged full-length lytic PLY 
pET33b-Δ6PLY Lea-Ann Kirkham His6 tagged full-length non-lytic 
PLY 
pET33b-D123PLY Graeme Cowan His6 tagged truncation mutant of 
domains 1, 2 and 3 of PLY 
pET33b-Δ6D123PLY* Catherine Dalziel (Author) His6 tagged truncation mutant of 
domains 1, 2 and 3 of PLY with the 
Δ6 mutation (aa146-147 removed) 
pET33b-D4PLY Graeme Cowan His6 tagged truncation mutant of 
domain 4 of PLY 
pET33b-eGFPPLY Graeme Cowan Full-length lytic PLY tagged with 
both His6 and eGFP 
pET33b-eGFP Δ6PLY Jiang Tao Ma Full-length non-lytic PLY tagged 
with both His6 and eGFP 
pET33b-
eGFPD123PLY 
Jiang Tao Ma Truncation mutant of domains 1,2 
and 3 of PLY tagged with both His6 
and eGFP 
pET33b-eGFP 
Δ6D123PLY* 
Catherine Dalziel (Author) Truncation mutant of domains 1,2 
and 3 of PLY, with the Δ6 mutation 
and tagged with both His6 and 
eGFP 
pET33b-eGFPD4PLY Jiang Tao Ma Truncation mutant of domain 4 
PLY tagged with both His6 and 
eGFP 
pET33b-eGFP Graeme Cowan His6 tagged enhanced Green 
Fluorescent Protein only 
 
2.4.1.1 pET33b-Δ6D123  
The major difference in activity between PLY and Δ6PLY is, of course, lack of 
cytolytic activity; however, it was not known whether the Δ6 mutation had also 
introduced other deviations in function.  To address this, a D123PLY mutant 
containing the Δ6 mutation was constructed; this removed the confounding issue 
of pore formation from comparisons.  A ligation-dependent cloning strategy was 
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used for the construction of pET33b-Δ6D123.  Primers 9Y and 48I were used to 
amplify domains 1-3 from pET33b@6PLY adding BamHI and SacI sites, 
respectively (figure 2-3).   
 
 
Figure 2-3 DNA insert Δ6D123PLY.   
Primers 48I and 9Y were used to amplify domains 1-3 from pET33b-Δ6PLY creating a 1101bp 
PCR product (lane 2) for insertion into pET33b.  Lane 1 shows the negative control. 
Following PCR amplification of the insert using GoTaq PCR mastermix (Promega), 10μl of 
the PCR and control were loaded into a 0.8% agarose gel and electrophoresed at 100 V for 
20 minutes.  PCR products were visualised using the UVPro Gold gel-documentation 
system (UV Tech). 
 
The resulting PCR product and the vector pET33b were subjected to a 3 hour 
double digest at 37°C with SacI and BamHI.  The digested products were cleaned 
and ligated using T4 DNA ligase at a molecular ratio of 3:1 (insert:vector) for 4 
hours at room temperature.  XL-1 blue electrocompetent E. coli were 
transformed with 3μl of the ligation reaction and plated onto LB agar plates 
containing 50μg/ml kanamycin.  Positive colonies were screened by PCR for the 
presence of the insert using primers 9Y and 48I before storage as glycerol stocks 
(figure 2-4).   
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Figure 2-4 Colony screening PCR.  
 Following transformation of XL-1 blue E. coli with pET33b-Δ6D123PLY any resulting 
colonies were screened for the presence of the insert using primers 48I and 9Y.  Following 
PCR amplification of the insert using GoTaq PCR mastermix (Promega), 5μl of the PCR and 
control were loaded into a 0.8% agarose gel and electrophoresed at 100 V for 20 minutes.  
PCR products were visualised using the UVPro Gold gel-documentation system (UV Tech). 
Lanes 3, 8 and 11 are positive and give a band of 1101bp, identical to that of the positive 
control (lane 1, pET33b-D123PLY template).   
 
The new plasmid sequence was verified by Sanger sequencing at the Source 
Biosciences facility in Nottingham.  Following confirmation of sequence the new 
construct was then used to transform E. coli BL21 cells for protein expression 
and purification. 
 
 
2.4.1.2 pET33b-eGFPΔ6D123PLY 
Site-directed mutagenesis was employed to create an eGFP-tagged version of 
Δ6D123PLY in pET33b.  The mutagenic primers 23B and 23C were used to create 
the Δ6 deletion mutation in pET33bD123PLY. The SDM protocol was followed as 
detailed in section 2.3.2, following mutagenesis parental DNA template was 
removed by digestion with DpnI at 37°C for 1 hour.    XL-1 blue 
electrocompetent E. coli were transformed with 3μl of the ligation reaction and 
plated onto LB agar plates containing 50μg/ml kanamycin.  Positive colonies were 
screened by PCR for the presence of the insert using primers 9Y and 48I plus 20G 
and 20H before storage as glycerol stocks.  The new plasmid sequence was 
verified by Sanger sequencing at the Source Biosciences facility in Nottingham.  
Following confirmation of sequence the new construct was then used to 
transform E. coli BL21 cells for protein expression and purification. 
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2.4.2 pFN18A: PLY derivatives and eGFP. 
To construct HaloTagged versions of PLY, Δ6PLY, D123PLY, Δ6D123PLY, D4PLY 
and eGFP in the vector pFN18A the manufacturer’s (Promega, UK) ligation-
dependent cloning strategy was followed.  The primers, templates and creators 
of the pFN18A constructs are detailed in table 2-2.  Briefly, target genes were 
amplified using primers designed to append SgfI and PmeI sites to the target, 
both the PCR product and acceptor vector (pFN18A) were digested with SgfI and 
PmeI at 37°C for 30 minutes.  The digest reactions were inactivated by 
incubation at 65°C for 10 minutes, the PCR product was cleaned but the vector 
digest was not.  Digested insert and vector were ligated at a molecular ratio of 
10:1 (insert: vector) using T4 DNA ligase at room temperature for 1 hour.  XL-1 
blue electrocompetent E. coli were transformed with 3μl of the ligation reaction 
and plated onto LB agar plates containing 100μg/ml ampicillin.  Positive colonies 
were screened by PCR for the presence of the insert before storage as glycerol 
stocks.  The new plasmid sequence was verified by Sanger sequencing at the 
Source Biosciences facility in Nottingham.  Following confirmation of sequence 
the new construct was then used to transform E. coli BL21 cells for protein 
expression and purification. 
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Table 2-10 Table of primers and DNA templates used to clone PLY and its derivatives into 
pFN18A. 
Construct Name PCR Template PCR Primers Constructed By 
pFN18A-PLY pET33b-PLY 62R and 62S Jiang Tao Ma 
pFN18A-Δ6PLY pET33b- Δ6PLY 62R and 62S Catherine Dalziel 
(author) 
pFN18A-D123 pET33b-D123 62R and 62T Freiderike 
Vollmer/Catherine 
Dalziel (author) 
pFN18A-Δ6D123 pET33b- Δ6D123 62R and 62T Catherine Dalziel 
(author) 
pFN18A-D4 pET33b-D4 62S and 62U Freiderike 
Vollmer/Catherine 
Dalziel (author) 
pFN18A-eGFP pET33b-eGFP 62V and 62W Catherine Dalziel 
(author) 
 
 
2.5 Protein expression and purification 
2.5.1 Protein expression in E. coli BL21 (DE3) 
Proteins of interest were expressed in BL21 (DE3) E. coli cells transformed with 
the required plasmid (see tables 2-9 and 2-10).  Typically, 4 x 1L flasks of LB 
broth containing 50μg/ml kanamycin were inoculated with 10ml of an O/N 
culture of transformed BL21 cells.  The cultures were incubated at 37°C with 
shaking at 220rpm until an OD600nm of 0.8-1 was reached.  Protein expression was 
induced by the addition of Isopropyl-β-D-thio-galactopyranoside (IPTG) to a final 
concentration of 1mM. The cultures were grown for a further 6hr at 30°C with 
shaking before harvesting the cells by centrifugation at 5000rpm for 30min at 
4°C.  Cell pellets were stored at -20°C until required for protein purification. 
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2.5.2 Lysate preparation 
Frozen culture pellets were resuspended in 10mls (per L of culture) of ice-cold 
PBS supplemented with 300 units of DNase I (Sigma-Aldrich, Gillingham UK) and 1 
complete protease inhibitor tablet, EDTA-free (Roche, Welwyn UK).  The 
bacterial cell suspension was passed through the One Shot Cell Disruptor 
(Constant Systems, Warwick UK) and the resultant lysates were centrifuged at 
13000rpm for 30 mins to pellet cell debris.  Lysates were sterilized by passing 
through a 0.22μm syringe filter (Sartorius, Hannover Germany) to remove any 
whole bacteria or remaining cell wall debris. 
2.5.3 Purification of His-tagged Proteins 
2.5.3.1 Nickel-affinity chromatography (NAC) 
Using a peristaltic pump, a 5ml HisTrap™ HP affinity column was washed with 
sterile dH2O then packed with 0.2M nickel sulphate solution.  The column was 
washed again with PBS before loading with filtered lysate (section 2.5.2.1). A 
final wash with PBS removed unbound proteins from the column.  The AKTA-
PrimePlus system was used to remove His-tagged proteins from the column.  
Using a pre-programmed His-tag gradient elution programme, increasing 
concentrations of imidazole were used to compete with his-tagged proteins for 
binding space on the column.  As the concentration of imidazole increases His-
tagged proteins are removed from the column into collection tubes (fractions).  
The AKTA-PrimePlus analysis software uses UV spectrophotometry to indicate 
fractions that contain eluted protein; these fractions were electrophoresed on 
an SDS-PAGE gel, stained with coomassie and destained.  Figure 2-5 shows an 
example of NAC purification of Δ6D123PLY.  The fractions that contained the 
most protein with the fewest contaminating bands on the gel were then selected 
for dialysis at 4°C O/N in anion-exchange chromatography (AEC) start buffer. 
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Figure 2-5 Example purification of Δ6D123PLY by NAC.  
 The Akta PrimePlus UV absorption trace (A) indicated that Δ6D123PLY was eluted from the 
HisTrap column into fractions 16-26.  The peaks shown in fraction 11-14 routinely appear 
and are always identified as contaminants.  To check for the presence of Δ6D123PLY, 
fractions 15-27 were analysed by SDS-PAGE (B).  Fraction samples were diluted 1:5 in 
sample buffer and 10μl of each was loaded into a 10%SDS-PAGE gel, the fraction proteins 
were separated by electrophoresis at 180 V for 40 minutes and the gel was stained with 
coomassie blue. 
 
2.5.3.2 Anion-exchange chromatography (AEC) 
Following nickel-affinity chromatography proteins were further purified by 
anion-exchange chromatography.  A peristaltic pump was used to load proteins 
purified by NAC onto a 1ml HiTrap™ Capto™ Q affinity column, to ensure the 
entire sample had been passed through the column a final wash with 15mls of 
AEC start buffer was performed.  The Akta-PrimePlus system was utilised again, 
this time using the pre-programmed anion exchange Capto Q gradient.  As with 
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NAC, fractions containing eluted protein were analysed by SDS-PAGE (figure 2-
6(B)).  The purest fractions were pooled and dialysed twice in a 50-fold volume 
of sterile PBS at 4°C for 24hrs. 
 
 
Figure 2-6 Example purification of Δ6D123PLY by AEC.   
The Akta Primeplus UV absorption trace (A) indicated that Δ6D123PLY was eluted from the 
HiTrap CaptoQ column into fractions 13-23.  Fractions 11-23 were analysed for the presence 
of Δ6D123PLY by SDS-PAGE (B).  Fraction samples were diluted 1:5 in sample buffer and 
10μl of each was loaded into a 10%SDS-PAGE gel, the fraction proteins were separated by 
electrophoresis at 180 V for 40 minutes and the gel was stained with coomassie blue. 
 
 
Following dialysis purified proteins were concentrated using Amicon ultra 
centrifugal filters (Millipore, Watford UK) with an appropriate molecular weight 
cut-off.  Purified proteins were aliquoted and stored at -20°C for further 
analysis. 
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2.5.4 Purification/Isolation of HaloTagged Proteins 
Although the HaloTag can also be used for protein purification the covalent 
binding of the HaloTag to Halo-link resin requires cleavage of the desired protein 
from the tag using TEV protease.  If desired, the proteins could be purified by 
size-exclusion chromatography but for the purposes of this study whole bacterial 
cell lysates were deemed suitable.  Lysates were obtained from BL21 cells 
expressing HaloTagged proteins as described in sections 2.5.1 and 2.5.2. 
 
2.6 Analysis of Isolated proteins 
2.6.1 SDS-PAGE and western blotting 
SDS-PAGE and western blotting were used to check for the presence and purity 
of recombinant proteins, figure 2-7 shows an example analysis of Δ6D123PLY.  
SDS-PAGE gels were either purchased as pre-cast 4-12% gels (Invitrogen, Paisley 
UK) or cast using the Bio-Rad mini protean system with a 10% resolving gel and a 
4% stacking gel (appendix). 
Samples were diluted in 5 X SDS-PAGE sample buffer (see appendix) and 
denatured at 70°C for 20min.  10μl of sample and 5μl Seeblue® Plus 2 pre-
stained molecular weight marker were loaded onto the gel.  The gel was 
electrophoresed at 180v for 40min then stained with coomassie R250 stain, 
destain was applied several times to remove excess stain followed by several 
washes of dH2O to obtain a clear background.  Alternatively, silver staining was 
performed using the SilverQuest™ kit (Invitrogen).  Silver staining can detect as 
little as 0.3ng of protein and was used to detect proteins of low abundance. 
Western blotting was performed using SDS-PAGE gels prepared as above, instead 
of performing a coomassie stain the proteins were transferred onto a Hybond-C 
nitrocellulose membrane (Amersham biosciences, Buckinghamshire UK) using an 
Xcell™ blot module (Invitrogen, UK) at 30v for 1hr.  The membranes were 
blocked at 4°C in 3% skimmed milk overnight.  After blocking, the membranes 
were washed x 4 in 0.05% PBS-Tween™ and incubated with the primary antibody 
for 3hrs at 37°C with shaking.  The membranes were washed again and 
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incubated with the secondary antibody for 1hr at 37°C with shaking.  After a 
final wash step the membranes were developed by enhanced chemiluminescence 
(ECL) (Millipore, UK) following the manufacturer’s instructions.  Alternatively, 
membranes were developed using 4-chloronapthol developer (see appendix). 
 
Figure 2-7 Analysis of purified protein by SDS-PAGE and western blotting.   
SDS-PAGE of purified Δ6D123PLY (A) and corresponding western blot using rabbit anti-PLY 
developed using 4-chloronapthol (B). Purified Δ6D123PLY was diluted to 1mg/ml and mixed 
1:5 with SDS-PAGE loading buffer. 5μl of Seeblue Plus 2 molecular weight marker and 10μl 
of the protein were loaded into the wells of a 10% SDS-PAGE gel and electrophoresed at 180 
V for 40 minutes.  The proteins were transferred onto nitrocellulose membrane and detected 
by western blotting using rabbit anti-PLY (1:1000) and donkey anti-rabbit-HRP (1:2000).  The 
blot was developed using 4-chloro 1-napthol.   
 
2.6.2 Haemolytic assay 
The haemolytic activity of PLY and its derivatives was measured by haemolytic 
assay.  Briefly, 50µl of PBS was added to each required well of a round-bottomed 
96-well plate, purified PLY of a known concentration was diluted 1/1000 and 
50µl of this was added to the plate in duplicate, serial dilutions of PLY were 
performed along both rows.  This step was repeated with test samples of either 
purified protein (diluted 1/1000) or bacterial lysates (1/5 dilution).  50µl of 
10mM DTT was added to each well before incubating the plate at 37°C for 15-
30min.  1ml of sheep blood was washed by centrifugation at 13000rpm for 1min, 
the supernatant was removed and replaced with PBS and the process repeated 
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until the supernatant was clear.  The blood was then used to prepare a 2% 
erythrocyte solution; 50µl of this solution was added to each well.  The plate 
was incubated at 37°C for a further 30min.  After incubation 50µl PBS was added 
to each well and the plate as centrifuged at 1000rpm for 1min. 100µl of 
supernatant was transferred from each well to a flat-bottomed 96-well plate and 
the absorbance at 540nm was measured.  Figure 2-8 shows an example 
haemolytic assay using purified PLY. 
 
 
Figure 2-8  Example haemolytic assay.   
Sheep erythrocytes were treated with either PBS or serial dilutions of PLY (1μg/ml starting 
conc.) in duplicate for 30 mins.  50μl of purified PLY (1μg/ml) and 50μl of PBS was added in 
duplicate to the first wells of a 96-well plate and serially diluted (1:2) horizontally across the 
plate.  Following incubation with a 2% sheep RBC solution for 30 minutes the plate was 
centrifuged at 1000rpm for 1 min, intact erythrocytes were visible as pellets (A).  Released 
haemoglobin from lysed erythrocytes was analysed by measuring the absorbance at 540nm 
of cell supernatants using a Fluostar Optima plate reader (B). 
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The absorbance data from haemolytic assays were used to calculate % lysis for 
each test using the calculation: 
 
Percentage lysis = ((X-Y)/(Z-Y))*100 
Where X = the A540 for the sample, Y = the background A540 and Z = the 
A540 from a positive control sample (i.e. 100 lysis). 
 
By plotting % lysis values against log toxin concentration the specific activity in 
HU/pmol of a sample can be calculated. 
 
2.6.3 Determination of protein concentration 
2.6.3.1 Lysates 
Total protein concentration of lysates was measured by Bradford assay.  Briefly, 
protein standards were prepared by diluting a 2μg/ml solution of bovine serum 
albumin (BSA) in PBS as described in table 2-11. 
Table 2-11 Preparation of Protein standards for Bradford Assay 
Final BSA Concentration 
(μg/ml) 
Volume of BSA (2μg/ml) 
required (μl) 
Volume of PBS required (μl) 
1500 75 25 
1000 50 50 
750 33 67 
500 25 75 
250 12.5 87.5 
125 6.25 93.75 
62.5 3.12 96.83 
0 0 100 
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10μl of both standards and test solutions were added in duplicate to a flat-
bottomed 96-well plate, 200μl of Bradford reagent (Sigma) was added to each 
well and incubated for 5-60 minutes.  The A570 of each well was determined 
using the BMG fluostar Optima.  The protein concentration of samples was 
determined by extrapolating A570 values against the BSA standard curve. 
2.6.3.2  HaloTagged Proteins 
To assess the concentration of HaloTagged proteins in lysates a TEV cleavage 
was performed.  Briefly, 200μl of lysate was mixed with 100μl of HaloLink resin 
and incubated at room temperature with rotation for 2 hours.  The resin was 
washed and treated with 100µl of Turbo TEV protease (Geneway, USA) overnight 
at 4°C.  The concentration of cleaved proteins was then measured using the 
NanoDrop ND-1000 (Fisher scientific, Loughborough UK) as detailed in section 
2.6.3.3, the calculated protein concentrations for HaloTagged proteins can be 
found in the appendix. 
2.6.3.3 Purified proteins 
Protein concentration was determined by UV spectrophotometery using a 
NanoDrop ND-1000 (Fisher scientific, Loughborough UK) at absorbance 280nm 
(A280).  At A280 the amino acid residues tyrosine and tryptophan contribute 
significantly to absorption; it is necessary to account for this to obtain an 
accurate protein concentration.  Beer’s law states that the concentration of a 
protein is equal to its absorbance at 280nm divided by its molecular extinction 
coefficient.  The molecular extinction coefficient is the molecular weight of a 
protein divided by its molar extinction coefficient.  These calculations were used 
to determine accurate protein concentration following purification. 
 
2.6.4 Separation of His-tagged protein from solvent using nickel 
magnetic beads 
In this study vehicle controls for purified protein were generated by removal of 
the His6-tagged proteins from solution using PureProteome nickel magnetic 
beads.  The protein free solvents were then used in equal volumes to purified 
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protein solutions when analysing cellular responses to the toxins.  This allowed 
confidence that the observed results were due to the purified protein in 
question and not contaminants such as LPS.  The PureProteome nickel magnetic 
beads were used according to the manufacturer’s instructions; approximately 
200μl of nickel bead solution was used for every 100μg of protein removed. 
 
2.6.5 Determination of LPS concentration in purified protein 
preparations 
The Charles River Endosafe® portable testing system was used to accurately 
measure the LPS concentration in purified proteins.   
 
2.7 Tissue culture techniques 
2.7.1 Generation and analysis of bone marrow derived 
macrophages (BMDM) 
2.7.1.1 Preparation of L929 conditioned culture medium 
The cell line L929 secretes monocyte colony stimulating factor (MCSF) into 
culture supernatant.  This supernatant can be harvested and used for the 
differentiation of primary macrophages.  L929 were cultured in complete RPMI + 
pen/strep and maintained at 50-90% confluency for 10 days.  Once established 
culture supernatant was harvested during routine subculturing and sterilized by 
filtration through a 2μm syringe filter.  Sterile L929 conditioned medium was 
stored at -20°C until required. 
2.7.1.2 Isolation and differentiation of BMDM 
To generate primary BMDM female mice were euthanized under CO2 by 
exsanguination and cervical dislocation.  The femurs and tibias were dissected 
out and the joints removed.  Under sterile conditions, using a 10ml syringe and 
25G needle complete RPMI 1640 was flushed through the bones to expel the 
bone marrow.  The resulting suspension was then repeatedly drawn up and 
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expelled through the needle and syringe to create a single cell suspension.  The 
bone marrow was pelleted by centrifugation at 2000rpm for 2min; the pellet was 
resuspended in 1ml of ACK lysis buffer (LONZA) and allowed to stand for 1min to 
lyse RBCs.  The suspension volume was made up to 10ml with complete RPMI and 
centrifuged at 2000rpm for 2min to wash off the lysis buffer.  After a final 
resuspension in complete RPMI the cells were counted using a haemocytometer 
and the cell concentration was adjusted to 3x106/ml.  BMDM were cultured by 
adding 2ml of cell suspension + 4ml of L929 conditioned medium + 14ml of 
complete RPMI to a 75cm2 vented TC flask and incubating at 37°C, 5% CO2.  After 
3 days in culture the cells were fed by the addition of another 14mls of complete 
RPMI + 4ml of L929 conditioned medium.  On day 6 the cells were harvested 
manually by scraping after incubation for 5min in ice-cold PBS.  
 
2.7.1.3 Analysis of BMDM culture phenotype by flow cytometry 
Bone marrow derived macrophages were cultured from 6-week-old female MF1 
mice; on day 6 of BMDM culture 1x106 cells were harvested.  Half of the 
harvested cells were stained with Fluorescein Isothiocyanate (FITC) anti-mouse 
F4/80 –Pan macrophage marker (eBioscience), half were left as an unstained 
control population and both samples were run on the FACscalibur flow cytometer 
following appropriate user instructions (figure 2-9). 
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Figure 2-9 Analysis of BMDM culture phenotype by flow cytometry.  
 On day 6 of culture BMDM were harvested, 1X10
6
 cells were stained with anti-mouse F4/80 
(FITC) and 1X10
6
 cells were left unstained.  Samples were analyzed for fluorescence 
intensity (A).  The size and granularity of the stained sample was analyzed and groups were 
created for mature and immature macrophages, indicating percentage of the total sample 
(B). The percentage of cells that were positive for F4/80 was analyzed and grouped 
according to size and granularity (C). 
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2.7.2 Cell line information and culture requirements 
Table 2-12 Description of Cell line Origins, Characteristics and Growth Requirements 
HEK293- NFκB/TLR4/MD2 Human Complete DMEM/G418 + 
blasticidin + puromycin 
HEK293- NFκB/TLR5 Human Complete DMEM/G418 + 
blasticidin 
The HEK293 reporter cell lines (Imgenex) are stably transformed with full length human TLR/co-
receptors and an SEAP reporter gene under the control of an NFκB response element.  Following 
exposure to appropriate TLR ligands these cells express SEAP which can be detected with the use 
of quanti-blue media (Invivogen).  SEAP expression increases linearly with increasing ligand dose.  
These cell lines have epithelial-like morphology and are adherent. 
L929 Murine Complete RPMI/none 
The L929 cell line was isolated from induced sarcomas in a male C3H mouse.  It is used routinely 
for cytotoxicity testing; its culture supernatant also provides a source of MCSF for the 
differentiation of primary macrophages from mouse bone marrow.  This cell line has fibroblastic 
morphology and is adherent. 
RAW264.7 Murine Complete RPMI/none 
RAW 264.7 is a monocyte/macrophage cell line isolated from an Abelson leukaemia virus-induced 
tumour in a BALB/c mouse.  This cell line is useful for studying some aspects of host response 
and as a transfection host.  This cell line has fibroblastic morphology and is adherent. 
THP1-blue™- CD14 Human Complete RPMI/ blasticidin + 
zeocin 
The THP1 cell line is derived from an acute monocytic leukaemia found in the peripheral blood 
of a 1year old male.  These cells can be differentiated to a macrophage-like phenotype by the 
addition of phorbol 12-mysristate 13-acetate (PMA) to culture media.  THP1-blue™-CD14 cells are 
reporters expressing full-length human TLR1-10 as well as CD14, a co-receptor for some TLRs.  
Interaction between TLRs and their cognate ligand results in the expression of SEAP under the 
control of a promoter induced by NFκB and AP-1.  SEAP expression increases linearly with 
increasing ligand dose.  This cell line has lymphoblast-like morphology and grows in suspension. 
  
2.7.3 Resuscitation of frozen cell lines 
Cell lines were resuscitated from liquid nitrogen by quick thawing in a 37°C 
water bath followed by suspension in 9ml of appropriate culture medium.  The 
cell suspension was pelleted by centrifugation at 2000rpm for 2min followed by 
resuspension in 5mls of appropriate culture medium before removal to a 25cm2 
vented tissue culture flask.  Cells were cultured until 90% confluent at 37°C, 5% 
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CO2 and then sub-cultured into 75cm
2 vented tissue culture flasks to be bulked 
up for use. 
2.7.4 Routine sub-culturing techniques 
Adherent cell lines were harvested for sub-culture when between 80-90% 
confluent.  All adherent cell lines were harvested by trypsinization with the 
exception of the RAW 264.7 cell line which is harvested manually using a cell 
scraper.  Cells were treated with 2 or 4ml of trypsin-EDTA (Sigma Aldrich, UK) 
for 25cm2 or 75cm2 culture sizes, respectively.  Following addition of trypsin-
EDTA cells were incubated at 37°C for no more than 5min until all cells had 
dissociated from the flask surface.   Active trypsin was inhibited by a 5x dilution 
in appropriate culture media and removed by centrifugation of the cell 
suspension at 2000rpm for 2min.  Non-adherent cells were harvested simply by 
centrifugation at 2000rpm for 2min.  Harvested cells were counted using a 
haemocytometer and sub-cultured at the appropriate density for the particular 
cell line used. 
2.7.5 Storage of cell line aliquots in liquid nitrogen 
Additional aliquots of cell lines were prepared from 80-90% confluent T75cm2 
cultures.  Cells were harvested as detailed in section 2.7.3 and cell pellets were 
resuspended in 5ml of appropriate freeze media (either FBS + 10% DMSO or 
complete media + 10% DMSO as dictated by the cell line supplier).  5 x 1ml 
aliquots of the resuspended cells were prepared and stored at -80°C for 24hr 
before removal to liquid nitrogen. 
 
2.8 Microscopy 
2.8.1 Analysis of PLY interactions with RAW 264.7 macrophages 
2.8.1.1 Staining with CellMask deep red plasma membrane stain and Halo 
TMR-direct ligand 
1 x 106 RAW 264.7 cells were seeded on cover slips in 6 well plates and allowed 
to adhere overnight at 37°C, 5% CO2.  Non-adherent cells were removed by 
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gently washing twice with warm complete media.  1ml of 2.5µg/ml CellMask 
Deep Red Plasma membrane stain (Invitrogen, Paisley UK) was added to each 
cover slip and incubated for 5 mins at 37°C.  Cover slips were then washed three 
times with warm complete media to remove the stain.  HaloTag® fusion lysates 
were added to the cells (100µl lysate in 900µl warm complete media) and 
incubated for 30mins at 37°C.  After incubation the cells were washed gently 
three times with warm sterile PBS and fixed by incubation for 10 mins at room 
temperature with 1 ml of warm 4% paraformaldehyde/0.2M sucrose/1xPBS (pH 
7.5).  Following fixation the HaloTag® TMRDirect Ligand (Promega, Southampton 
UK) was added to the cells to label fusion proteins; a 1:200 dilution of the ligand 
was prepared in warm media to create a 5X stock solution, 100µl of stock was 
then added to 400µl of warm PBS and cells were incubated for a further 2hrs at 
37®C.  After the final incubation cells were washed three times with PBS and 
mounted onto microscope slides using Dako fluorescence mounting media 
(Dako).  
Images were captured using a Zeiss M1 Axioskop microscope at 100x 
magnification with filter set TRITC and lasers 555ex/580em and Alexa647.  
Images were taken as z – stacks 0.25µm apart to allow 3D visualization of cells 
following analysis using the Volocity software package (PerkinElmer, UK). 
 
2.8.1.2 Staining with rhodamine phalloidin and eGFP tagged PLY variants 
RAW 264.7 macrophages were cultured and prepared for staining as detailed in 
section 2.8.1.1.  1ml of a 1µg/ml solution of eGFP- tagged WT-, @6-, D123- and 
D4-PLY and an eGFP only control were added to the cover slips and incubated at 
37°C for 30mins.  The cover slips were washed and fixed as detailed above.  
Cells were permeabilized by adding 1ml of 0.1% triton x-100 and incubating at -
20°C for 3mins.  Cells were washed twice with PBS and stained by adding 5µl of 
methanolic rhodamine phalloidin (Invitrogen) stock to 200µl of PBS and 
incubating at room temperature for 20mins. The cells were washed and mounted 
as described in section 2.8.1.1 and imaged using eGFP and RFP filter sets. 
 
2.8.2 Image analysis  
Following image acquisition images were analysed using the Volocity image 
analysis software package (PerkinElmer, UK).  The captured Z- stacks were 
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compiled to produce 3D images and colocalization of stained cell features was 
analysed using the software’s colocalization tools and Pearson’s correlation 
coefficient (PCC). 
 
2.9 In Vitro analysis of recombinant PLY and its 
derivatives 
2.9.1 Analysis of PLY cytotoxicity  
2.9.1.1 Lactate Dehydrogenase Release 
Lactate dehydrogenase is a stable cytosolic enzyme that is released upon cell 
lysis.  The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega) is a 
colourimetric assay that allows % lysis in treated cells to be calculated by 
measuring LDH presence in cell culture supernatants.  This assay was performed 
according to the manufacturer’s instructions. 
 
2.9.1.2 Analysis of Apoptosis 
The ApoTox-Glo™ Triplex assay (Promega) is capable of measuring viability, 
cytotoxicity and apoptosis simultaneously in treated cells.  Cells were treated 
with PLY and its derivatives by serially double diluting the proteins from an 
initial concentration of 175nM in duplicate.  The cells were incubated at 37°C 
for 6 hours before performing the assay according to the manufacturer’s 
instructions.   
2.9.2 Treatment of mammalian cells with PLY and its derivatives 
Cellular responses to purified PLY and its derivatives were analysed by a variety 
of techniques.  In all cases PLY derivatives such as truncation mutants were 
added at equimolar concentrations e.g 1μg of PLY in 1ml is equivalent to a 
17.56nM solution therefore all PLY derivatives were used at the same molarity to 
account for differences in molecular weight.  To maintain consistency between 
assays the number of PLY monomers per cell was kept constant, for example, if 
1x105 macrophages were treated with 200μl of PLY at a concentration of 17.5nM 
this would give approximately 2.3x107 PLY monomers per cell.  This allowed the 
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use of optimum cell number and culture volume without compromising 
treatment dose. 
Note – where whole mouse serum was added to in vitro assays the total assay 
volume was kept constant as detailed above.  Serum (prepared as detailed in 
section 2.10.3) was added to each well to a concentration of 10%, i.e. 20μl of 
serum per well. 
 
2.9.3 Analysis of cytokine expression 
Culture supernatants from PLY treated cells were tested for the presence of IL-1 
beta, IL-6 and KC using R and D systems ELISA Duosets.  The manufacturer’s 
instructions were followed with the exception of volumes used; half-volumes of 
samples, antibodies and developing reagents were used, this did not affect assay 
sensitivity. 
 
2.9.4 Analysis of gene expression by RT2 qPCR 
2.9.4.1  Isolation of RNA from PLY treated mammalian cells 
2x106 Bone marrow derived macrophages were treated with 100ng/ml of LPS, 
100ng/ml (or equimolar equivalent) of PLY or its derivates or left untreated and 
incubated for 6hrs at 37°C at 5% CO2. RNA was immediately harvested using the 
GeneJet RNA isolation kit (Fermentas).  RNA samples were aliquoted and stored 
at -80°C for future analysis. 
2.9.4.2  Analysis of RNA quality and concentration 
The concentration of RNA in samples was determined using the Quibit™ 
fluorimeter (Invitrogen), according to the manufacturer’s instructions. 
RNA quality was then determined using the agilent Nano-, or Pico-chip 
depending on the concentration of RNA available.  The quality of RNA is given as 
the RNA integrity number (RIN).  RINs are given on a scale of 1-10, only samples 
with a RIN of 8 or above are taken for further analysis.   
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2.9.4.3  cDNA synthesis 
The RT2 first strand cDNA synthesis kit (Qiagen) was used to synthesize cDNA 
from RNA samples; the manufacturer’s instructions were followed.  Typically, 
1μg of starting RNA was used.  The amount of starting RNA was kept constant 
where samples were to be directly compared. 
2.9.4.4 Real-Time PCR using RT2 qPCR primer assays or RT2 qPCR profiler 
assays and RT2 SYBR green mastermixes 
RT2 qPCR profiler assays were used to analyse the expression of genes associated 
with the murine antibacterial response (cat. PAMM-148) and inflammatory 
cytokine and chemokine response (cat. PAMM-112) following PLY treatment of 
BMDM.  A selection of genes was chosen to validate these assays by individual 
PCR using the RT2 qPCR primer assays.  In both cases the manufacturer’s 
instructions for use were followed, including cycling conditions for a Chromo4, 
DNA engine opticon cycler. 
 
2.9.5 QUANTI-Blue™ assay for detection of SEAP secreted by 
reporter cell lines 
The QUANTI-Blue™ (Invivogen) assay is an enzymatic colourimetric assay that is 
used to detect alkaline phosphatase in biological samples.  In this case the assay 
was used to detect secreted embryonic alkaline phosphatase (SEAP) in reporter 
cell culture supernatants.  The assay media was prepared and used according to 
the manufacturer’s instructions.  In addition a standard curve of SEAP was 
created using cell-based alkaline phosphatase standard (Cayman Chemical), an 
eight point standard was created by performing double dilutions from a top 
concentration of 50mU/ml to 0mU/ml.  50μl of standard or sample was added to 
150μl of QUANTI-Blue™ media in a flat-bottomed 96-well plate, the plate was 
incubated at 37°C for 24hrs.  The OD 625-655nm of samples, standards and 
controls were measured using the BMG Fluostar Optima. 
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2.9.6 Analysis of protein-protein interaction by pull-down using 
HaloTagged proteins 
The HaloTag® Mammalian Pull-down system (Promega, G6500) was used 
according to a modified version of the manufacturer’s instructions.  50µl samples 
were taken at every step of the protocol for analysis by SDS-PAGE and western 
blotting to ensure stringency of the protocol.  Briefly, 400µl of HaloTag® fusion 
lysate was diluted in 800µl of 1 x TBS and added to 200µl of prepared Halo-link 
resin; binding reactions were incubated at room temperature for 1hr on a tube 
rotator.  Unbound proteins were removed by washing x 5 with 1x TBS + 0.05% 
IGEPAL (Sigma-Aldrich, CA-630).  Mammalian cell lysate was prepared for each 
reaction from 1 x 106 RAW 264.7 cells by resuspending pelleted cells with 300µl 
of mammalian lysis buffer and 30µl protease inhibitor (kit components).  The 
mammalian cell lysate + 700µl of 1 x TBS was added to the Halo-link resin and 
incubated at 37°C for 1hr with shaking.  The resin preparation was washed x5 
with 1 x TBS + 0.05% IGEPAL.  Bound proteins were eluted by incubation at room 
temperature for 30min with 100µl of SDS-elution buffer (kit component).  
Finally, to confirm the presence of fusion proteins the resin preparation was 
treated with 100µl of Turbo TEV protease (Geneway, USA) overnight at 4°C.  
Cleaved proteins were harvested by centrifugation of the resin at 2000 RPM for 2 
minutes before removal of the supernatant. 
Fraction samples were initially analysed by SDS-PAGE, western blot and silver 
staining (Invitrogen, LC6070) to ensure absence of proteins in the wash fractions 
and absence of PLY in the elution fractions. 
Samples were then run on a large SDS-PAGE gel (Hoefer, USA) and stained with 
coomassie blue.  Bands of interest were excised and stored at -20°C until ready 
for analysis by mass spectrometry. 
 
 Mass Spectrometry 
 
 Proteins within the excised bands were identified by tandem mass spectrometry 
(MS/MS) at the Burchmore lab mass spectrometry facility at the University of 
Glasgow.  Results were provided as analysed Mascot files. 
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2.9.7 Analysis of Actin Binding by ELISA 
2.9.7.1 Preparation of actin solution 
This assay was replicated from Hupp et al, 2013.  Briefly, non-muscle actin 
(Cytoskeleton Inc.) was reconstituted in dH2O to a conc. of 0.4mg/ml and 
incubated on ice for 60 minutes.  The resulting monomeric actin solution was 
diluted 1:10 in actin polymerization buffer (APB, appendix) and incubated at 
room temperature for 1 hour.  The solution was centrifuged for 1 hour at 
100,000g at room temperature for 1 hour to pellet polymerized actin.  25.2μl of 
the resulting supernatant was diluted in 4974.8μl of PBS + 0.1% BSA. 
2.9.7.2  Actin binding ELISA 
A 96-well high binding ELISA plate (Costar) were coated in duplicate with 350, 
175 and 87.5nM of PLY, Δ6PLY, D123PLY, D4PLY or 1μg/ml BSA as a negative 
control and incubated overnight at 4°.  The plates were washed x5 with 
PBS/Tween and blotted before addition of 50μl of actin solution.  After a two 
hour incubation at room temperature the plate was washed x5 and 50μl of anti-
actin antibody (Cytoskeleton, Inc.) (diluted 1:1000) was added to each well, the 
plate was incubated for a further 1 hour at room temperature.  The plate was 
washed x5 and 50μl of anti-rabbit HRP (1:1000) was added to the plate.  After 30 
minutes at room temperature 50μl of streptavidin (1:200) was added.  The plate 
was incubated for 20 minutes, washed x5 and developed using 50μl of Fast OPD 
(Sigma), development was stopped after 5 min by addition of 50μl 3M HCL.  The 
OD at 485-10nm was read using the BMG labtech Fluostar Optima. 
 
 
2.10  In Vivo analysis of recombinant PLY and its 
derivatives 
All in vivo experiments were carried out in accordance with the UK animals 
(scientific procedures) act 1986.  Mice had access to food and water ad libitum 
and were kept at a constant room temperature of 20-22°C with a 12 hour 
light/dark cycle.  All animal procedures were performed under the project 
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license of Professor Tim Mitchell and received ethical approval from the Ethical 
Review Board at the University of Glasgow.  Unless otherwise stated all animal 
handling, sample processing and analysis was performed by the author, 
Catherine Dalziel. 
2.10.1 Intranasal vaccination 
To study murine mucosal and systemic immune responses to pneumolysin fusion 
vaccines, animals were vaccinated intranasally according to the schedule 
detailed in table 2-13.  Briefly, mice were lightly anaesthetized using 3.5% 
isofluorane/1.5% O2 (1.5L per minute) (Astra-Zeneca, Macclesfield UK) and 20μl 
of prepared pneumolysin fusion vaccine was instilled into the nares by gentle 
pipetting.  The doses used were 0.2μg of lytic fusions or 2μg of non-lytic fusions 
in a total volume of 20μl PBS, 10μl was added to each nostril.  Following 
vaccination the animals were monitored until they had recovered from the 
effects of anaesthesia.  As indicated in table 2-13 animals were vaccinated 3 
times over a 42 day schedule with a 14 day period between each vaccination, 
blood samples were taken from the lateral tail vein before each dose of vaccine.  
On day 42 animals were humanely sacrificed and terminal samples were taken by 
cardiac puncture (blood) and nasopharyngeal wash.  
Table 2-13 Immunization schedule. 
Day Procedure 
0 Take 20μl sample of venous blood from lateral 
tail vein (PB).  Intranasally immunize with 20μl 
of test vaccine. 
14 Take 20μl sample of venous blood from lateral 
tail vein (B1).  Intranasally immunize with 20μl 
of test vaccine. 
28 Take 20μl sample of venous blood from lateral 
tail vein (B2).  Intranasally immunize with 20μl 
of test vaccine. 
42 Humanely sacrifice animal by exsanguination 
under terminal anaesthetic (B3), perform nasal 
wash. 
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Table 2-14 Table of transgenic animals and their genetic backgrounds 
Transgenic animal Genetic background 
C3-/- C57BL/6 
NLRP3-/- BALB/c 
TLR4-/- BALB/c 
IL-17-/- C57BL/6 
 
2.10.2 Analysis of Antibody Response in Immunized Mice 
2.10.2.1 Analysis of immunoglobulin G presence in serum 
Sera obtained following intranasal vaccination were tested for the presence of 
IgG by ELISA.  96-well EIA plates (Corning) were coated with 50μl of capture 
antigen at a concentration of 1μg/ml (except those in the second column which 
are negative control wells) and incubated O/N at 4°C. The plates were washed 
X3 with PBST (PBS + 0.05% tween-20) and blotted dry.  Free binding sites were 
blocked by adding 150μl of 1% BSA in PBS and incubating for 1hr at 37°C.  The 
wash step was repeated.  The plates were prepared for sample addition by 
adding 98μl of PBS to each well across the top row and 80μl to every other well.  
2μl of positive control sera was added to the first two wells and 2μl of test sera 
was added in duplicate to the rest of the top row.  The samples and control 
were diluted 1 in 5 by transferring 20μl from the top row to the second row and 
mixing well, this was repeated until all rows had been diluted.  The plate was 
incubated for 2hr at 37°C.  The wash step was repeated.  The detection 
antibody, anti-mouse gamma (γ chain) biotin conjugate (Sigma) was diluted 1 in 
1000 and 50μl of this solution was added to each well of the plate.  The plate 
was incubated for 1hr at 37°C.  The wash step was repeated.  Streptavidin HRP 
conjugate (Sigma) was also diluted 1 in 1000 and 50μl was added to every well of 
the plate and incubated for 30min at 37°C.  A final wash step was performed.  
The plates were developed using 50μl of Fast OPD (Sigma) and development 
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stopped after 5 min by addition of 50μl 3M HCL.  The OD was read using the BMG 
labtech Fluostar Optima.  
2.10.2.2 Analysis of IgA presence in nasal washes 
Nasal washes were collected from immunized mice at the end of the 
immunization schedule (Day 42).  The presence of IgA in nasal washes was 
measured by ELISA as detailed in section 2.10.2.1 with the following exceptions; 
nasal wash samples were added neat to the top well of the ELISA plate before 
serial dilution, the detection antibody used is anti-mouse IgA alpha-chain 
specific (Sigma) at a 1:500 dilution and the plates are incubated for 1 hour with 
streptavidin HRP solution rather than 30 minutes. 
2.10.2.3 Determining IgG clonotype generated in response to PLY-fusion 
vaccines 
Following confirmation of an IgG antibody response in immunized mice the 
Southern Biotech Antibody Clonotyping ELISA kit was used to determine the 
clonotype(s) of the response i.e (IgG1, 2a, 2b or 3).  The manufacturer’s 
protocol was altered slightly to give optimized performance with available 
reagents and samples.  Briefly, 96-well EIA plates (Corning) were coated with 
50μl of capture antigen at a concentration of 1μg/ml and incubated O/N at 4°C. 
The plates were washed X3 with PBST (PBS + 0.05% tween-20) and blotted dry.  
Free binding sites were blocked by adding 200μl of 1% BSA in PBS and incubating 
for 2 hours at room temperature.  The wash step was repeated.  The plates were 
prepared for sample addition by adding 98μl of PBS to wells A2-12 and 80μl to 
every other well, except A1 to which 100μl of diluent was added.  2μl of test 
sera was added to every well in the top row.  The samples were diluted 1 in 5 by 
transferring 20μl from the top row to the second row and mixing well, this was 
repeated down the plate until discarding 20μl from row H.  The plate was 
incubated for 2hr at room temperature.  The wash step was repeated.  The 
Southern Biotech kit provides HRP conjugated antibodies directed against the 
following antibody isotypes/subclasses – Ig, IgG1, IgG2a, IgG2b, IgG3 and IgA, 
these antibodies were diluted 1:500 and added to the plate as shown in table 2-
15. 
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Table 2-15 Subclasses ELISA Secondary Antibody Layout. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
B αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
C αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
D αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
E αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
F αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
G αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
H αIg αIg αIgG1 αIgG1 αIgG2a αIgG2a αIgG2b αIgG2b αIgG3 αIgG3 αIgA αIgA 
 
The plates were incubated at room temperature for 1 hour, the wash step was 
repeated and 50μl of extravidin HRP (1:2000) was added to each well.  The 
plates were incubated at room temperature before performing a final wash step.  
The plates were developed using 50μl of Fast OPD (Sigma) and development 
stopped after 5 min by addition of 50μl 3M HCL.  The OD at 485-10nm was read 
using the BMG labtech Fluostar Optima. 
 
2.10.3 Preparation of whole mouse serum and preservation of 
complement activity. 
Briefly, mice were anaesthetized using 3.5% isofluorane/1.5% O2 (1.5L per 
minute), while under anaesthesia the animals were humanely culled by 
performing a terminal bleed via cardiac puncture, followed by cervical 
dislocation.  Harvested blood was immediately transferred to a pre-chilled 15ml 
Falcon tube and allowed to clot on ice for 1 hour.  Serum was separated from 
clotted blood by centrifugation at 15,000rpm for 20 minutes at 4°C and 
immediately aliquoted and stored at -80°C.  It is essential that harvested serum 
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is thawed on ice, kept chilled and handled carefully until point of use; allowing 
the serum to reach room temperature or rough handling risks activating the 
alternative pathway of complement activation and depleting/exhausting 
complement components in the sample. 
 
2.11 Statistical analysis 
All statistical analysis was performed using GraphPad® instat (GraphPad® 
software, San Diego, California, USA).  ELISA, LDH and Quanti-blue assay results 
were analysed by one-way analysis of variance (one-way ANOVA) followed by a 
Bonferroni’s post-test.  The only exception to this was analysis of antibodies 
present in the sera of immunised mice (chapters 5), this was analysed by 
unpaired t test.  Probability (p) values of <0.05 were considered statistically 
significant.  Statistically significant differences in this work are indicated by * 
(p=<0.05), ** (p=<0.01), *** (p=<0.001). 
 
 
  
 90 
 
 
  
91 
 
 
3. Functional Analysis of Recombinant Pneumolysin 
and its Derivatives 
This chapter describes preliminary studies into the biological functions of PLY 
potentially responsible for its adjuvant activity.   
As previously discussed, there is evidence in the literature that PLY can directly 
bind TLR4.  However, there is not a consensus in the field and it is often 
suggested that biological responses attributed to PLY are in fact due to 
contaminating LPS.  This work sought to further elucidate the relationship 
between PLY and TLR4, with particular reference to cytokine induction via this 
pathway. 
Throughout this project it was essential to appropriately control for potential 
contaminating TLR ligands; a novel process for creating vehicle controls was 
devised and used to test for contaminating TLR ligands that could generate false 
positive results.  Additionally, the quality and cytolytic activity for all PLY 
variants was analyzed and in vitro treatment models were devised and 
optimized. 
The nomenclature of proteins used in this project has been refined for ease of 
understanding and to conserve space, the key in table 3-1 defines all 
abbreviations used in this project. 
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Table 3-1 Abbreviations and Definitions of PLY variants used in this Project 
Abbreviation Description 
PLY Full-length lytic pneumolysin 
Δ6 deletion of the amino acids alanine and 
arginine at positions 146-147, removes lytic 
activity in full-length PLY 
D123 A truncation mutant consisting of domains 1,2 
and 3 of PLY (aa 1-359) 
D4 A truncation mutant consisting of domain 4 of 
PLY (aa 360-471) 
e- Indicates the protein has been N-terminally 
tagged with eGFP 
h- Indicates the protein has been N-terminally 
tagged with the Halo-Tag. 
No precursor Where there is no precursor a protein should 
be assumed to be N-terminally His-tagged for 
purification purposes only. 
 
 
 
3.1 Analysis of Cytolytic Activity in Purified Recombinant 
PLY and its Derivates 
To determine the optimum conditions for analyzing immunological properties of 
PLY in vitro, the cytolytic activity of PLY and its derivatives was determined in 
multiple cell types.   
3.1.1 Haemolytic Activity 
The haemolytic activity of all proteins used in this project was determined prior 
to use.  The haemolytic activity of PLY and its derivatives is measured in 
haemolytic units per picomole (HU/pmol) of toxin; one haemolytic unit is 
defined as the concentration of toxin required to lyse 50% of a 2% erythrocyte 
solution. 
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Analysis of haemolytic activity showed that all PLY truncation mutants and those 
containing the delta 6 mutation did not have lytic activity, all other full length 
versions of PLY including retained lytic activity (figure 3-1).   
 
 
Figure 3-1  Analysis of haemolytic activity of PLY variants.  
Haemolytic assays were performed to calculate the specific activity of His-tagged PLY 
variants (A), eGFP-tagged PLY variants (B) and Halo-tagged PLY variants (C). 50μl of 
purified PLY or derivatives (17.5nM) and 50μl of lysates (diluted 1:5) was added in duplicate 
to the first wells of a 96-well plate and serially diluted (1:2) horizontally across the plate.  
Following incubation with a 2% sheep RBC solution released haemoglobin was measured at 
540nm using a Fluostar Optima plate reader.  O.D. measurements were used to create dose 
response curves in Graphpad Prism indicating % haemolysis and subsequently to calculate 
specific activity (HU/pmol).  Data points are mean % haemolysis and represent technical 
duplicates. 
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The log dose response curves shown in figure 3-1 were used to calculate specific 
activity for each lytic version of PLY; these values are given per picomole in 
table 3-2. 
Table 3-2 Calculated Haemolytic Activity of Lytic PLY Variants 
Protein HU/pmol 
PLY 41.27 
e-PLY 10.40 
h-PLY 49.87 
 
 
3.1.2 Cytotoxic Activity/Lysis  
Analysis of the haemolytic activity of PLY and its derivatives showed that only 
full-length wild-type PLY was capable of causing erythrocyte lysis.  This is also 
true in nucleated cells, none of the truncation or Δ6 mutants caused lysis of 
bone marrow derived macrophages (BMDM), L929 fibroblasts or RAW264.7 
macrophages as determined by LDH release (data not shown except where figure 
3-3 shows Δ6PLY treated BMDM).  The purpose of the lactate dehydrogenase 
assay (LDH) was two-fold, firstly LDH release was used as an indicator of pore 
formation (it should be noted that apoptotic cells do not release LDH and so this 
is a measure of necrosis and/or pore formation rather than total cell death).  
Secondly, as IL-1β initially exists in a precursor form (Pro-IL-1β) which is also 
detected by ELISA, the % pore formation was used to adjust IL-1β measured by 
ELISA to account for pro-IL-1β that may have ‘leaked’ into the supernatant as a 
result of pore formation. 
It has been shown previously that human monocytic and epithelial cell lines have 
different sensitivities to PLY (Hirst et al., 2002); analysis of LDH release by L929, 
RAW264.7 and BMDM concurs with these findings (figures 3-2 and 3-3). Both the 
L929 and RAW264.7 cell line were equally resistant to lysis at treatment 
durations of 1 and 3 hours, even at high doses of 175nM PLY both cell lines 
showed less than 20% lysis.  After 6 hours of treatment with PLY there is a 
marked difference in survival between the cell lines.   Analysis of dose response 
curves revealed that 50% lysis was achieved in PLY treated L929 at 100nM, in 
comparison only 25nM PLY was required to lyse 50% of RAW264.7 cells.   
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Figure 3-2 Analysis of cytolytic activity of PLY against L929 and RAW264.7 macrophages.   
L929 and RAW 264.7 cell lines were seeded at 1x10
5
 cell/well in 100μl complete RPMI in a 96-
well plate.  In a separate 96-well plate PLY was serially diluted (1:2) across the plate in 
triplicate from a starting conc. of 350nM. 100μl of PLY dilutions were transferred to the plate 
containing L9292 and RAW 264.7, this resulted in a top PLY conc. of 175nM. The cells were 
incubated at 37°C for 1, 3 and 6 hours. Supernatants were collected and analysed for LDH 
release using the Cytotox®96 Non-radioactive Cytotoxicity Assay (Promega).  LDH release 
from both cell lines was used to create dose-response curves in Graphpad Prism and 
subsequently to calculate percentage lysis. These experiments were performed once, data 
are mean % lysis from three technical replicates. 
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Bone marrow derived macrophages were used in in vitro models of PLY 
treatment to investigate cytokine/chemokine and gene expression.  To optimize 
the treatment conditions the degree of cytotoxicity caused in PLY treated BMDM 
was measured by LDH release at PLY conc. of 175, 17.5 and 1.75nM and 
incubation periods of 3, 6, 12 and 24 hours (figure 3-3).  The percentage of lysed 
cells in PLY treated BMDM is significantly increased compared to untreated or 
LPS treated BMDM.  The cytotoxic activity of PLY was dose-dependent; PLY conc. 
of 175, 17.5 and 1.75nM caused ~50, 30 and 10% lysis, respectively.  The 
percentage lysis does not significantly increase after 3 hours of treatment.  In 
addition BMDM were more resistant to lysis than either L929 or RAW264.7, 175nM 
of PLY was required to achieve 50% lysis.   
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Figure 3-3  LDH release in PLY treated bone marrow derived macrophages at 3(A), 6(B), 
12(C) and 24(D) hours.  
BMDM were seeded at 1x10
5
 cell/well in a 96-well plate and treated with PLY at 
concentrations of 175, 17.5 and 1.75nM for 3, 6, 12 and 24 hours in a total well volume of 
200μl.  Supernatants were collected and analysed for LDH release using the Cytotox®96 
Non-radioactive Cytotoxicity Assay (Promega).  LDH release from cells was used to 
calculate percentage lysis.  Statistical significance was tested by one-way ANOVA 
comparing all columns to the control column (untreated), *(p<0.05), **(p<0.01), ***(p<0.001).  
Two experiments were performed with three technical replicates per condition, data are 
mean+SEM. 
 
 
 
PLY has previously been shown to induce apoptosis in dendritic cells and 
cochlear hair cells (Beurg et al., 2005; Littmann et al., 2009).  Figure 3-4 
confirms an apoptotic response to PLY in BMDM and also demonstrates that this 
is dependent on lysis as Δ6PLY, D123PLY and D4PLY did not induce apoptosis.   
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Figure 3-4 Apoptosis in BMDM treated with PLY, Δ6PLY, D123PLY, D4PLY.  
 BMDM were seeded at 1x10
5
 (100μl total volume) in a 96-well plate and incubated for 6 
hours at 37°C with 100μl of either PLY, Δ6PLY, D123PLY or D4PLY at a final conc. ranging 
from 175nM to 1.36nM (serial double dilutions), an untreated control was included.  The 
Promega Apotoxglo assay was used to measure caspase3/7 by luminescence as per the 
manufacturer’s instructions. Data shown are mean+SEM from three technical replicates, this 
experiment was performed once. 
 
3.2 Analysis of LPS Content and Preparation of Vehicle 
Controls 
As the recombinant proteins for this study were expressed and purified from E. 
coli it was necessary to ensure that contamination with endogenous proteins etc. 
was negligible.  One particular concern when purifying proteins from E. coli is 
the presence of contaminating LPS, anion-exchange chromatography is able to 
separate LPS from the desired protein, however, LPS is extremely difficult to 
remove entirely and so must be quantified to ensure levels are acceptably low.  
To ensure that trace contaminants were not responsible for any observed 
biological activity in these studies vehicle controls were prepared using Ni-
magnetic beads to remove the toxin.  The Ni-magnetic beads were used to 
remove His-tagged proteins from solution, leaving behind any contaminants.  
The remaining solutions were used as vehicle controls to demonstrate that the 
responses seen to PLY and its derivatives were due to the specific proteins and 
not contaminants.   
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3.2.1 LPS testing  
As this study centred around the immune response to PLY, with a particular 
focus on TLR4, it was vital that responses observed were due to PLY and not LPS.  
The minimum threshold dose of LPS required to elicit an inflammatory response 
in macrophages is 1ng/ml (Pestka & Zhou, 2006; Zhang & Morrison, 1993).  Table 
3-3 gives the LPS concentration of a range of proteins purified by the same 
methods as those used in this project.  Given that in this study the maximum 
treatment dose of PLY in vitro is 175nM and that 1ng of LPS is equivalent to 
10EU, the purified proteins are below the defined LPS concentration cut-off 
(table 3-3). 
Table 3-3 LPS Concentration in Purified Recombinant PLY and its Derivatives. 
Protein LPS (EU/μg of protein)  
PLY 0.10 
Δ6PLY 0.073 
D123PLY 0.047 
D4PLY 0.068 
e-PLY 0.37 
e-Δ6PLY 0.98 
e-D123PLY 0.37 
e-D4PLY 0.067 
 
3.2.2 Preparation of vehicle controls 
Vehicle controls were prepared from His-tagged PLY and its derivatives using 
PureProteome nickel-magnetic beads.  The beads were washed with PBS to 
remove the storage buffer and resuspended in the undiluted protein 
preparations.  Following an incubation period the nickel-bead bound proteins 
were removed from the suspension using a magnetic rack; the resulting solutions 
were used as vehicle controls.  Finally, proteins were eluted from the beads 
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using the recommended elution buffer as additional controls.  It was not possible 
to elute either D123PLY or D4PLY from the beads (table 3-4); however, it was 
possible to achieve total protein removal in all vehicle controls (figure 3-5 shows 
complete removal of PLY and Δ6PLY from vehicle controls).   Equal volumes 
(200µl) of protein solution and elution buffer were used and so the reduced 
protein concentration in elution controls is not a consequence of dilution. 
Table 3-4 Protein Concentration of Controls Created using Ni-magnetic Beads 
Protein Starting Conc. Vehicle Conc. Elution Conc. 
PLY 1.065mg/ml 0mg/ml 0.253mg/ml 
Δ6PLY 0.786mg/ml 0mg/ml 0.053mg/ml 
D123PLY 1.900mg/ml 0mg/ml 0 
Δ6D123PLY 1.200mg/ml 0mg/ml 0 
D4PLY 0.530mg/ml 0mg/ml 0 
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Figure 3-5  Analysis of vehicle controls and eluted proteins following Ni-magnetic bead 
treatment of PLY and Δ6PLY.  
 Purified and eluted proteins were diluted to 1mg/ml (vehicle controls were undiluted) and 
mixed 1:4 with SDS-PAGE loading buffer. 5μl of Seeblue Plus 2 molecular weight marker 
and 10μl of the proteins were loaded into the wells of a 10% SDS-PAGE gel and 
electrophoresed at 180 V for 40 minutes.  The proteins were transferred onto nitrocellulose 
membrane and detected by western blotting using rabbit anti-PLY (1:1000) and donkey anti-
rabbit-HRP (1:2000).  The blot was developed using 4-chloro 1-napthol.  Lane 1 =purified 
PLY, 2= PLY vehicle, 3= eluted PLY, 4=purified Δ6PLY, 5= Δ6PLY vehicle, 6= eluted Δ6PLY. 
 
The haemolytic activity in PLY, PLY vehicle control and PLY eluted control from 
nickel-magnetic beads was assessed by haemolytic assay (figures 3-6 and 3-7).  
Haemolytic activity was absent in the vehicle control as expected, however, 
haemolytic activity was also absent in the eluted PLY control.  There is no 
obvious explanation for the absence of haemolytic activity following nickel-
magnetic bead treatment; this is further explored in the discussion section of 
this chapter.  
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Figure 3-6  Haemolytic assay of purified PLY, Ni-cleaned PLY vehicle and eluted PLY.  
 Purified PLY was serially diluted from a starting conc. of 1μg/ml whereas PLY vehicle and 
eluted PLY were added neat.  Intact erythrocytes were pelleted (A) by centrifugation and 
supernatants (B) were collected and analysed for the presence of haemoglobin by 
measuring absorbance at 540nm.   
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Figure 3-7 Analysis of haemolytic activity of PLY, PLY vehicle and eluted PLY following Ni-
magnetic bead treatment. 
 50μl of purified PLY (17.5nM) and 50μl of vehicle and eluted PLY controls (prepared with 
equal volumes as PLY control) were added in duplicate to the first wells of a 96-well plate 
and serially diluted (1:2) horizontally across the plate.  Following incubation with a 2% 
sheep RBC solution released haemoglobin was measured at 540nm using a Fluostar Optima 
plate reader.  OD measurements were used to create dose response curves in Graphpad 
Prism and calculate % haemolysis.  Data points are mean % haemolysis from two technical 
replicates per dilution, this experiment was performed once. 
 
 
 
Figure 3-8 shows the final SDS-PAGE analysis of PLY, Δ6PLY, D123PLY, 
Δ6D123PLY, D4PLY and their respective vehicle controls.  All the proteins and 
vehicle controls are free from contaminating proteins.   
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Figure 3-8 SDS-PAGE analysis of purified PLY derivatives. 
Purified proteins were diluted to 1mg/ml (vehicle controls were undiluted) and mixed 1:4 
with SDS-PAGE loading buffer. 5μl of Seeblue Plus 2 molecular weight marker and 10μl of 
the proteins were loaded into the wells of a 10% SDS-PAGE gel and electrophoresed at 180 
V for 40 minutes.  The gel was subsequently stained using coomassie blue stain.  PLY (1), 
Δ6PLY (3), D123PLY (5), Δ6D123PLY (7), D4PLY (9) and their respective vehicle control 
(2,4,6,8 and 10). 
 
 
 
3.3  Is PLY a TLR4 ligand? 
The THP-1 blue CD14 cell line (table 2-12) is a reporter cell line stably 
transformed with a plasmid expressing secreted embryonic alkaline phophatase 
(SEAP) in a dose-dependent manner upon ligation of TLR.  Human TLR1-10 are 
expressed by this cell line, upon ligation the transcription factors NfκB and AP-1 
induce expression of SEAP.  A colourimetric assay, QUANTI-Blue™, is used to 
detect SEAP in cell culture supernatants.   
To determine if there were any TLR ligands in the purified proteins THP-1 blue 
CD14 cells were treated for 24 hours with either purified proteins, their vehicle 
controls or (where possible) eluted proteins.  Protein solutions were prepared 
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for a final concentration of 175, 17.5 or 1.75nM and vehicle controls solutions 
were prepared using the same volumes as their respective protein at 175nM.  
After 24 hours the culture supernatants were collected and analysed for SEAP 
presence using the QUANTI-blue™ assay (figure 3-9). 
The THP-1 blue CD14 cells did not report any TLR activity in the vehicle controls. 
Interestingly, the cells did respond in a dose-dependent manner to all PLY 
variants. The production of SEAP was restored in response to vehicle controls 
when eluted PLY and Δ6PLY was added back into the solution.  No SEAP is 
produced in response to 175nM PLY (A), this is likely because of early cell death.  
As seen in figures 3-6 and 3-7 the elution process abrogated lytic activity in PLY, 
this results in significant SEAP production in response to eluted PLY at 175nM 
demonstrating that TLR activation is not dependent on lytic activity.  This is 
mirrored in figure 3-9 (B), non-lytic Δ6PLY treatment results in significant SEAP 
production at all three doses.  However, the production of SEAP in response to 
Δ6PLY at doses of 17.5 and 1.75nM was lower than that induced by PLY at the 
same concentrations; it was for this reason that the Δ6D123PLY truncation 
mutant was created to test the effects of the delta 6 deletion without the 
confounding factor of pore formation.  Both D123PLY and D4PLY induced SEAP 
production in the THP-1 blue CD14 cell line indicating TLR ligand sites in both 
domains.   
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Figure 3-9 SEAP production in THP1-blue CD14 reporter cells following treatment with PLY 
variants.   
Cells were treated with (A) - PLY, (B) - Δ6PLY, (C) – D123PLY and (D) – D4PLY, their 
respective vehicle controls and where possible eluted proteins. THP1-blue CD14 cells were 
seeded at 1x10
5
 cells/well and treated with PLY variants at 175, 17.5 and 1.75nM in a total 
well volume of 200μl.  Vehicle controls were prepared identically to PLY variants.  Following 
a 24 hour incubation at 37°C supernatants were harvested from treated cells and tested for 
the presence of SEAP using QUANTI- Blue medium.  Statistical significance was tested by 
one-way ANOVA comparing all columns to the control column (untreated), *(p<0.05), 
**(p<0.01), ***(p<0.001).  The experiments were performed twice with three technical 
replicates per condition, data are mean+SEM. 
 
The results using THP-1 blue CD14 cells gave strong indications that PLY could be 
a TLR4 ligand, to test this further HEK293/TLR4/MD2/SEAP and 
HEK293/TLR5/SEAP reporter cell lines were tested with full length and 
truncation versions of PLY.  The HEK293 cell lines (table 2-12) are reporters that 
function similarly to THP-1 blue CD14 cells.  The only TLR endogenously 
expressed by HEK293 cells is TLR5, therefore, it is possible to isolate interactions 
between individual TLR and PLY using the HEK293/TLR5/SEAP reporter as a 
control.  The HEK293/TLR5/SEAP cell line produced SEAP in response to flagellin 
but not to LPS or any of the PLY variants (figure 3-10).  The 
HEK293/TLR4/MD2/SEAP cell line responded to both LPS and flagellin (due to 
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the presence of endogenous TLR5).  Figure 3-11 shows that the 
HEK293/TLR4/MD2/SEAP cell line reported TLR4 ligation in response to Δ6PLY, 
D123 and Δ6D123 but not PLY or D4PLY.  There was no significant difference in 
SEAP production between D123 and Δ6D123. 
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Figure 3-10 SEAP production in HEK293/SEAP/TLR5 reporter cells following treatment with 
PLY variants.   
HEK293/SEAP/TLR5 cells were seeded at 1x10
4
 and treated with PLY, Δ6PLY, D123PLY, 
Δ6D123PLY or D4PLY at 175, 17.5 or 1.75nM in a total assay volume of 200μl for 24 hours at 
37°C.  Supernatants were harvested from treated cells and the presence of SEAP was tested 
using QUANTI- Blue medium.  A standard curve of purified SEAP was used to quantify the 
concentration of SEAP in supernatants. Statistical significance was tested by one-way 
ANOVA comparing all columns to the control column (untreated), *(p<0.05), **(p<0.01), 
***(p<0.001).  This experiment was performed once with three technical replicates per 
condition, data are mean+SEM. 
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Figure 3-11 SEAP production in HEK293/SEAP/TLR4/MD2 reporter cells following treatment 
with PLY variants.   
HEK293/SEAP/TLR4/MD2 cells were seeded at 1x10
4
 cells/well and treated with either (A) – 
PLY or Δ6PLY, (B) – D123PLY or Δ6D123PLY or (C) – D4PLY.  Cells treated with PLY variants 
at 175, 17.5 or 1.75nM in a total well volume of 200μl for 24 hours at 37°C.  Supernatants 
were harvested from treated cells and the presence of SEAP was tested using QUANTI- Blue 
medium.  A standard curve of purified SEAP was used to quantify the concentration of 
SEAP in supernatants. Statistical significance was tested by one-way ANOVA comparing all 
columns to the control column (untreated), *(p<0.05), **(p<0.01), ***(p<0.001).  This 
experiment was performed once with three technical replicates per condition, data are 
mean+SEM. 
 
These findings concur with those in the literature that show PLY to be capable of 
binding TLR4, in addition this study identified that domains 1-3 contain the TLR4 
binding site.  Interestingly, D4PLY showed TLR activity in the THP-1 CD14 blue 
screen but further analysis has shown that this did not belong to TLR4.  This 
would suggest that D4 also contains an as yet unidentified TLR binding site. 
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3.4  Cytokine expression in PLY treated BMDM 
The cytokine and chemokine profile induced in the initial response to an 
adjuvant instructs the phenotype of the final immune response (cell type, 
antibody isotype and clonotype etc.).  Initial investigations into the cytokine 
profile induced by PLY were focussed on IL-6, KC and IL-1β.  PLY has previously 
been shown to induce IL-6 in vitro (Malley et al., 2003; Rijneveld et al., 2002) is 
induced during pneumococcal infection (Antunes et al., 2002) and has a 
protective role in pneumococcal disease (van der Poll et al., 1997), little or no 
IL-6 was found in the BMDM treatment model.  In a pilot study of PLY-induced 
gene expression in the BMDM model, IL-6 was found to be upregulated 
(appendix).  It is possible that the production of IL-6 is a late response and 
additional time points should be added to the in vitro assay as IL-6 was found in 
BALF of mice following instillation of PLY into the lungs (Kirkham, 2006). 
3.4.1 The IL-1β hypothesis 
Interleukin-1 beta is a pleiotropic inflammatory cytokine and its production is 
tightly controlled, this process can be simplified into two stages caused by 
pathogen associated molecular patterns (PAMP).  The first stage is transcription 
of pro-IL-1β mediated by TLR ligation, the second is assembly of the 
inflammasome which culminates in the catalytic cleavage of Pro-IL-1β into its 
active form.  Pro-IL-1β must be catalytically cleaved by caspase-1, which itself 
exists in precursor form (Pro-caspase-1).  Pro-caspase-1 is cleaved into its active 
form by the inflammasome, a multi-protein platform.  The Nod-like receptors 
NLRC4, NLRP1 and NLRP3 are involved in the assembly of inflammasomes 
(Franchi et al,. 2009), the NLRP3 inflammasome (described in section 1.6.1) is 
known be activated by PLY via pore formation. 
It was hypothesized that as PLY is a putative TLR4 ligand and induces NLRP3 
activation via pore formation that IL-1β would be expressed and secreted in 
BMDM in response to PLY treatment.  As IL-1β is a highly inflammatory cytokine 
it was thought that this could explain the difference in the magnitude of 
antibody titres seen in response to e-PLY and e-Δ6PLY immunization (figure 3-
12). 
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Figure 3-12 The IL-1β hypothesis. 
 
 
As shown in figure 3-13 PLY treated BMDM do not produce IL-1β in response to 
treatment with either PLY or Δ6PLY alone.  However, IL-1β is produced in a 
dose-dependent manner in response to PLY where a 2 hour pre-treatment with 
100ng/ml LPS has been given.   
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Figure 3-13 IL-1β production in BMDM treated with PLY or Δ6PLY.   
BMDM were seeded at 1x10
5
/well in a 96-well plate.  A 2 hour pre-treatment with 100ng/ml 
LPS was given to half of the seeded cells (200μl total well volume).  After two hours all cell 
supernatants were removed and replaced with either 100ng/ml LPS, medium, PLY or Δ6PLY 
at 175, 17.5 or 1.75nM (200μl total well volume) and incubated for 6 hours at 37°C.  The cell 
supernatants were harvested and IL-1β was measured by ELISA.  Statistical significance 
was tested by one-way ANOVA comparing all columns to the control column (untreated), 
*(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed three times with three 
technical replicates per condition, data are mean+SEM. 
 
 
This study has shown that in the BMDM model of PLY treatment IL-1β is not 
produced in response to PLY alone, this is unexpected as results from this 
chapter clearly show that PLY is capable of TLR-binding and PLY is known to 
activate the NLRP3 inflammasome (McNeela et al., 2010).  Therefore the 
hypothesis of IL-1β production initially proposed is not true (at least in this cell 
type) as shown in figure 3-14. 
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Figure 3-14 Putative model of PLY-dependent IL-1 beta production, version 1.   
This model of IL-1β production, where PLY induces Pro-IL-1β via TLR stimulation and 
mediates its cleavage into active IL-1β through activation of the NLRP3 inflammasome by 
pore formation does not results in IL-1β production in BMDM.  
 
 
3.4.2 KC expression in response to PLY and the role of TLR4 
KC is the murine homologue of IL-8 (CXCL-1).  This chemokine is highly 
chemotactic for neutrophils and is rapidly upregulated by tissue resident 
macrophages in response to ligation of TLR2, 3 and 4 (Filippo et al., 2013a).  
BMDM produced significant concentrations of KC in response to PLY, Δ6PLY and 
D123 but not D4PLY (figure 3-15(A)).  In a model using BMDM generated from 
TLR4-/- mice KC was produced in response to full length PLY variants only and 
the KC previously seen in response to D123 was lost (figure 3-15(B)).   
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Figure 3-15 KC production in (A – MF1) or (B – TLR4-/-) BMDM treated with either PLY, 
Δ6PLY, D123PLY or D4PLY.   
BMDM were seeded at 1x10
5
 cells/well and treated with either 100ng/ml LPS, culture medium 
(untreated control) or PLY variants at 17.5nM (200μl total well volume) for 6 hours at 37°C.  
The cell supernatants were harvested and KC was measured by ELISA (R AND D SYSTEMS). 
Statistical significance was tested by one-way ANOVA comparing all columns to the control 
column (untreated), *(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed twice 
with three technical replicates per condition, data are mean+SEM. 
 
 
 
3.5 Discussion 
All PLY variants were tested for haemolytic activity and behaved as expected, 
only Δ6 deletion and truncation mutants lacked lytic activity (figure 3-1).   There 
is variability in the HU/pmol between lytic versions of PLY, particularly where 
PLY has been N-terminally tagged with eGFP.  This is possibly due to variability 
in the quality of protein preparations; PLY is known have reduced haemolytic 
activity following long-term storage, particularly if stored above -80°C or if 
subjected to freeze-thaw.  If the reduction in haemolytic activity is due to N-
terminal fusion it may give insight into the process of pore formation; there is 
still some debate as to whether pore formation begins with assembly of the pre-
pore on the cell surface before insertion into the membrane, or, if PLY 
monomers assemble into a pore after insertion of individual monomers.   The 
fact that haemolytic activity is retained demonstrates that PLY is amenable to 
N-terminal tagging and that structural integrity of the protein is unaffected, this 
is important as it suggests that other functions of the toxin are unlikely to be 
affected by fusion to potential vaccine antigens.  It is possible that fusion 
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proteins physically inhibit formation of a complete pore in some instances by 
interrupting oligomerization or preventing the domain rotation necessary for 
membrane insertion; this could be visualized by electron microscopy.  If the tag 
is indeed interrupting oligomerization it is likely to have a greater effect once 
PLY is membrane bound (as the monomer would be less mobile) suggesting that 
the pre-pore assembles on the cell surface.  A study of pore-formation by cryo-
electron microscopy has visualised the conformational change required for pore-
formation occurring after oligomerization (Tilley et al., 2005) and the evidence 
put forward in this chapter would concur with that model. 
Analysis of pore formation by LDH release revealed that there were dramatic 
differences in PLY sensitivity in different cell types.  In figure 3-2, both L929 and 
RAW 264.7 cells showed less than 20% lysis following 1 and 3 hours incubation 
with PLY at 175nM, however by 6 hours there was a marked difference in lysis at 
the highest PLY concentration (50 and 100%, respectively).  In contrast, 
following 3 hours incubation with 175nM PLY BMDM showed ~50% lysis and this 
did not increase significantly with time (figure 3-3).  This would suggest that 
BMDM are initially more susceptible to PLY-mediated pore formation compared 
to L929 and RAW 264.7 cells but have greater resistance to pore 
formation/membrane disruption over time.  A study by Hirst et al. examining the 
differences in PLY sensitivity between epithelial and monocytic cells suggested 
that differences in both membrane cholesterol levels and dynamics of the 
plasma membrane could explain the variation in sensitivity, for example, certain 
cell types have been shown to shed toxin-bound membrane and even repair 
damaged areas of membrane by excising pores via endocytosis (Cassidy & 
O’Riordan, 2013).   It could also be possible that differences in the 
differentiation state of these cells results in variations in sensitivity, THP-1 cells 
are monocytic, RAW264.7 are in fact an immature macrophage or 
monocyte/macrophage phenotype whereas BMDM are fully differentiated, 
mature (but not activated) macrophages and may be more capable of membrane 
repair by endocytosis.   A study of sensitivity to SLO in monocyte/macrophage 
cell lines demonstrated that cells with a more mature phenotype were more 
resistant to SLO-mediated lysis (Tanigawa et al., 1996).  Furthermore, in a study 
of cell susceptibility to streptolysin-O (SLO) mediated lysis it was found that 
inhibition of cholesterol synthesis had a protective effect.  It may be of interest 
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to investigate the variation in membrane cholesterol between the cell types 
studied as well as the possibility of PLY-induced changes in cholesterol synthesis. 
 Compared to nucleated cells RBC are far more sensitive to PLY-mediated lysis; 
although the assays are not directly comparable (due to variations in cell 
number, assay volume, duration and output) by extrapolating the number of PLY 
monomers/cell at the point at which 50% lysis occurs the equivalent number at 
the same cell concentration as the LDH assays can be calculated as 5.4nM.  This 
level of lysis is reached after a treatment time of 30 minutes, far earlier than 
any of the nucleated cells tested which at 30 minutes showed no observable 
lysis.  An approximate ranked order of PLY sensitivity for all cells types studied 
is shown in table 3-5.  Following analysis of PLY-dependent lysis in L929, 
RAW264.7 and BMDM PLY conc. of 175, 17.5 and 1.75nM were chosen for future 
treatment models to ensure a wide range of lytic activity. 
Table 3-5 Ranked Order of Cell Sensitivity to PLY-mediated Lysis.  
* LDH release was not investigated for THP-1 or HEK 293 reporters, however, based on 
observations of reduced SEAP at 175nM PLY at 6 hours they are judged to be at least as 
sensitive to PLY mediated lysis as the RAW264.7 cells. 
Name Cell Type PLY conc. at which 50% 
lysis Occurs (nM)/time 
RBC Erythrocyte 5.4nM/30 mins 
HEK293 Unknown/ epithelial-like * 
THP-1 Monocyte * 
RAW 264.7 Monocyte/immature 
macrophage 
25nM/6 hours 
L929 Fibroblast 100nM/6 hours 
BMDM  Macrophage 175nM/6 hours 
 
The use of Ni-magnetic beads has proven to be an effective method for creating 
vehicle controls and is able to remove all toxin/toxoid from solution (table 3-4, 
figure 3-5).  However, this method would not be a suitable alternative for 
protein purification as elution of bound protein from the beads was not possible 
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for truncation mutants and resulted in total loss of cytolytic activity in PLY 
(figures 3-6 and 3-7).  It appears that PLY has been in some way denatured or 
damaged in the binding or elution process.  It may be possible to optimize the 
elution buffer to improve removal from the beads; the elution buffer is a simple 
solution of 50mM sodium phosphate, 300mM sodium chloride and 300mM 
imidazole (pH8) and does not differ substantially from the elution buffer used in 
NAC (appendix).  Increasing the concentration of imidazole could cause elution 
of the truncations; however, it seems unlikely that modifying the elution buffer 
would allow retention of lytic activity in PLY.  It will be of interest to investigate 
the loss of lytic activity during Ni-magnetic bead treatment as this could lead to 
a method for chemical detoxification of PLY. 
Although purified proteins were shown to have acceptably low levels of LPS, the 
absence of response in reporter cells treated with vehicle controls has increased 
confidence that the presence of even low levels of LPS can be ruled out as a 
cause of TLR4 activation in PLY treated cells (figures 3-9, 3-10 and 3-11).  
 New evidence has been found to support the claim that PLY is a TLR4 ligand and 
additionally suggests that there could potentially be more than one TLR site 
within PLY.  The TLR4 binding site was found to reside in domains 1-3 of PLY and 
was not affected by the Δ6 mutation (figure 3-11).  As discussed above, the THP-
1 blue CD14 cell line is particularly susceptible to PLY at the highest conc. 
(175nM) and this resulted in absent or weak SEAP responses at this dose, the 
same was true of the HEK293 cell line.  Interestingly, when PLY eluted from Ni-
magnetic beads lacking lytic activity was used to treat the cell line a higher 
SEAP response than that of Δ6PLY was observed; this suggested that the delta 6 
mutation did in some way interfere with TLR ligation.  However, when this was 
investigated using the Δ6D123PLY truncation mutant no difference could be 
found, this may suggests that the delta 6 mutation has an effect on the full-
length protein but not on domains 1-3 in isolation.  Previously, it has been shown 
that the apoptotic response to PLY is mediated by TLR4 (Srivastava et al., 2005), 
the data presented in this chapter would suggest that the apoptotic mechanism 
is also dependent on pore formation, as the presence of a TLR4 site in domains 
1-3 did not induce apoptosis where cells were treated with the truncation 
mutant D123PLY (figure 3-4). 
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Interestingly, THP-1 blue CD14 cells indicated a TLR site within domain 4 of PLY, 
however, this should be confirmed with the use of  HEK293/SEAP reporter cell 
lines to clearly demonstrate if an additional TLR is inducing the response seen in 
THP-1 blue CD14 cells.  This is particularly important as both reporter cell lines 
produce SEAP in an NFκB-dependent manner; although the HEK293/TLR5 
reporter could be interpreted as showing that the SEAP response is not a result 
of non-specific PLY-mediated NFκB activation, a HEK293/NFκB/SEAP control cell 
line should be used as a definitive control.  Domain 4 of PLY is essential for pore 
formation (Baba et al., 2001) and contains the undecapeptide common to the 
cholesterol-dependent cytolysin family (Jacobs et al., 1999).  The identification 
of a TLR-binding site within domain 4 could help to identify further functions of 
domain 4 in the immunological response to PLY. 
 The role of TLR4 in cytokine production has been investigated and has given 
insights into the immunogenic properties of the different domains of PLY.  
Analysis of KC production in PLY treated BMDM has shown that D4PLY alone is 
not capable of stimulating KC production but that D123PLY alone is (figure 3-15).   
Both PLY and Δ6PLY induced KC in a TLR4-independent manner, however, the 
production of KC in response to D123PLY alone was TLR4-dependent.  As the 
production of KC in macrophages is mediated by stimulation of TLR2, 3 and 4 
(Filippo et al., 2013) this provides further evidence that PLY may contain Toll-
like receptor binding sites other than TLR4. This could also suggest that there is 
either an additive effect where both domains are required or that in creating 
the truncation mutants an immunogenic region of the protein has been disrupted 
or removed.   
 Initial studies into the production of IL-1β have shown that PLY alone is not 
capable of inducing IL-1β production.  This concurs with other studies of PLY-
treated BMDM where an additional TLR ligand was required to induce release of 
IL-1β into the cell supernatants (Malley et al., 2003). This does not rule out the 
hypothesis that IL-1β is involved in the adjuvant activity of PLY and this 
hypothesis is further investigated in chapter 5.  BMDM were chosen for this in 
vitro model as IL-1β production is regulated by a two signal process (detailed in 
chapter one).  Unlike BMDM, human blood monocytes are capable of producing 
mature IL-1β following treatment with TLR2 and TLR4 ligands, this is due to a 
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combination of constitutive caspase-1 activation and upregulation of ATP in 
response to TLR ligation (Netea et al., 2009).  Cell types such as THP-1 and 
RAW264.7 are monocytic and therefore do not have the same requirements for 
IL-1β production as mature macrophages, this may explain why IL-1β has been 
seen in response to other PLY treatment models. 
 
To conclude, this chapter has shown that the proteins used throughout this 
project are of high purity and has increased confidence that the immunological 
responses observed are due to PLY or its variants and not contaminants such as 
LPS.  An essential role for domains 1-3 in the production of KC has been 
identified and this has been shown to be at least partially TLR4-dependent.  
Finally, analysis of TLR activation by PLY and its derivatives has identified TLR 
binding sites within PLY, a TLR4 site within domains 1-3 and potentially an 
additional TLR binding site within domain 4 of PLY.  This could prove to be an 
essential feature of the adjuvant activity of PLY. 
 
 
 
 
 
  
119 
 
 
4. Investigating Direct Interactions between PLY 
and Mammalian Cell Receptors and Cytoskeleton 
PLY is known to interact with cholesterol (Tweten, 2005b) and is thought to 
interact with TLR4 (Malley et al., 2003); we sought to discover other potential 
interactions with host cell molecules that may contribute to adjuvanticity 
through both fluorescence microscopy and pull-down experiments.   
 The multifunctional HaloTag® technology (Promega) was utilized in this study as 
the HaloTag® can interact with multiple synthetic ligands to allow microscopy, 
protein purification and pull-down studies to be performed after creating a 
single construct.  We analysed cell localization and protein: protein interactions 
by fluorescence microscopy and mass spectrometry.  Interactions between full-
length PLY, Δ6PLY and the functional domains D123PLY and D4PLY with the 
mouse macrophage cell line RAW 264.7 were analyzed. 
 
4.1 Analysis of Binding of PLY and its Derivatives to 
Mammalian Cells by Confocal Fluorescence Microscopy 
In this study, the binding patterns of PLY variants were analyzed as well as the 
gross morphological changes induced in PLY treated cells.  It was shown that all 
HaloTag-PLY variants were able to bind directly to the cell surface and that this 
was not dependent on the HaloTag itself.  It was also shown that each PLY 
variant had a unique pattern of distribution across the cell surface. 
Initially, the rapidity of PLY binding to the RAW 264.7 cell lines was analysed to 
gauge the most appropriate time point for image capture.  Although the RAW 
264.7 cell line was particularly susceptible to lysis by PLY at later time points (3-
6hrs) (figure 3-2) it was resistant to lysis up to 1 hour after toxin addition at 
17.5nM.  Too high a concentration of toxin could disrupt the cell membranes to 
the extent that visualisation by microscopy is impossible.  A toxin concentration 
of 17.5nM typically gave the greatest biological response (e.g. SEAP production), 
therefore, this concentration struck a balance between cellular responses and 
cytotoxicity.  Incubation times of 30 seconds, 2, 5, 10 and 30 minutes were 
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selected for analysis.  In figure 4-1 h-PLY can be seen to bind RAW 264.7 cells 
rapidly, within thirty seconds a single focus of h-PLY binding can be observed, 
the image at 2 minutes shows a similar level of binding however by 5 minutes 
there are multiple h-PLY foci on the cells.  The observable binding of h-PLY 
increases over time and by 30 mins there is considerable binding of h-PLY to the 
cells.  Figure 4-1 also shows the changes in cell morphology that develop over 
time and with increased PLY-binding; after 30 seconds exposure to the toxin RW 
264.7 cells have a healthy morphology, although signs of increased filopodia can 
be observed, this is even more noticeable after 2 minutes and the cells now 
appear “stressed”.  The cells have become distinctly rounded after 5 minutes 
exposure and this increases up to 30 minutes where the cells appear obviously 
rounded and have no visible projections such as filopodia, this may be a sign of 
imminent detachment.  For future binding analysis a concentration of 17.5nM 
and 30 minutes incubation was used for all PLY variants. 
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Figure 4-1 Analysis of h-PLY binding to RAW264.7 cells at different incubation times.  
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well flat bottomed plate containing cover 
slips and allowed to adhere O/N.  The cells were treated with approximately 1μg/ml h-PLY 
(1ml total well volume) from lysates and incubated with the toxin for 30 seconds, 2, 5, 10 or 
30 minutes before washing with warm PBS and staining with Deep-red plasma membrane 
stain (Alexa 647) and Halo-TMR direct ligand (RFP).  The cells were fixed in 4% 
paraformaldehyde before a final rinse in PBS. The cover slips were removed and mounted 
onto microscope slides using Dako Fluorescent Mounting Media, images were captured 
using the Zeiss-axio imager at 100X magnification.  This experiment was performed once, 
multiple images were taken at each time point and the above were selected as 
representative images.  The arrows in images taken at 30 seconds and 2 minutes highlight 
areas of h-PLY binding that are less obvious than those in subsequent images. 
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4.1.1 Analysis of PLY binding using HaloTag technology 
Figure 4-2 shows that the distribution of PLY across the cells is punctate and 
there does not seem to be a particular focal binding site.  Instead PLY is evenly 
distributed across the image, membrane shedding can be observed and deep-red 
plasma membrane staining shows that membrane integrity has been disrupted.  
Compared to cells treated with the control h-eGFP which have a bipolar or 
tripolar morphology, around 50% of the h-PLY treated cells have become 
rounded indicating that the cells are in the process of detaching.   
 
Figure 4-2 2D merged image of h-PLY treated RAW 264.7 cells stained with CellMask Deep-
red plasma membrane stain and HaloTag TMR-direct ligand.  
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with h-PLY lysate diluted in culture 
medium to a final conc. of 17.5nM (1ml total well volume).  The cells were incubated for 30 
minutes before staining with CellMask Deep Red plasma membrane stain and HaloTag TMR-
direct ligand according to the protocol in section 2.8.1.1.  The cells were fixed in 4% 
paraformaldehyde before a final rinse in PBS. The cover slips were removed and mounted 
onto microscope slides using Dako Fluorescent Mounting Media, images were captured 
using the Zeiss-axio imager at 100X magnification.  Images of the cells were captured using 
DIC (differential interference contrast) and using RFP and Alexa-647 channels to create a 
merged image.  This experiment was performed twice, multiple images were taken of each 
slide and the above was selected as a representative image. 
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3D image analysis (figure 4-3) shows PLY distributed both around the edges of 
the cells and visible within the cell; it is unclear if PLY has entered the cell 
passively (either through pores formed by cytolysis or lack of membrane 
integrity) or has been actively taken into the cell by endocytosis.   
 
 
Figure 4-3 3D image of h-PLY treated RAW 264.7 cells stained with Deep-red plasma 
membrane stain and Halo TMR-direct ligand.  
 The z-stacks of image 4-2 were combined using Volocity® software to create a 3D image of 
h-PLY binding to the RAW 264.7 cell lines.  The software was also used to create a movie of 
this image by compiling snapshots taken from different angles, this movie can be viewed in 
the compact disk accompanying this thesis.    
 
 
4.1.2 Analysis of Δ6PLY binding using HaloTag technology 
While h-PLY clearly damaged the cell membranes of treated cells, h-@6PLY 
treated cells maintained cell membrane integrity (figure 4-4).  The punctate 
distribution pattern seen with h-PLY is also seen with h-Δ6PLY. In addition, the 
binding particles appear to be larger. 
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Figure 4-4 2D merged image of h-Δ6PLY treated RAW 264.7 cells stained with CellMask Deep 
Red plasma membrane stain and HaloTag TMR-direct ligand.  
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with h-Δ6PLY lysate diluted in culture 
medium to a final conc. of 17.5nM (1ml total well volume).  The cells were incubated for 30 
minutes before staining with CellMask Deep Red plasma membrane stain and HaloTag TMR-
direct ligand according to the protocol in section 2.8.1.1.  The cells were fixed in 4% 
paraformaldehyde before a final rinse in PBS. The cover slips were removed and mounted 
onto microscope slides using Dako Fluorescent Mounting Media, images were captured 
using the Zeiss-axio imager at 100X magnification.  Images of the cells were captured using 
DIC (differential interference contrast) and using RFP and Alexa-647 channels to create a 
merged image.   This experiment was performed twice, multiple images were taken of each 
slide and the above was selected as a representative image. 
 
It is clearer from the 3D analysis of h-Δ6PLY treated cells in figure 4-5 that the 
protein has been internalized; as membrane integrity remains intact this is most 
likely due to an active process such as endocytosis.  The CD accompanying this 
thesis contains a movie of figure 4-5 where internalized h-Δ6PLY can be observed 
more clearly.  It would be possible to test this using inhibitors of endocytosis, for 
example by treating the cells with cytochalasin D it would be possible to 
distinguish actin-dependent endocytosis from, for instance, endocytosis via 
clathrin-coated pits (Lamaze, 1997).   
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Figure 4-5 3D image of h-Δ6PLY treated RAW 264.7 cells stained with Deep-red plasma 
membrane stain and Halo TMR-direct ligand.   
The z-stacks of image 4-4 were combined using Volocity® software to create a 3D image of 
h-Δ6PLY binding to the RAW 264.7 cell lines.  The software was also used to create a movie 
of this image by compiling snapshots taken from different angles; this movie can be viewed 
in the compact disk accompanying this thesis.    
 
4.1.3 Analysis of D123PLY binding using HaloTag technology 
Previously, PLY binding to the cell surface has been attributed almost 
exclusively to domain 4, h-D123PLY was not expected to bind to the cell surface 
at all; however, h-D123PLY can be seen to form large aggregates on the cell 
surface in figure 4-6.   The distribution is not punctate or distributed as in h-PLY 
and h-Δ6PLY treated cells but instead appears as large single foci. 
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Figure 4-6 2D merged image of h-D123PLY treated RAW 264.7 cells stained with CellMask 
Deep Red plasma membrane stain and HaloTag TMR-direct ligand.  
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with h-D123PLY lysate diluted in 
culture medium to a final conc. of 17.5nM (1ml total well volume).  The cells were incubated 
for 30 minutes before staining with CellMask Deep Red plasma membrane stain and 
HaloTag TMR-direct ligand according to the protocol in section 2.8.1.1. The cells were fixed 
in 4% paraformaldehyde before a final rinse in PBS. The cover slips were removed and 
mounted onto microscope slides using Dako Fluorescent Mounting Media, images were 
captured using the Zeiss-axio imager at 100X magnification.  Images of the cells were 
captured using DIC (differential interference contrast) and using RFP and Alexa-647 
channels to create a merged image.  This experiment was performed twice, multiple images 
were taken of each slide and the above was selected as a representative image.  Further 
analysis of individual z-stacks for this image has shown that it is not an extended image of 
the entire cell and is in fact a cross-sectional image, this is likely due to user error when 
determining the depth settings for image capture.  
 
At first glance the image analysis of h-D123PLY binding does not appear to show 
internalization of PLY, however, looking at the image from both above and 
below it is clear that h-D123PLY appears on both sides of the image (figure 4-7).   
Further analysis of the z-stacks used to compile this 3D image shows that the 
defined height of the cell (set by the user within the image capture software - 
top and bottom of the cell) before capturing the z-stacks was too narrow and 
has in fact captured a cross-section of the cells.  It is unclear if this cross-section 
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captures an internal image.  The unusual binding pattern of h-D123PLY is further 
assessed in section 4.3.4. 
 
Figure 4-7 3D image of h-D123PLY treated RAW 264.7 cells stained with Deep-red plasma 
membrane stain and Halo TMR-direct ligand.   
The z-stacks of image 4-6 were combined using Volocity® software to create a 3D image of 
h-D123PLY binding to the RAW 264.7 cell lines.  The software was also used to create a 
movie of this image by compiling snapshots taken from different angles; this movie can be 
viewed in the compact disk accompanying this thesis.    
 
4.1.4 Analysis of D4PLY binding using HaloTag technology 
In figure 4-8 h-D4PLY can be seen to bind around the edges of cells as well as 
extending along the adherens junctions.  h-D4PLY can also be seen binding to 
the edges of two daughter cells in the process of dividing in this image.  Unlike 
h-D123PLY, h-D4PLY has a punctate binding pattern, much like that of h-PLY and 
h-Δ6PLY.  However, h-D4PLY does not have the even cellular distribution of h-
PLY and h-Δ6PLY; it may be that domain 4 of PLY binds to a specific molecule 
that is present in high concentrations at these cellular locations, for instance 
cytoskeletal proteins.   
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Figure 4-8 2D merged image of h-D4PLY treated RAW 264.7 cells stained with CellMask 
Deep Red plasma membrane stain and HaloTag TMR-direct ligand.   
RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with h-D4PLY lysate diluted in culture 
medium to a final conc. of 17.5nM (1ml total well volume).  The cells were incubated for 30 
minutes before staining with CellMask Deep Red plasma membrane stain and HaloTag TMR-
direct ligand according to the protocol in section 2.8.1.1. The cells were fixed in 4% 
paraformaldehyde before a final rinse in PBS. The cover slips were removed and mounted 
onto microscope slides using Dako Fluorescent Mounting Media, images were captured 
using the Zeiss-axio imager at 100X magnification.  Images of the cells were captured using 
DIC (differential interference contrast) and using RFP and Alexa-647 channels to create a 
merged image.  This experiment was performed twice, multiple images were taken of each 
slide and the above was selected as a representative image. 
 
As shown in figure 4-9 3D image analysis of h-D4PLY binding does not show 
internalization of the protein.  The binding of h-D4PLY around the edges of the 
cells is more clearly visible in these images.  It would be of interest to extend 
the time-course of h-D4PLY treatment; at 30 minutes there is no evidence of 
internalization, this could indicate that uptake of PLY is mediated by a different 
region of the toxin.   
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Figure 4-9 3D image of h-D4PLY treated RAW 264.7 cells stained with Deep-red plasma 
membrane stain and Halo TMR-direct ligand.   
The z-stacks of image 4-8 were combined using Volocity® software to create a 3D image of 
h-D4PLY binding to the RAW 264.7 cell lines.  The software was also used to create a movie 
of this image by compiling snapshots taken from different angles; this movie can be viewed 
in the compact disk accompanying this thesis.    
 
4.1.5 Analysis of eGFP (control) binding using HaloTag technology 
To control for any endogenous binding properties of the HaloTag, a HaloTagged 
version of eGFP was constructed.  No bound protein is observed under these 
conditions demonstrating that the binding of previously shown PLY derivatives 
was not mediated by the HaloTag (figure 4-10). 
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Figure 4-10 2D merged image of h-eGFP treated RAW 264.7 cells stained with CellMask 
Deep Red plasma membrane stain and HaloTag TMR-direct ligand. 
  RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate and allowed to adhere O/N at 
37°C.  The cells were treated with h-eGFP lysate diluted in culture medium to a final conc. of 
17.5nM.  The cells were incubated for 30 minutes before staining with CellMask Deep Red 
plasma membrane stain and HaloTag TMR-direct ligand according to the protocol in section 
2.8.1.1.  The cells were fixed in 4% paraformaldehyde before a final rinse in PBS. The cover 
slips were removed and mounted onto microscope slides using Dako Fluorescent Mounting 
Media, images were captured using the Zeiss-axio imager at 100X magnification.  Images of 
the cells were captured using DIC (differential interference contrast) and using RFP and 
Alexa-647 channels to create a merged image.   This experiment was performed once, 
multiple images were taken from the slide and the above was selected as a representative 
image. 
 
This investigation of PLY and its derivatives binding to host cells has revealed 
that the individually purified domains exhibit strikingly different binding 
patterns and suggests specific binding interaction with molecules on the host 
cell surface.  The following section describes a high-throughput method used to 
discern what these molecules may be. 
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4.2 Investigating PLY-Host Interactions by Protein Pull-
down 
To investigate potential binding partners for PLY a modified version (Figure 4-11) 
of the Promega mammalian pull-down system protocol was devised.  The pull-
down method was used as a screening approach both to identify novel 
interactions between PLY and the host and also to confirm those already 
presented in the literature e.g. TLR4.  It was of particular interest to assign 
interaction to different regions of the toxin, therefore, following the pull-down 
and sample separation by SDS-PAGE, only samples from h-D123PLY and h-D4PLY 
were sent for identification by mass spectrometry. 
 
 
 Figure 4-11 Schematic 
The full pull-down protocol is detailed
 
 
of a modified Halo-tag pull-down protocol.   
 in section 2.9.6. 
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4.2.1 Analysis of Pull-down efficiency by western blot and SDS-
PAGE 
At each stage of the pull-down samples were taken for analysis of protein 
content.  Table 4-1 indicates the samples analyzed and whether HaloTagged 
proteins or their purified His-tagged controls are expected to be present.  Silver 
staining was employed initially as its higher sensitivity range compared to 
coomassie staining would allow sensitive detection of contaminating carry-over 
following wash steps, additionally, it was possible that PLY or its derivatives 
could interact with less abundant mammalian proteins and silver staining would 
give a greater chance of their detection. 
Table 4-1 Fractions Analyzed Following Protein Pull-down Protocol 
Sample name Description PLY variant expected to be 
detected by western blot 
(S1) - Positive control 
(purified protein) 
Relevant His-tagged protein at 
1μg/ml. 
Yes 
(S2)H-protein lysate Undiluted lysate containing 
HaloTagged protein. 
Yes 
(S3) Unbound 1 Supernatant removed after 
incubating halo lysate with 
Halo-link resin. 
Either acceptable, excess 
protein may carry over into 
this fraction. 
(S4) Wash fraction 5 Resin is washed 5 times with 
PBS, final wash is sampled. 
No 
(S5) Mammalian cell lysate Obtained from RAW 264.7 
cells treated with lysis buffer. 
No 
(S6) Unbound 2 Supernatant removed after 
incubating mammalian cell 
lysate with Halo-link resin. 
No 
(S7) Wash fraction 10 Resin is washed a further 5 
times with PBS, final wash is 
sampled. 
No 
(S8) SDS-elution fraction Bound proteins are eluted 
with SDS-elution buffer. 
Yes 
(S9) TEV cleavage fraction Proteins are cleaved from the 
HaloTag with TEV protease. 
Yes 
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A distinct band of between 55-65 kDa can be seen in the wash fractions of most 
of the silver stained gels (figures 4-12 to 4-13).  This is most likely human keratin 
as it is a commonly observed contaminant in silver stained SDS-PAGE gels (Xu et 
al., 2011).  HaloTagged PLY and its derivatives are detectable in all of the 
lysates.  The wash fraction 5 samples were free from contaminating HaloTagged 
protein carry over with the exception of the h-D4PLY pull down.  In figure 4-13 
(D) h-D4PLY carry over can be seen until lane 6 (Unbound 2) this is likely an 
artefact caused by the intense signal in lanes 1 and 2, in any case, no h-D4PLY is 
detected in lane 7 (wash fraction 10) and so any proteins pulled down in the 
SDS-elution fraction will have bound to h-D4PLY bound to resin and not in 
solution.   Δ6PLY was not detectable in the TEV cleavage fraction (figure 4-12 
(D)).  In figure 4-13 (C) and (D) several bands are observed in the SDS-elution 
and TEV cleavage fractions, this is potentially because h-D123PLY and h-D4PLY 
have complexed with other proteins however, it is more likely that h-D123PLY 
has degraded during the TEV cleavage process.  It also seems likely that the 
Halo-tag has been cleaved from the protein (in the absence of TEV protease) as 
in lanes 2 and 3 bands of the correct size for non-tagged D123PLY and D4PLY (41 
and 13 kDa respectively) are present. 
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Figure 4-12 Analysis of pull-down efficiency by silver staining and western blot.  
 h-PLY pull-down silver staining (A) and western blot (B), h-Δ6PLY pull-down silver staining 
(C) and western blot (D). Lane 1 = purified His-tagged protein, 2 = Halo lysate, 3 = unbound 
fraction 1, 4 = wash fraction 5, 5 = mammalian cell lysate, 6 = unbound fraction 2, 7 = wash 
fraction 10, 8 = SDS elution fraction, 9 = TEV cleavage fraction.  Purified PLY/Δ6PLY was 
diluted to 1mg/ml, pull-down samples were undiluted and mixed 1:4 with SDS-PAGE loading 
buffer. 5μl of Seeblue Plus 2 molecular weight marker and 10μl of the proteins or pull-down 
samples were loaded into the wells of a 10% SDS-PAGE gel and electrophoresed at 180 V 
for 40 minutes.  The presence or absence of PLY and Δ6PLY or mammalian proteins was 
determined by silver staining (SilverQuest, Invitrogen) and western blot using rabbit anti-
PLY antibodies.  The proteins in unstained gels were transferred onto nitrocellulose 
membrane and detected by western blotting using rabbit anti-PLY (1:1000) and donkey anti-
rabbit-HRP (1:40,000) using enhanced chemiluminescence (ECL) (Millipore). 
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Figure 4-13 Analysis of pull-down efficiency by silver staining and western blot.  
h-D123PLY pull-down silver staining (A), and western blot (B), h-D4PLY pull-down silver 
staining (C) and western blot (D).  Lane1 = purified His-tagged protein, 2 = Halo lysate, 3 = 
unbound fraction 1, 4 = wash fraction 5, 5 = mammalian cell lysate, 6 = unbound fraction 2, 7 
= wash fraction 10, 8 = SDS elution fraction, 9 = TEV cleavage fraction.  Purified 
D123PLY/D4PLY was diluted to 1mg/ml, pull-down samples were undiluted and mixed 1:4 
with SDS-PAGE loading buffer. 5μl of Seeblue Plus 2 molecular weight marker and 10μl of 
the proteins or pull-down samples were loaded into the wells of a 10% SDS-PAGE gel and 
electrophoresed at 180 V for 40 minutes.  The presence or absence of D123PLY and D4PLY 
or mammalian proteins was determined by silver staining (SilverQuest, Invitrogen) and 
western blot using rabbit anti-PLY antibodies.  The proteins in unstained gels were 
transferred onto nitrocellulose membrane and detected by western blotting using rabbit 
anti-PLY (1:1000) and donkey anti-rabbit-HRP (1:40,000) using enhanced 
chemiluminescence (ECL) (Millipore). 
 
 
4.2.2 Separation and extraction of Pull-down proteins by SDS-
PAGE 
This initial analysis of the pull-down fractions indicated that it had been 
successful and that eluted proteins should be sent for identification by mass 
spectrometry, however, the eluted proteins were not sufficiently separated 
making it impossible to excise individual protein bands.  Additionally, the 
sensitivity of silver staining means that bands of insufficient concentration for 
mass spectrometry could be excised.  For these reasons the elution and TEV 
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cleavage fractions were separated on larger gels cast and electrophoresed using 
the Hoeffer 2600 system.  The gels were stained with coomassie blue rather than 
silver stained to ensure proteins were of a high enough concentration to be 
identified by mass spectrometry. 
 
As shown in Figures 4-14 and 4-15 seventy-two potential binding partners across 
the four pull-downs were identified.  It was decided that only bands from h-
D123PLY and h-D4PLY pull-downs would be sent for analysis by mass 
spectrometry so that any proteins identified could be assigned to different 
domains of the toxin.  Although the final wash fractions were clean and did not 
identify any carry-over of unbound proteins we decided to only send those bands 
that were present in both the elution and TEV cleavage fractions.  The reasoning 
for this was that those bands were most likely to have a strong interaction with 
PLY and therefore not be entirely dissociated by SDS-elution.   
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Figure 4-14 Separation and excision of proteins from h-PLY and h-Δ6PLY pull-down.   
The Hoefer SE600 system was used to separate proteins isolated from the pull-down 
protocol.  Lane 1 = purified PLY, 2 = final wash fraction (h-PLY), 3 = SDS-elution fraction (h-
PLY), 4 = TEV cleavage fraction (h-PLY), 5 = purified ∆6PLY, 6 = final wash fraction (h-
∆6PLY), 7 = SDS-elution fraction (h-∆6PLY), 8 = TEV cleavage fraction (h-Δ6PLY). Purified 
PLY/Δ6PLY was diluted to 1mg/ml, pull-down samples were undiluted and mixed 1:4 with 
SDS-PAGE loading buffer. 20μl of Seeblue Plus 2 molecular weight marker and 50μl of the 
proteins or pull-down samples were loaded into the wells of a large 10% SDS-PAGE gel and 
electrophoresed at 50V for 2 hours followed by 3 hours at 250V.  The gel was stained in 
coomassie blue stain for 1 hour and destained O/N followed by several washed in dH2O. As 
protein bands were identified they were numbered, excised and stored at -80°C for future 
analysis by mass spectrometry.   
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Figure 4-15 Separation and excision of proteins from h-D123PLY and h-D4PLY pull-down.   
The Hoefer SE600 system was used to separate proteins isolated during the pull-down 
protocol.  Lane 1 = TEV cleavage fraction (h-D4PLY), 2 = SDS-elution fraction (h-D4PLY), 3 = 
final wash fraction (h-D4PLY), 4 = purified D4PLY, 5 = TEV cleavage fraction (h-D123PLY), 6 
= SDS-elution fraction (h-D123PLY), 7 = final wash fraction (h-D132PLY), 8 = purified 
D123PLY).  Purified D123PLY/D4PLY was diluted to 1mg/ml, pull-down samples were 
undiluted and mixed 4:1 with SDS-PAGE loading buffer. 20μl of Seeblue Plus 2 molecular 
weight marker and 50μl of the proteins or pull-down samples were loaded into the wells of a 
large 10% SDS-PAGE gel and electrophoresed at 50V for 2 hours followed by 3 hours at 
250V.  The gel was stained in coomassie blue stain for 1 hour and destained O/N followed 
by several washed in dH2O. As protein bands were identified they were numbered, excised 
and stored at -80°C for future analysis by mass spectrometry.  As protein bands were 
identified they were numbered, excised and stored for analysis by mass spectrometry. 
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4.2.3 Mass Spectrometry results 
Of the bands sent for identification by mass spectrometry six returned positive 
hits for M. musculus (mouse) proteins; one protein was identified as Bos taurus 
(bull), however there is 100% sequence homology between Bos taurus and Mus 
muculus tubulin β-5 chain (appendix) and so this was taken as a positive hit.  The 
identified proteins and their functions are detailed in table 4-2, probability 
scores over 42 indicate confirmed identity or extensive homology (p<0.05). 
Table 4-2 Proteins identified my MS/MS mass spectrometry. 
Band No. Protein Identity 
and Species 
Probability 
Score 
Description 
26 pyruvate kinase 
(Mus musculus) 
305 Pyruvate kinase is a transferase 
with key role in glycolysis.  
Typically located in the cytosol.  
Has been linked with caspase-
dependent cell death. 
27 vimentin (Mus 
musculus) 
305 Vimentin is a cytoskeletal 
protein involved in supporting 
cell organelles; it has direct 
attachments to the nucleus, ER 
and mitochondria (Katsumoto, 
1990).  
28 tubulin β-5 chain 
(Bos taurus) 
178 A subunit of microtubules; 
cytoskeletal structures that 
provide structural support and 
act as platforms for intracellular 
transport (Hammond et al., 
2008).  
29 ATP synthase 
subunit β (Mus 
musculus) 
306 Mitochondrial membrane ATP 
synthase (F1F0 ATP synthase or 
Complex V) produces ATP from 
ADP in the presence of a proton 
gradient across the membrane 
which is generated by electron 
transport complexes of the 
respiratory chain (Jonckheere et 
al., 2011).  
30 ATP synthase 
subunit β ( E. 
coli) 
404  
31 transcription 
termination 
factor rho (E. 
coli) 
434  
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Table 4-2 continued 
32 Trypsin 108 Protease added by MS facility. 
33 elongation factor 
(E. coli) 
451  
34 outer membrane 
protein F (E. 
coli) 
349  
35 60s acidic 
ribosomal protein 
PO (Mus 
musculus) 
143 Located in the cytoplasm this 
ribosomal protein forms 
pentamers with P1 and P2 
dimers. 
51 heat shock 
protein 1 (Mus 
musculus) 
392 Hsp90AB1, also known as Hsp84, 
is a chaperon and belongs to the 
HSP90 class of heat shock 
proteins in mammals. It plays a 
role in response to temperature 
elevation and cytotoxic stresses 
and is expressed constitutively in 
the cytosol (Fukuyama et al., 
2008).  
52 Leucine rich PPR 
containing 
protein (Mus 
musculus) 
103 LLPPRC is thought to have a role 
in many cellular processes (such 
as trafficking) through regulation 
of the cytoskeleton (Fukuda et 
al., 2004).  
 
Bands 26, 27 and 52 were of particular interest, they corresponded to vimentin, 
tubulin β-5 chain and leucine rich PRR containing protein, respectively.  As these 
proteins were all associated with the cell cytoskeleton/cellular trafficking they 
could potentially be involved in the antigen uptake mechanism of PLY-based 
vaccines.  Additionally, there is already evidence in the literature that PLY 
associates with the actin cytoskeleton (Hupp et al., 2013; Iliev et al., 2009), 
therefore the interaction(s) between PLY and the actin cytoskeleton in 
macrophages was further investigated. 
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4.3 Interactions between PLY and the Actin Cytoskeleton 
The initial microscopy results using HaloTag-PLY variants and the results of mass 
spectrometry indicated direct interactions between PLY and the cell 
cytoskeleton.  To further investigate this theory phalloidin staining was used to 
visualize the actin cytoskeleton of RAW 264.7 macrophages stimulated with 
eGFP-PLY variants.  The binding patterns observed were consistent with those 
seen with HaloTag-PLY variants.  In addition there were obvious conformational 
changes to the actin cytoskeleton in PLY treated cells.   
 
4.3.1 Visualising interactions between eGFP and the actin 
cytoskeleton using purified eGFP 
In figure 4-16 the actin of eGFP treated control cells is visible as podosomes 
(actin dense foci that may facilitate adherence, usually visible as ring like 
structures at the substrate binding edges of cells (Linder et al., 2000)) around 
the edges of the macrophages and along adherens junctions but is also visible 
throughout the cytoplasm. 
 143 
 
 
Figure 4-16 2D merged image of eGFP treated RAW 264.7 cells stained with rhodamine 
phalloidin. 
RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with 1ml 17.5nM eGFP for 30 minutes; 
the cells were washed and stained with rhodamine phalloidin according to the protocol in 
section 2.8.1.2.  The cells were fixed in 4% paraformaldehyde before a final rinse in PBS. 
The cover slips were removed and mounted onto microscope slides using Dako Fluorescent 
Mounting Media, images were captured using the Zeiss-axio imager at 100X magnification. 
Images of the cells were captured using DIC (differential interference contrast) and using 
RFP and GFP channels to create a merged image.   This experiment was performed twice, 
multiple images were taken of each slide and the above was selected as a representative 
image. 
 
 
4.3.2 Visualising interactions between PLY and the actin 
cytoskeleton using eGFP-tagged PLY 
The binding pattern and morphological changes seen in response to h-PLY are 
replicated in e-PLY treated cells (figure 4-17).  In e-PLY treated cells there 
appears to be widespread actin destabilization and podosome degradation, the 
actin cytoskeleton seems granular in appearance.  In the merged image there 
does seem to be colocalization of e-PLY and actin (seen as a yellow spots). 
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 3D analysis of the same image (figure 4-18) shows that the actin cytoskeleton is 
condensed and flattened, e-PLY can be observed both centrally within the cells 
and peripherally, binding to the edges and adherens junctions of cells. 
 
 
Figure 4-17 2D merged image of e-PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin.   
 
RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C. The cells were treated with 1ml 17.5nM e-PLY for 30 minutes; 
the cells were washed and stained with rhodamine phalloidin according to the protocol in 
section 2.8.1.2.  The cells were fixed in 4% paraformaldehyde before a final rinse in PBS. 
The cover slips were removed and mounted onto microscope slides using Dako Fluorescent 
Mounting Media, images were captured using the Zeiss-axio imager at 100X magnification. 
Images of the cells were captured using DIC (differential interference contrast) and using 
RFP and GFP channels to create a merged image.    This experiment was performed twice, 
multiple images were taken of each slide and the above was selected as a representative 
image. 
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Figure 4-18 3D image of e-PLY treated RAW 264.7 cells stained with rhodamine phalloidin.  
The z-stacks of image 4-17 were combined using Volocity® software to create a 3D image of 
e-PLY binding to the RAW 264.7 cell lines.  The software was also used to create a movie of 
this image by compiling snapshots taken from different angles; this movie can be viewed in 
the compact disk accompanying this thesis.    
 
4.3.3 Visualising interactions between Δ6PLY and the actin 
cytoskeleton using eGFP-tagged Δ6PLY 
 
The actin destabilization and podosome degradation seen in e-PLY treated cells 
is also observed in e-@6PLY treated cells though to a lesser degree, perhaps to 
due greater membrane integrity (figure 4-19).    
The 3D image analysis in figure 4-20 shows that in contrast to e-PLY treated 
cells, the actin cytoskeleton of e-Δ6PLY treated cells is not flattened and 
appears less condensed. 
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Figure 4-19 2D merged image of e-Δ6PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin. 
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with 1ml 17.5nM e-Δ6PLY for 30 
minutes; the cells were washed and stained with rhodamine phalloidin according to the 
protocol in section 2.1.1.2.  The cells were fixed in 4% paraformaldehyde before a final rinse 
in PBS. The cover slips were removed and mounted onto microscope slides using Dako 
Fluorescent Mounting Media, images were captured using the Zeiss-axio imager at 100X 
magnification.  Images of the cells were captured using DIC (differential interference 
contrast) and using RFP and GFP channels to create a merged image.    This experiment 
was performed twice, multiple images were taken of each slide and the above was selected 
as a representative image. 
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Figure 4-20 3D image of e-Δ6PLY treated RAW 264.7 cells stained with rhodamine phalloidin.  
 The z-stacks of image 4-19 were combined using Volocity® software to create a 3D image 
of e-Δ6PLY binding to the RAW 264.7 cell lines.  The software was also used to create a 
movie of this image by compiling snapshots taken from different angles; this movie can be 
viewed in the compact disk accompanying this thesis.    
 
 
4.3.4 Visualising interactions between D123PLY and the actin 
cytoskeleton using eGFP-tagged D123PLY 
In figure 4-21 RAW 264.7 cells treated with e-D123PLY have a rounded 
appearance and increased number of filopodial projections.  The podosomes of 
treated cells appear intact; and there does not seem to be a reduction in 
cytoplasmic actin compared to control cells.   
The binding pattern of h-D123PLY is replicated in figure 4-22 using e-D123PLY, in 
this 3D image analysis the binding pattern is striking and in some cases the 
entire surface of the cell is coated in protein.  This image would indicate the 
that the 3D composite in figure 4-6 was too narrow and is in fact a slice from the 
inside of the cell potentially suggesting internalization of D123PLY. 
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Figure 4-21 2D merged image of e-D123PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin.  
 RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with 1ml 17.5nM e-D123PLY for 30 
minutes; the cells were washed and stained with rhodamine phalloidin according to the 
protocol in section 2.8.1.2.  The cells were fixed in 4% paraformaldehyde before a final rinse 
in PBS. The cover slips were removed and mounted onto microscope slides using Dako 
Fluorescent Mounting Media, images were captured using the Zeiss-axio imager at 100X 
magnification.  Images of the cells were captured using DIC (differential interference 
contrast) and using RFP and GFP channels to create a merged image.  This experiment was 
performed twice, multiple images were taken of each slide and the above was selected as a 
representative image. 
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Figure 4-22 3D image of e-D123PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin.   
The z-stacks of image 4-21 were combined using Volocity® software to create a 3D image of 
e-D123PLY binding to the RAW 264.7 cell lines.  The software was also used to create a 
movie of this image by compiling snapshots taken from different angles; this movie can be 
viewed in the compact disk accompanying this thesis.    
 
 
 
4.3.5 Visualising interactions between D4PLY and the actin 
cytoskeleton using eGFP-tagged D4PLY 
In contrast to e-D123PLY treated cells, in figure 4-23 e-D4PLY treated cells the 
‘rings’ of actin around the edges of the cells are less visible and are condensed 
in a punctate formation.  Additionally, there is no actin visibly associated with 
e-D4PLY, which could suggest that D4PLY disrupts the actin cytoskeleton upon 
binding, this could potentially indicate podosome degradation and may be 
associated with the cell rounding and detachment observed in PLY-mediated cell 
death. 
In figure 4-24 the 3D image analysis shows that in common with e-D123PLY 
treated cells there is an absence of cytoplasmic actin in e-D4PLY treated cells. 
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Figure 4-23 2D merged image of e-D4PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin.   
RAW 264.7 cells were seeded at 1x10
6
/well in a 6-well plate containing cover slips and 
allowed to adhere O/N at 37°C.  The cells were treated with 1ml 17.5nM e-D4PLY for 30 
minutes; the cells were washed and stained with rhodamine phalloidin according to the 
protocol in section 2.8.1.2.  The cells were fixed in 4% paraformaldehyde before a final rinse 
in PBS. The cover slips were removed and mounted onto microscope slides using Dako 
Fluorescent Mounting Media, images were captured using the Zeiss-axio imager at 100X 
magnification.  Images of the cells were captured using DIC (differential interference 
contrast) and using RFP and GFP channels to create a merged image.   This experiment was 
performed twice, multiple images were taken of each slide and the above was selected as a 
representative image. 
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Figure 4-24 3D image of e-D4PLY treated RAW 264.7 cells stained with rhodamine 
phalloidin.   
The z-stacks of image 4-23 were combined using Volocity® software to create a 3D image of 
e-D4PLY binding to the RAW 264.7 cell lines.  The software was also used to create a movie 
of this image by compiling snapshots taken from different angles; this movie can be viewed 
in the compact disk accompanying this thesis.    
 
4.3.6 Analysis of colocalization by thresholded Pearson’s 
correlation coefficient (PCC) 
The thresholded Pearson’s correlation coefficient (PCC) is a statistical tool for 
demonstrating the strength of a relationship between two variables.  PCC 
analysis cannot be used as confirmation of a direct interaction, however, it can 
be used to demonstrate colocalization and to indicate interactions for further 
analysis.  Rather than relying on visible overlap from different channels (e.g red 
and green equals yellow/orange) PCC defines values (thresholds) within each 
channel, this removes objectivity when assessing colocalization.  Briefly, the 
pixels within a pair of fluorescent images are mapped, the mean pixel intensity 
for the each image is subtracted from the intensity of each pixel.  The individual 
pixel values from each image are multiplied to give the product of the 
difference of the mean.  The products of the difference of the mean are 
summed for the entire image and divided by the maximum possible sum for the 
difference of the mean for the entire image.  PCC analysis generates values 
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between 1 and -1, where 1 = a perfect correlation, 0 = no correlation and -1 = a 
perfect but inverse correlation.  Table 4-3 shows the PCC values for the 
relationships between PLY variants and actin, the strongest correlation is 
between e-D123PLY (0.75) and actin followed by e-PLY and actin (0.45), both e-
Δ6PLY and e-D4PLY have weak, positive relationships with actin.   
Table 4-3 PCC values for PLY variants and actin 
Protein PCC Strength and 
direction of 
correlation 
e-PLY 0.45 Moderate, positive. 
e-Δ6PLY 0.32 Weak, positive. 
e-D123PLY 0.75 Strong, positive. 
e-D4PLY 0.24 Weak, positive. 
 
 
4.3.7 Quantifying binding affinity between PLY and actin by 
ELISA 
The ability of PLY and its derivates to directly bind actin was recently described 
(Hupp et al., 2013), following microscopic analysis of interactions with the actin 
cytoskeleton, an ELISA based binding assay described in this paper was 
replicated to see if similar results were obtained.  It was seen that all PLY 
variants tested were capable of directly binding actin in a dose-dependent 
manner; D4PLY had both the strongest and weakest binding affinity at the 
highest and lowest concentrations, respectively.  At 175nM and 17.5nM Δ6PLY 
has the weakest binding affinity compared to other PLY variants, this replicates 
what was observed in the Hupp et al., 2013 study.  This also fits with the 
changes in cytoskeleton structure observed microscopically, where e-@6PLY 
caused the least disruption to the actin cytoskeleton. 
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Figure 4-25 Actin Binding ELISA.   
ELISA plates were coated with 50μl purified PLY and its derivatives (plus BSA control 
1mg/ml) O/N at 4°C.  The plates were washed x5 with PBS/Tween before incubating with 50μl 
non-muscle actin (Cytoskeleton, Inc.)  Bound actin was detected using monoclonal anti-
actin antibody (1:1000, Cytoskeleton, Inc.) followed by anti-rabbit-HRP (1:1000, Promega) 
and developing with OPD, absorbance at 405nm was measured using a BMG fluostar 
Optima.  Statistical significance was assessed by one-way ANOVA with a Bonferroni post-
test (comparing all pairs of columns). To conserve space, as all but one condition (D4PLY 
87.5nM) was significantly (***) higher than the control (BSA 1mg/ml), the different protein 
conc. were grouped together, *(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was 
performed once with three technical replicates per condition, data are mean+SEM. 
 
 
4.4 Discussion 
The HaloTag® system was an ideal platform for these studies which have given 
key insights into interactions with host cells that may contribute to 
adjuvanticity.   We have found that all PLY variants studied were capable of 
binding to the cell surface of RAW 264.7 macrophages and that this was not due 
to the HaloTag (as h-eGFP did not bind to cells). The morphology of RAW 264.7 
cells was most changed in response to h-PLY, unsurprising as this was the only 
cytolytic protein tested.  The h-PLY treated cell were visibly rounded and 
membrane shedding could be observed (figure 4-2), this a documented cellular 
reaction to pore-forming toxins (Walev et al., 1994)  and may be linked to 
cellular recovery, however, as seen in chapter 3, RAW 264.7 cells are not 
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particularly resistant to PLY-mediated lysis and so this could be a sign of necrosis 
(Hirst et al., 2004; Zysk et al., 2001).  
 
This study has highlighted the ability of domains 1-3 to directly bind host cells, a 
function not previously recognized in pneumolysin.  This has however been noted 
previously in domain 1-3 of listeriolysin (LLO) and could be a common attribute 
of CDCs, it was also found that separately purified domains 1-3 and domain 4 of 
LLO could recombine on the cell surface and cause lysis of RBCs (Dubail et al., 
2001); this experiment was replicated using D123PLY and D4PLY but lysis of RBC 
did not occur, this could however be due to the His6 tag.  The unusual binding 
pattern of D123PLY could indicate aggregation of a specific receptor.  In the 
previous chapter a TLR4 binding site was identified in domains 1-3, D123PLY was 
also shown to induce KC production. Combined, these findings identify domains 
1-3 as a region of interest for future studies into host cell binding and 
interactions that are conducive to adjuvanticity.  In the case of D4PLY it is 
already known that binding to membrane cholesterol is an essential process in 
adherence to the cell membrane, the distinct binding pattern may simply be a 
reflection of cholesterol localization within this cell type.  As the binding 
patterns differed so obviously between the truncation mutants and full-length 
PLY variants it may be assumed that the individual binding properties of the 
different domains combine to create that of the full-length proteins.  The 
punctate distribution pattern seen in both PLY and Δ6PLY suggests that the delta 
6 mutation does not interrupt oligomerization, but instead somehow prevents 
insertion or coherent formation of the pre-pore.  This has previously been 
demonstrated in electron microscopy, where Δ6PLY was seen to form structures 
like pores on the cell surface as well as dysfunctional structures such as arcs 
(figure 4-26) (Kirkham, 2006; Nöllmann et al., 2004).   
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Figure 4-26 Electron microscopy image of pore formation. 
This image was taken from (Kirkham et al., 2006) and shows a) 0.2mg/ml PLY, b) 0.2mg/ml 
PdB, c) 0.2mg/ml ∆6PLY and d) PBS  bound to horse erythrocytes.   
 
Current knowledge of the adjuvant activity of Δ6PLY suggests that 
internalization of the protein does occur and is necessary to generate adaptive 
immune responses to target antigens.  In a study of adjuvanticity antibody 
responses to the model antigen eGFP were only observed when eGFP was 
genetically fused to PLY/Δ6PLY, no response was generated to eGFP admixed 
with the protein (Douce et al., 2010).   Internalization of either truncation 
domain was not clearly observable, however, h-Δ6PLY had clearly been taken 
into the cell, this cannot be due to passive passage through pores therefore we 
can hypothesize a specific uptake mechanism such as receptor mediated 
endocytosis is involved.  This could be further investigated using a model of 
antigen presentation; an antigen presentation assay was devised using PLY 
variants genetically fused to OVA323-339 and a T-cell hybridoma reporter cell line 
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specific to this peptide, however, at the time of writing this thesis the 
preliminary results were inconclusive. 
 
Using HaloTag technology to perform protein pull-down has identified seven 
potential binding partners for PLY; of particular interest are the cytoskeletal 
components vimentin and tubulin β-5 chain as other studies have also shown 
interactions between PLY and the cytoskeleton (Iliev et al., 2007).  One aim of 
this study was to verify the interaction between D123PLY and TLR4, bands of the 
expected size (90kDa) were analyzed by mass spectrometry however TLR4 was 
not identified.  It is possible that the interaction between PLY and TLR4 is weak 
or transient; therefore its identification by pull-down would be difficult, if this 
experiment were repeated it would useful to test for the presence of TLR4 in 
the mammalian cell lysate by western blot.  No immune receptors were 
identified following the pull-down; however, not all of the excised bands were 
analyzed so it is possible that these may be identified in the remaining bands.  It 
is important to understand that the pull-down results may not necessarily 
indicate direct interactions with PLY or its variants.  Following a direct 
interaction with PLY any other molecules complexed with the target protein 
could also be pulled out, this may explain some of the less expected hits from 
mass spectrometry. For example, PLY has been shown to directly interact with 
the actin cytoskeleton, therefore it is feasible that other proteins associated 
with cellular structure and transport such as vimentin and LLPPRC would be 
associated with actin and could be pulled out simultaneously.  These proteins in 
turn could be associated with other proteins, for example, vimentin provides 
support to organelles such as the nucleus, endoplasmic reticulum and 
mitochondria, this could explain the presence of the proteins pyruvate kinase 
and 60s acidic ribosomal protein P0.  Although the h-eGFP microscopy 
experiments showed no binding of h-eGFP to RAW264.7 cells a further pull-down 
using a HaloTag only control would be appropriate to conclusively demonstrate 
that proteins identified are binding only to PLY variants and not the HaloTag.  To 
further confirm protein-protein interactions between PLY and mammalian cells 
it may be essential to perform direct binding assays such as that performed using 
actin (figure 4-25).  In particular, it may be of interest to confirm a direct 
interaction between PLY and tubulin β-5 chain, this protein is a subunit of 
microtubules and binding to this protein could be essential for the ability of PLY 
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to inhibit ciliary beat, an important factor in pneumococcal colonization and 
spread of infection (Beurg et al., 2005; Rubins et al., 1992). 
The pull-down showed a clear relationship between PLY and the cytoskeleton, 
this has previously been described in the literature.  Studies by the Iliev group 
have recently shown that PLY directly interacts with cytoskeletal actin (Hupp et 
al., 2013).  These findings were replicated in this work, PCC analysis of 
colocalization (table 4-3) produced the same pattern as that of binding affinity, 
where PLY and D123PLY have the highest affinity followed by Δ6PLY and finally 
D4PLY.   The analysis of direct binding by ELISA (figure 4-25) did not replicate 
these results exactly and assigned the highest binding affinity to D4PLY; 
however, these results are from a single assay and should be repeated to provide 
statistical validity.   Previously, it has also been shown by the same group that 
the changes in cell morphology observed in PLY treated cells are dependent on 
cholesterol-binding and pore formation (Förtsch et al., 2011; Iliev et al., 2009), 
these studies did not include truncation mutants and could explain why the most 
dramatic changes in the actin cytoskeleton were observed in cells treated with 
e-PLY and e-D4PLY.  In contrast to eGFP treated cells the actin cytoskeleton in 
cells treated with PLY and its derivatives is clearly altered, actin destabilisation 
and podosome degradation can be observed in response to both e-PLY and e-
@6PLY (figures 4-17 and 4-19, respectively), in contrast the actin cytoskeleton in 
e-D123PLY (figure 4-21) treated cells does not differ significantly from control 
cells.  The proposed model for interaction between D123PLY and the actin 
cytoskeleton only allows for contact between the two proteins following 
insertion of full-length PLY into the cell membrane, a portion of domains 1-3 
could then feasibly interact with the cytoskeleton.  The evidence presented in 
this chapter indicates that D123PLY is capable of interacting with cellular actin 
in a solid phase binding assay.  The strong correlation seen by PCC analysis may 
simply be a reflection of the ubiquitous presence of both proteins and the 
proximity of membrane bound D123PLY to intracellular actin rather than a direct 
interaction.  It is unlikely that domains 1-3 of PLY are capable of interacting 
with the actin cytoskeleton unless present in the context of lytic PLY.  In e-
D4PLY treated cells the actin cytoskeleton is visibly condensed and disrupted 
(figure 4-23).  In addition e-D4PLY does not appear to be associated with actin 
(which correlates with PCC analysis) suggesting that some aspects of PLY-
dependent changes in the actin cytoskeleton do not require direct binding and 
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could be a consequence of/induced by distal interactions with the cell such as 
cholesterol binding. 
The work presented in this chapter has given insight into interactions with the 
cells that could be further investigated as mechanisms of adjuvant activity; for 
example, the role of the different domains in internalization and antigen 
presentation.  Given that the binding patterns of the separated domains are 
markedly different, it will be of interest to discover whether they are trafficked 
or processed by different mechanisms and how this relates to the same 
processes in the full-length protein(s).  As mentioned earlier, as an adjuvant PLY 
does not create a bystander effect i.e. antibody responses are not mounted 
against antigens unless they are genetically coupled to the toxin; this suggests 
that both PLY and the fusion antigen are pulled into the cell by a specific uptake 
mechanism.  It will be of interest to further study localization of PLY and its 
derivatives (particularly after longer incubation periods) and to isolate the 
mechanism of antigen uptake through the use of specific endocytosis inhibitors 
such as cytochalasin D.  These studies have also revealed new properties of 
D123PLY and increased the recognition of its potential role(s) in adjuvanticity.  
The use of truncation mutants in this study has unveiled properties of the 
domains in isolation, it remains to be seen if this gives insight into how the toxin 
works as a complete protein or confuses the study by unmasking properties not 
belonging to the whole molecule.   
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5. The Role of TLR4, Complement and IL-1β in the 
Adjuvant Activity of Pneumolysin 
As described in chapter three TLR ligation is the first step (signal one) in IL-1β 
production, and given the increasing evidence that PLY is a TLR4 ligand and can 
activate the NLRP3 inflammasome through pore formation (signal two) (McNeela 
et al., 2010; Witzenrath et al., 2011) it was expected that IL-1β would be 
produced in PLY treated BMDM.  However, as shown in figure 3-13 PLY alone 
cannot stimulate IL-1β production in BMDM and an exogenous TLR ligand such as 
LPS is required.  Initial studies into PLY-dependent gene expression (appendix 5, 
table 1) showed that IL-1β was upregulated at the mRNA level in a single sample 
of PLY treated BMDM.  It therefore seemed possible that PLY was providing TLR4 
ligation and IL-1β was upregulated in response (signal one).  However, at this 
time it was unclear why IL-1β was not then found in the supernatants of PLY 
treated cells. 
In recent years the role of complement in both innate and adaptive immunity 
has been expanded, of particular relevance are several studies demonstrating a 
synergistic relationship between complement activation and TLR ligation (Fang 
et al., 2009; Zhang et al., 2007). In particular, complement activation has been 
shown to increase the production of pro-inflammatory cytokines such as IL-1β.  
Analysis of gene expression in response to PLY treatment showed an upregulation 
of complement C3 in response to PLY treatment in BMDM (appendix 5, table 5).  
PLY is known to activate the classical complement pathway (Paton & Ferrante, 
1984; Yuste et al., 2005) and therefore a new hypothesis was generated, where 
the activation of complement and TLR ligation by PLY would synergize to alter 
the cytokine expression profiles of PLY treated BMDM.  The in vitro BMDM PLY 
treatment model used in this thesis was altered to include a complement source 
(whole serum) and the presence of complement in conjunction with PLY 
treatment was found to induce secretion of IL-1β into cell supernatants.   
The first hypothesis, detailed in chapter 3, figure 3-12, which proposed a model 
of adjuvanticity where IL-1β production in response to PLY led to increased 
antibody magnitude compared to Δ6PLY immunization was now further 
investigated.   Using a previously published (Douce et al., 2010) in vivo model of 
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immunization the role(s) of both complement and IL-1β in the adjuvant activity 
of e-PLY and e-Δ6PLY were investigated.  These studies provide a new model of 
PLY adjuvanticity where complement and NLRP3 activation and subsequent IL-1β 
production are beneficial but not essential for the adjuvant activity of PLY.  
5.1 The production of IL-1β in PLY Treated BMDM is 
Dependent on Pore Formation and NLRP3 Activation 
Evidence in the literature has shown that PLY is able to activate the NLRP3 
inflammasome through pore formation (Chu et al., 2009; McNeela et al., 2010).  
Using BMDM generated from NLRP3-/- transgenic mice it is shown that PLY-
dependent IL-1β production is entirely dependent on the NLRP3 inflammasome 
(figure 5-1). 
 
Figure 5-1 IL-1 beta and KC production in NLRP3-/- BMDM treated with PLY and Δ6PLY.   
Transgenic BMDM were seeded at 1x10
5
 cells/well in a 96-well plate and allowed to adhere.  
The cells were treated with either PLY or Δ6PLY (17.5nM final conc.) alone or in the presence 
of 10% C3-/- sera or complement sufficient sera (total well volume 200μl) and incubated for 6 
hours at 37°C.  A positive control of 100ng/ml LPS + 5mM ATP was performed. The cell 
supernatants were harvested and IL-1β and KC were measured by ELISA (R and D systems).  
Statistical significance was tested by one-way ANOVA comparing all columns to the control 
column (untreated), *(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed three 
times with three technical replicates per condition, data are mean+SEM. 
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Although NLRP3-/- BMDM are incapable of producing IL-1β in response to the 
standard positive control (LPS+ ATP), KC production in response to LPS is 
unaffected.  Similarly, the KC response to PLY treatment in unchanged; 
however, the KC response to Δ6PLY is reduced compared to BMDM from MF1 
mice. 
5.2 The Role of Complement in IL-1β Production in PLY 
Treated BMDM 
The in vitro PLY treatment assay previously used was altered by the addition of 
10% whole, fresh mouse serum as a complement source.  This assay was used to 
investigate the effect on cytokine production of simultaneous complement 
activation during BMDM treatment with PLY variants. 
Figure 5-2 shows that the addition of complement sufficient serum significantly 
increased IL-1β in PLY treated cells.  IL-1β production was dependent on lytic 
activity of PLY (most likely through activation of the NLRP3 inflammasome), 
however, there is a balance between lytic activity and IL-1β production as 
treatment with 175nM PLY results in less IL-1β than treatment with 17.5nM, and 
this is likely due to cell death. Where complement sufficient serum was replaced 
with serum from mice lacking the C3 component of the complement cascade IL-
1β production was reduced but still present.  IL-1β production in BMDM treated 
with 17.5nM PLY in the presence of C3-/- sera was significantly lower than those 
treated with 17.5nM PLY in the presence of complement sufficient (MF1) sera 
(p= <0.05). 
 
 163 
 
 
Figure 5-2 IL-1β production in BMDM treated with PLY plus sera.   
BMDM were seeded at 1x10
5
 cells/well in a 96-well plate and allowed to adhere.  The cells 
were treated with PLY or Δ6PLY at 175, 17.5 or 1.75nM (final conc.).  Before addition of the 
proteins 20μl of the cell supernatant was replaced with whole, fresh serum obtained from 
complement sufficient (MF1) or C3-/- mice (final well volume 200μl).  The cells were treated 
with the proteins or LPS positive control for 6 hours at 37°C.  Assay supernatants were 
harvested and tested for the presence of IL-1β by ELISA (R and D systems).  Statistical 
significance was tested by one-way ANOVA with a Bonferroni’s post test (comparing all 
pairs of columns), shown above each column is significance compared to the control 
(untreated), comparisons between other columns are indicated by solid black lines, 
*(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed three times with three 
technical replicates per condition, data are mean+SEM. 
 
To further investigate the role of complement in IL-1β production in vitro 
increasing ratios of complement sufficient serum of either heat treated 
complement sufficient sera or C3-/- sera were added to PLY treated cells.  The 
production of IL-1β increased proportionally in response to the increasing 
presence of complement components (figure 5-3), demonstrating a dose-
response curve. 
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Figure 5-3 IL-1β production in BMDM treated with PLY in the presence or absence of 
complement.   
BMDM were seeded at 1x10
5
 cells/well and allowed to adhere. The cells were treated with 
PLY or Δ6PLY at 17.5nM (final conc.) for 6 hours.  Before addition of the proteins 10% of the 
cell supernatant was replaced with sera.  Heat treated (HT) or C3-/- sera were mixed with 
increasing ratios of complement sufficient sera (MF1). Assay supernatants were harvested 
and tested for the presence of IL-1β by ELISA (R and D systems). This experiment was 
performed once with two technical replicates per condition, data are mean+SEM. 
 
These initial experiments demonstrated that simultaneous complement 
activation plays a role in the immune response to PLY, specifically IL-1β 
production.  Figure 5-4 shows an updated model of PLY-dependent IL-1β 
production.  Now that it had been demonstrated that PLY treated BMDM were 
capable of producing IL-1β under certain conditions, the IL-1β hypothesis (figure 
3-12) was futher investigated. 
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Figure 5-4 Putative model of PLY-dependent IL-1 beta production, version 2.   
In this model the production of IL-1β occurs in response to PLY treatment and simultaneous 
complement activation, the mechanism remains undefined but is possibly due to synergy 
between complement components and TLR stimulation. 
 
5.3 Cytokine Production in PLY Treated Transgenic BMDM 
Given the evidence in the literature for synergy between TLR ligation and 
complement activation (Fang et al., 2009; Zhang et al., 2007) and the increasing 
evidence of PLY as a TLR4 ligand (chapter 3), the contributions of these immune 
components in the cytokine responses of BMDM to PLY treatment were further 
investigated. 
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5.3.1 C3-/- BMDM 
Macrophages are a known source of peripheral complement C3 production 
(Strunk et al., 1983) and as C3 was upregulated in response to PLY treatment 
(table 5-5) it was possible that in situ C3 production could be responsible for the 
residual IL-1β production in BMDM treated with PLY and C3-/- serum.  To 
investigate this hypothesis BMDM were generated from C3-/- transgenic mice and 
used in the treatment assay (figure 5-5).  It was found that the complete 
absence of complement component C3 (from either exogenous or endogenous 
sources) resulted in no significant change in IL-1β production compared to 
control cells or C3-/- cell treated with complement sufficient serum.  However, 
all other complement components are assumed to be present at normal 
concentrations, the potential involvement of other complement components is 
considered in the discussion section of this chapter. 
 
Figure 5-5 IL-1β production in C3-/- BMDM. 
Transgenic macrophages were seeded at 1x10
5
 cells/well and allowed to adhere.  The cells 
were treated with PLY or Δ6PLY at 17.5nM (final conc.) either alone or in the presence of 
10% C3-/-sera or complement sufficient sera for 6 hours at 37°C.  A positive control of 
100ng/ml LPS + 5mM ATP was performed.  Assay supernatants were tested for the presence 
of IL-1β by ELISA (R AND D SYSTEMS).  Statistical significance was tested by one-way 
ANOVA comparing all columns to the control column (untreated), *(p<0.05), **(p<0.01), 
***(p<0.001).  This experiment was performed twice with three technical replicates per 
condition, data are mean+SEM. 
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A lack of complement C3 had no effect on the production of KC in response to 
PLY treatment.  KC was used a control for response to PLY, neither a lack of 
complement C3 (figure 5-6(A)) nor addition of complement sufficient serum 
(figure 5-6(B)) significantly altered the production of KC in response to PLY. 
 
Figure 5-6 KC production in (A) C3-/- and (B) MF1 BMDM.  
 BMDM generated from (A) C3-/- and (B) MF1 mice were seeded at 1x10
5
 cells/well and 
allowed to adhere.  The cells were treated with PLY or Δ6PLY at 17.5nM (final conc.) and LPS 
(100ng/ml) for 6 hours at 37°C.  PLY/Δ6PLY treated MF1 BMDM were additionally treated with 
10% complement sufficient sera (200μl total well volume).  Assay supernatants were tested 
for the presence of KC by ELISA (R and D systems).  Statistical significance was tested by 
one-way ANOVA with a Bonferroni’s post test (comparing all pairs of columns), shown 
above each column is significance compared to the control (untreated), comparisons 
between other columns are indicated by solid black lines, *(p<0.05), **(p<0.01), ***(p<0.001).  
This experiment was performed three times with three technical replicates per condition, 
data are mean+SEM. 
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5.3.2 TLR4-/- BMDM and VIPER treated BMDM 
It has been demonstrated that PLY is a TLR4 ligand; therefore it was thought this 
would provide ‘signal 1’ (figure 3-12) and induce transcription of pro-IL-1β for 
subsequent cleavage by the NLRP3 inflammasome ‘signal 2’.  To further 
investigate this BMDM generated from TLR4-/- transgenic mice were used in the 
PLY treatment assay (figure 5-7).  Interestingly, it was found that IL-1β was 
produced in response to PLY alone as well as in the presence of complement 
sufficient sera; the concentration of IL-1β in cell supernatants was 
approximately six-fold less than that produced by BMDM generated from MF1 
mice when comparing PLY treated cells in the presence of complement 
sufficient sera.  The production of IL-1β in response to the standard positive 
control (LPS+ATP) was completely lost.   
 
Figure 5-7 IL-1β production in TLR4-/- BMDM.   
BMDM generated from TLR4-/- mice were seeded at 1x10
5
 cells/well and allowed to adhere.  
The cells were treated with PLY or Δ6PLY at 17.5nM (final conc.) either alone or in the 
presence of 10% C3-/-sera or complement sufficient sera (200μl total well volume) for 6 
hours at 37°C.  A positive control of 100ng/ml LPS + 5mM ATP was performed.  Assay 
supernatants were tested for the presence of IL-1β by ELISA (R and D systems).  Statistical 
significance was tested by one-way ANOVA with a Bonferroni’s post test (comparing all 
pairs of columns), shown above each column is significance compared to the control 
(untreated), comparisons between other columns are indicated by solid black lines, 
*(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed twice with three technical 
replicates per condition, data are mean+SEM. 
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As an additional method for determining the role of TLR4 in IL-1β production, 
BMDM were treated with a TLR4 inhibitor (VIPER) before PLY treatment (figure 
5-8).  The pattern of IL-1β production in this variation of the treatment assay 
was virtually identical to that observed in a TLR4-/- model.  Again, the LPS+ATP 
positive control did not induce IL-1β but IL-1β production was seen in response 
to PLY alone as well as PLY + complement sufficient serum.   
 
Figure 5-8 IL-1β production in VIPER treated BMDM.   
BMDM were seeded at 1x10
5
 cells/well and allowed to adhere. The BMDM were pre-treated 
for 2 hours with VIPER (TLR4 inhibitor) at a final conc. of 30μM.  The supernatant was 
removed and replaced with fresh medium.  Macrophages were then treated with PLY or 
Δ6PLY at 17.5nM (final conc.) either alone or in the presence of 10% complement sufficient 
sera for 6 hours at 37°C.  A positive control of 100ng/ml LPS + 5mM ATP was performed.  
Assay supernatants were tested for the presence of IL-1β by ELISA (R and D systems). 
Statistical significance was tested by one-way ANOVA with a Bonferroni’s post test 
(comparing all pairs of columns), shown above each column is significance compared to 
the control (untreated), comparisons between other columns are indicated by solid black 
lines, *(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed once with three 
technical replicates per condition, data are mean+SEM. 
 
 
 
In contrast to the model in chapter 1 (figure 3-14), PLY alone was capable of 
inducing IL-1β production, but only in the absence or inhibition of TLR4 
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signalling.  The putative model of PLY-dependent IL-1β production was updated 
to show this (figure 5-9). 
 
 
Figure 5-9 Putative model of PLY-dependent IL-1 beta production, version 3.  
 In contrast to IL-1β models 1 and 2, PLY alone was capable of inducing IL-1β production 
when TLR4 was genetically absent or its signalling was inhibited with VIPER peptide. 
 
Before the PLY treatment model was performed in the absence of TLR4 
signalling it was thought that perhaps the proposed interaction between PLY and 
TLR4 was too weak or transient to induce IL-1β secretion unless an additional 
proinflammatory factor such as LPS or complement activation occurred 
simultaneously.  The response now seen to PLY alone (figures 5-7 and 5-8) 
challenges the model of IL-1β production proposed until now; it would seem that 
the presence of TLR4 and subsequent ligation is actively inhibiting the secretion 
of mature IL-1β (figure 5-10).  
In chapter 3 (section 3.3), evidence was presented that the TLR4 binding site of 
PLY is within domains 1-3 of the protein, in addition TLR activating ability was 
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found in D4PLY that could not be attributed to TLR4.  In the new model 
proposed above IL-1β is produced even in the absence of TLR4, this could be due 
to an additional TLR binding site (potentially within domain 4) causing 
transcription of pro-IL-1β. 
 
Figure 5-10 Putative model of PLY-dependent IL-1 beta production, version 4.  
 As stated in model 3, the absence of TLR4 results in IL-1β production to PLY alone.  This 
could suggest that TLR4 specifically inhibits IL-1β production and/or processing. 
 
 In appendix 5 table 5-1 upregulation of IL-1 receptor type II (IL1RII) was found in 
response to D123PLY and D4PLY (no significant difference in expression in 
response to PLY or @6PLY), this receptor is capable of binding both pro-IL-1β 
(preventing processing) and mature IL-1β (preventing binding to the type I IL-1 
receptor) (Symons et al., 1995).  This could indicate a possible mechanism for 
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TLR4-mediated suppression of IL-1β and it would be of interest to assess PLY-
mediated upregulation of IL1RII in TLR4-/- BMDM. 
In conclusion, the in vitro data from this chapter supports a model where PLY 
can induce IL-1β production (without the need for exogenous TLR ligands, this is 
more biologically plausible), although this model is more complex than initially 
thought. 
 
5.4 The Role of Complement and IL-1β in PLY Adjuvant 
Activity 
Using a previously published mouse model of immunization the role(s) of both IL-
1β and complement in PLY adjuvant activity were investigated (Douce et al., 
2010). 
5.4.1 The Role of Complement in Adjuvant Activity 
As the complement system was shown to have a synergistic role in cytokine 
production in response to PLY it was hypothesized that it could potentially have 
a role in adjuvant activity.  Due to the number of available transgenic animals 
only immunization with e-Δ6PLY was possible, there was no statistically 
significant difference in anti-eGFP IgG produced in C3-/- mice compared to their 
genetic background controls (C57BL/6). This is discussed further in the 
discussion section of this chapter. 
5.4.2 The Role of IL-1β in Adjuvant Activity 
It was hypothesized that IL-1β may play a role in the magnitude of the antibody 
response seen in mice immunized with PLY or its derivatives.  This would explain 
the difference in antibody titres between mice immunized with Δ6PLY fusions 
compared to PLY fusions.  Figure 5-11 expands the IL-1β hypothesis put forward 
in figure 3-12 to include the possibility of a third signal (complement activation) 
in the PLY-induced production of IL-1β. 
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Figure 5-11 IL-1 beta Hypothesis - expanded. 
 
Figures 5-12 and 5-13 show antibody responses in NLRP3-/- mice (that are 
incapable of producing IL-1β) and their genetic background controls (BALB/c) 
following immunisation with either e-Δ6PLY or e-PLY.  In the absence of NLRP3 
there is no significant difference in anti-eGFP titres between mice immunized 
with e-Δ6PLY or e-PLY.  In comparison, in the genetic background control mice 
the response to e-PLY is significantly higher than the response to e-Δ6PLY. 
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Figure 5-12 Anti-eGFP IgG titres in NLRP3-/- (A) and BALB/c (B) mice immunized with e-
Δ6PLY or e-PLY. 
 NLRP3-/- (A) and BALB/c (B) mice were intranasally immunized with 20ng e-Δ6PLY or 2ng 
PLY prepared in PBS to a volume of 20μl.  Immunizations were performed under light 
anaesthesia (3.5% isofluorane/1.5% O2, 1.5L per minute) by instilling the prepared vaccines 
into the nares by gentle pipetting. Immunizations were performed and blood samples were 
taken by tail bleed on days 0, 14 and 28.  On day 42 terminal blood samples were taken by 
cardiac puncture under anaesthesia.  Anti-eGFP titres were analysed by ELISA.  Statistical 
significance was measured by unpaired t test, comparing test serum samples to 
unimmunized control serum, *(p>0.05), ** (p>0.01, *** (p>0.001).  This experiment was 
performed once using 5 mice per condition, serum samples were tested in duplicate, data 
are mean+SEM. 
 
The difference in anti-eGFP antibody titres between mice immunized with either 
e-Δ6PLY or e-PLY in the presence or absence of NLRP3 (and therefore IL-1β) is 
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best demonstrated in figure 5-13 where it can be clearly observed that removing 
NLRP3 from the in vivo system reduces the adjuvanticity of PLY to that of Δ6PLY. 
 
Figure 5-13 Anti-eGFP IgG titres in NLRP3-/- (A) and BALB/c (B) mice immunized with e-
Δ6PLY or e-PLY.  
Results shown are the same as in figure 5-12 but with a reduced scale. (A) Direct 
comparison of anti-eGFP IgG present in NLRP3-/- and BALB/c mice immunized with e-Δ6PLY 
or e-PLY on day 42. (B) Anti-eGFP antibody titres on day 42 in NLRP3-/- mice immunized 
either e-PLY or e-Δ6PLY.  Shown above each column is significance compared to the control 
(untreated), comparisons between other columns are indicated by solid black lines, 
*(p<0.05), **(p<0.01), ***(p<0.001).  This experiment was performed once using 5 mice per 
condition, serum samples were tested in duplicate, data are mean+SEM. 
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Anti-PLY antibodies were not found in blood or nasal washes under any of the 
immunization conditions (data not shown).  This is consistent with previous 
immunization experiments performed within the Mitchell group (Douce et al., 
2010)(unpublished data).  
 
In figure 5-14 anti-eGFP titres in the four groups were also assessed, however, 
although there is a trend towards greater anti-eGFP IgA titres in BALB/c mice 
immunized with e-PLY there are no significant differences between the four 
groups, this is potentially due to the relatively low antibody titres and variation 
within groups. 
 
Figure 5-14 Anti-eGFP IgA titres in NLRP3-/- and BALB/c mice immunized with e-Δ6PLY.  
 Mice were intranasally immunized with 20ng e-Δ6PLY on days 0, 14 and 28.  On day 42 
animals were humanely sacrificed by terminal bleed under anaesthesia and nasal washes 
were collected for analysis of specific IgA by ELISA. Statistical significance was measured 
by unpaired T-test, comparing test nasal wash samples to nasal washes from unimmunized 
mice, *(p>0.05), ** (p>0.01, *** (p>0.001).  This experiment was performed once using 5 mice 
per condition, nasal wash samples were tested in duplicate.  Data are mean+SEM. 
 
 
Based on these experiments the increased magnitude of antibodies seen in fusion 
vaccines where lytic PLY is the adjuvant can be attributed to the following 
immunological events/premises –  
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1) – PLY ligates Toll-like receptors (TLR4, plus other TLR?) on host cells and 
induces transcription of Pro-IL-1β.  ‘Signal 1’. 
2) – PLY inhibits IL-1β processing or release, (mediated by TLR4?). 
3) – PLY forms pores on the cell surface and actives the NLRP3 
inflammasome.  ‘Signal 2’. 
4) – PLY-induced IL-1β production in vitro was enhanced or dependent on 
simultaneous complement activation. ‘Signal 3’? 
5) – Increased antibody magnitude was NLRP3-dependent in vivo. 
6) - IL-1β production was NLRP3-depedendent in vitro. 
 
These data suggest that the IL-1β hypothesis is correct and that the reduced 
antibody titres seen in mice immunized with Δ6PLY-based vaccines compared to 
PLY-based vaccines is due to a lack of IL-1β production. 
5.5 Analysis of IgG Subclasses Produced in Response to e-
PLY and e-Δ6PLY Immunization in NLRP3-/- and BALB/c 
Mice 
In addition to measuring titres of the antibody isotypes IgA and IgG, the specific 
subsets of IgG present in immune sera were analyzed.  There are four subclasses 
of IgG; this gives a greater breadth and specificity of IgG function (described in 
table 5-2) (Clark, 1997) and is thought to be based on differential affinities for 
Fc receptors (Nimmerjahn & Ravetch, 2005).  During isotype switching helper T 
cells (Th) secrete cytokines that inform B cells which antibody isotype to 
produce (IgA, IgE etc.), in addition, where IgG is induced these cytokines also 
determine which IgG subclass will be produced (table 5-1).  By analyzing the IgG 
subsets present in immune sera from mice immunized with PLY fusions, 
conclusions can be drawn about the type of T helper response generated in 
response to immunization.  Pinpointing the elements of fusion vaccines 
responsible for different adaptive immune phenotypes could allow manipulation 
of future fusion vaccines for increased efficacy. 
 
 178 
 
 
Table 5-1 Role of Cytokines in Regulating Ig Isotype Expression (recreated from 
Immunobiology, 6
th
 edition, Janeway et al.) 
Cytokines IgM IgG3 IgG1 IgG2b IgG2a IgE IgA 
IL-4 inhibits inhibits induces  inhibits induces  
IL-5       augments  
IFNγ inhibits induces inhibits  induces inhibits  
TGFβ inhibits inhibits  induces   induces 
 
Table 5-2 Description of IgG Subsets and their Functions 
IgG Subclass Function 
IgG1 Recognition of carbohydrate epitopes. 
IgG2a Complement fixation and binding of 
protein antigens. 
IgG2b Complement fixation and binding of 
protein antigens. 
IgG3 Mast cell binding. 
 
The role of IL-1β in influencing IgG subsets was determined by measuring anti-
eGFP IgG subsets in the final bleeds of NLRP3-/- and BALB/c mice immunized 
with e-Δ6PLY or e-PLY (figure 5-15).  As shown in figures 5-12 and 5-13 the IgG 
response to eGFP is reduced in mice immunized with e-Δ6PLY and in NLRP3-/- 
mice immunized with either of the vaccines.  This is reflected in the IgG subsets, 
cumulatively the IgG response in BALB/c mice immunized with e-@6PLY is lower 
than that of BALB/c mice immunized with e-PLY, the pattern of IgG subsets 
between the two groups is however the same, IgG1 is the dominant subset, 
followed by IgG2a and IgG2b.  Although IgG3 is present in BALB/c mice 
immunized with e-@6PLY it is only present at very low concentrations (titre is 
15.3). 
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NLRP3-/- mice immunized with either e-Δ6PLY or e-PLY do not produce the 
IgG2b subset, additionally, e-PLY immunization did not induce production of 
IgG2a in this model.  There is no difference in IgG1 production between the two 
groups (A and B). 
 
 Figure 5-15 Analysis of anti-eGFP IgG subsets.   
Terminal serum samples from NLRP3-/- mice immunized with e-Δ6PLY (A) or e-PLY (B) and 
from BALB/c mice immunized with either e-Δ6PLY (C) or e-PLY (D) were analysed for the 
presence of IgG subsets using the Southern Biotech ELISA based clonotyping system.  The 
IgG subsets from BALB/c mice immunized with e-Δ6PLY (C) have also been included on a 
smaller scale (E) so that the ratios of IgG subsets can be better observed.  This experiment 
was performed once using 5 mice per group, serum samples were pulled and tested in 
duplicate, data are mean+SEM. 
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Inbred mouse strains with the Igh1-b allele such as C57BL/6 mice do not produce 
the IgG2a antibody subclass, in its place they produce a unique subclass, IgG2c 
(Morgado et al., 1989).  There is no cross-reactivity between IgG2a and IgG2c 
(Martin & Brady, 1998), and no alternative detection antibody was available, 
therefore, considering immunization with e-Δ6PLY did not result in different 
antibody titres between C3 sufficient and deficient mice the influence of 
complement on IgG subclass was not investigated. 
 
5.6 Discussion 
This work has revealed a synergistic relationship between the complement 
system and PLY.  Establishing this mechanism of IL-1β production then allowed 
further investigation of the role(s) of TLR4 and the NLRP3 inflammasome in the 
immune response to PLY, it was shown that the IL-1β response in PLY treated 
BMDM is entirely dependent on activation of the NLRP3 inflammasome (figure 5-
1).  However, IL-1β production is not entirely dependent on TLR4 ligation and 
may even be suppressed in a TLR4-dependent manner (figure 5-7 and 5-8).  Using 
two TLR4 exclusion models it was found that IL-1β was produced in response to 
both PLY alone and PLY plus complement sufficient serum, albeit the 
concentration of IL-1β was less than that found in TLR4 sufficient models in the 
presence of PLY plus complement sufficient sera; this suggests two possible 
modes of PLY-mediated IL-1β production.  
1 – PLY binds TLR and up-regulates Pro-IL-1β transcription.  Simultaneously, IL-1β 
production is controlled in a TLR4-dependent manner.  PLY activates the 
classical complement pathway, this proinflammatory signal overrules the 
regulation of IL-1β and allows its processing and export to culture supernatants. 
2 – In the absence of TLR4 signalling PLY binds to an as yet unidentified TLR 
(possibly through a binding site located in domain 4) and pro-IL-1β is 
upregulated.  In the absence of TLR4 pro-IL-1β is processed and exported to the 
cytoplasm normally and without the need for additional pro-inflammatory signals 
such as complement activation.  
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Figure 5-16 incorporates these two modes of action into a final putative model 
of PLY-dependent IL-1β production. 
 
Figure 5-5-16 Final putative model of PLY-dependent IL-1β production.  
 The results presented in this chapter have revealed a complex mechanism for the PLY-
dependent production of IL-1β.  In the above diagram these results have been compiled to 
create a putative model of PLY-dependent IL-1β production.  In this model PLY stimulates 
TLRs resulting in the transcription of pro-IL-1β, it also activates the NLRP3 inflammasome 
by pore formation.  However, the stimulation of TLR4 inhibits either transcription or 
processing of pro-IL-1β into its active form, complement activation by PLY is then required 
to override this inhibition. 
 
The use of transgenic C3-/- mice for both sera and BMDM has suggested that C3 
presence increases the magnitude of IL-1β production but is not essential 
suggesting that complement components from higher in the classical activation 
pathway are involved.  In figure 5-7 the difference in IL-1β production between 
BMDM treated with complement sufficient or C3-/- sera is striking compared to 
other experiments.  Although VIPER was used in this experiment it seems 
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unlikely that this difference is due to TLR4 inhibition; as detailed in section 
2.10.3 the preparation of complement sufficient sera is a delicate process as 
mishandling of the sera can activate the alternative complement pathway and 
deplete complement components in the sample, in addition there will be 
inherent variability in the concentration and ratios of complement components 
in serum samples.  This could also explain the low IL-1β response to C3-/- sera in 
figure 5-2.  It is likely that more experimental replicates would reduce this 
variation.   As figure 5-17 shows there are several complement components that 
precede C3 in the classical complement cascade, while C3a and C5a 
(anaphylotoxins) are known pro-inflammatory mediators, C4a and C2a are 
increasingly being recognized as important mediators of inflammatory immune 
responses as well as essential components of the classical complement cascade 
(Mattsson et al., 2011).  It would be of interest to further investigate the role(s) 
of individual components of the complement cascade using Quidel’s depleted 
sera (where individual complement components have been removed), the use of 
commercially prepared sera could also reduce inter-experiment variation.  
Additionally, in an initial investigation into PLY dependent gene expression 
(appendix 5) complement C3 was shown to be upregulated in BMDM treated with 
both Δ6PLY and PLY, the production of C3 in situ could help to create an 
‘inflammatory focus’ at the site of fusion vaccine administration and is 
potentially an important factor in adjuvant activity.  Complement activation 
would clearly not be the only factor in adjuvant activity as demonstrated by the 
unchanged KC response to PLY and Δ6PLY in the presence or absence of 
exogenous (sera) or endogenous (C3 upregulation) complement.  However, it will 
be important to investigate the effect complement activation has on the 
production of other cytokines. 
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Figure 5-17 Diagram of the classical complement cascade.  
 All complement activation pathways converge on the C3 convertase, the classical pathway 
is typically initiated by the cross-linking of surface bound antibody with the C1 complex.  In 
the case of PLY-dependent activation a structural homology with antibody Fc within D4 of 
PLY may be recognized by the C1 complex. 
 
It was thought that complement activation could play a direct role in the 
adjuvant activity of PLY, however, C3-/- mice responded equally to their genetic 
background controls (C57BL/6) (data not shown).  This could however, be a 
reflection of the capabilities of this mouse strain rather than the role of 
complement in PLY adjuvanticity.  C57BL/6 mice have an unusual antibody 
phenotype in that the IgG subset IgG2a is not produced and instead a subclass 
named IgG2c is produced (Mestas & Hughes, 2012). This is also an important 
consideration for In vitro experiments, while control conditions such as LPS + 
ATP suggest that BMDM generated from different backgrounds respond similarly 
in these experiments (e.g. figures 5-2 and 5-5) it would be more appropriate to 
use BMDM generated from mice of the same genetic background for control 
experiments where transgenic BMDM are used.  If a transgenic complement 
deficient strain could be found on an alternative background it would be of 
interest to see if this alters the IgG subclass profile compared to complement 
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sufficient mice.  Additionally, as Δ6PLY induces a lower magnitude of antibody 
response compared to PLY, immunization of C3-/- mice with e-PLY could 
potentially highlight differences in antibody magnitude compared to 
complement sufficient strains.  This would also add strength to IL-1β hypothesis 
laid out in this thesis, where complement provides ‘signal 3’ in PLY-induced IL-
1β production, thereby increasing the magnitude of an antibody response. 
It has been shown that complement activation can synergize with TLRs and IL-6 
to promote Th17 biased adaptive immune responses (Fang et al., 2009).  While 
in this study antibody levels were assessed no T-cell outputs were measured.  As 
described in chapter 1, cell-based immunity (particularly Th17) is an essential 
component in protective immune responses against Streptococcus pneumoniae, 
and so in future experiments the impact of complement in promoting T-cell 
phenotypes in response to PLY-based vaccines should be assessed. 
Immunization of NLRP3-/- mice demonstrated that a lack of NLRP3 (and 
therefore IL-1β) reduces antibody titres in response to e-PLY to the same level 
as those raised against e-Δ6PLY (figure 5-13).  This suggests that the IL-1β 
hypothesis first described in chapter three is correct and a lack of IL-1β in 
response to non-lytic PLY variants is responsible for the reduction in antibody 
magnitude.   It could also be said that complement activation has an indirect 
role in adjuvant activity as its activation enhances IL-1β production in vitro and 
therefore could be involved in IL-1β production in vivo increasing antibody 
magnitude.   It cannot be determined from these experiments whether pre-
formed IL-1β stores (such as those found in PBMC, particularly monocytes) are 
involved in the immune response to PLY vaccines, although it is likely that they 
do.  As TLR4 alone is not responsible for the upregulation of IL-1β this would not 
be a suitable model for investigation, however, if an additional TLR site is found 
within PLY a double knock-out mouse model could be devised.  Previously,   
TLR4-/- mice have been used in the Mitchell group immunization model to 
investigate the role of TLR4 in adjuvanticity, however, a mixed response arose 
with no difference in mean antibody titres between TLR4-/- mice and their 
genetic backgrounds controls (BALB/c) (Ma, 2012).  It is possible that as with 
complement and IL-1β, TLR4 plays a non-essential role in the adjuvant activity 
of PLY but aids in the magnitude of response.  Combined these data suggest that 
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the adjuvant activity of PLY is pleiotropic and that the immune system is able to 
compensate for missing elements such as TLR4 making it difficult to identify a 
single essential component responsible for adjuvant activity. 
Analysis of IgG subsets in e-Δ6PLY and e-PLY immunized NLRP3-/- and BALB/c 
mice has suggested that NLRP3 may play a role in the induction of an IgG2b 
response (figure 5-15); in the absence of NLRP3 the IgG2b subset is not induced 
in response to either vaccines and the IgG2a response is lost in response to e-
PLY.  However, it is unlikely that this is due to IL-1β as aside from the magnitude 
of response there is little difference in IgG subsets raised against either vaccine 
(with the exception of small quantities of IgG3 raised against e-Δ6PLY).  This 
analysis suggests that the fundamental composition/phenotype of the immune 
response raised by PLY/Δ6PLY vaccines is the same regardless of lytic activity. 
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6. Effect of Fusion Antigens on Immunization 
Outcome 
As discussed in detail in the introduction (section 1.3.5) the Mitchell group have 
studied the efficacy of PLY based vaccines extensively in the form of 
pneumococcal protein fusion vaccines.  Briefly, the project was funded by the 
Programme for Appropriate Technology in Healthcare (PATH), PLY and delta6PLY 
were used as fusion partners for four chosen antigens based on evidence of some 
protective immunity induced by the proteins.  The four fusion antigens chosen 
were PsaA, PspA, PspC and PhtD, PATH nomenclature is detailed in table 6-1.  
The PATH vaccines were administered either intranasally or subcutaneously 
following the immunization schedule detailed in the materials and methods 
section 2.10.   After completion, sera from the PATH project were available as 
research materials; the IgG subsets within these sera were measured to give 
insight into the influence of both administration route and fusion antigen(s) on 
immune outcome following immunization with PLY based vaccines.  This study 
also gave further insight into the cytokine milieu generated by PLY that would 
influence the phenotype of the adaptive immune response to PLY immunization.   
Table 6-1 PATH Grant Experimental Nomenclature 
Experiment Name Fusion Antigen Immunization Route 
PATH 1 PsaA-PLY/Δ6PLY Intranasal  
PATH 2 PsaA-PLY/Δ6PLY Subcutaneous 
PATH 3 PspA-PLY/Δ6PLY Intranasal 
PATH 4 PspA-PLY/Δ6PLY Subcutaneous 
PATH 5 PspC-PLY/Δ6PLY Intranasal 
PATH 6 PspC-PLY/Δ6PLY Subcutaneous 
PATH 7 PhtD-PLY/Δ6PLY Intranasal 
PATH 8 PhtD-PLY/Δ6PLY Subcutaneous 
PATH 9 PsaA/PspA/PspC/PhtD-
Δ6PLY 
Intranasal 
PATH 10 PsaA/PspA/PspC/PhtD-
Δ6PLY 
Subcutaneous 
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Anti-PLY responses were not generated against PsaA or PspA fusion vaccines and 
so have not been included in those figures.  Antibody titres in all experiments 
were determined by calculating the reciprocal titre of the last well in which 
signal could be detected above background (OD485-10nm 0.3), it is for this reason 
that some readings are identical.  Due to the small sample volumes available 
sera were pooled within groups and tested in duplicate.   
 
6.1  IgG subclasses induced by Immunization with PsaA 
fusion vaccines 
Antibodies generated against PsaA in the PATH 1 experiment (figure 6-1) were 
predominantly of the IgG1 subtype, IgG2b was generated in response to PsaA-PLY 
but not PsaA-Δ6PLY.   
 
 
Figure 6-1 PATH 1.  
IgG subsets were determined in terminal serum samples from MF1 mice immunized 
intranasally with either PsaA-PLY or PsaA-Δ6PLY (following schedule detailed in table 2-13). 
Anti-PsaA antibodies were assessed by ELISA (Southern Biotech antibody clonotyping kit).  
Serum samples were pooled from 5 immunized mice, samples were added to the first well at 
1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody (Ab) titres were 
determined by calculating the reciprocal titre of the last well in which signal could be 
detected above background (OD485-10nm 0.3).  
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Subcutaneous immunization with PsaA-PLY or PsaA-Δ6PLY (figure 6-2) resulted in 
an altered IgG subset pattern compared to intranasal immunization.  Similarly to 
intranasal immunization, IgG2a did not feature as a dominant IgG subset in the 
PATH 2 group, IgG2b was also unaffected by immunization route.  There is an 
interesting trend reversal in IgG1 production; given intranasally PsaA-Δ6PLY does 
not induce substantial titres of IgG1 whereas PsaA-PLY does, the opposite is true 
when the fusion vaccines are given subcutaneously.  In addition subcutaneous 
immunization results in IgG3 production in response to PsaA-Δ6PLY where 
intranasal immunization does not, and IgG3 production in response to PsaA-PLY 
is approximately 4 times higher via this route compared to intranasal 
immunization. 
 
 
Figure 6-2 PATH 2. 
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
subcutaneously with either PsaA-PLY or PsaA-Δ6PLY (following schedule detailed in table 
2-13).  Anti-PsaA antibodies were assessed by ELISA (Southern Biotech antibody 
clonotyping kit).  Serum samples were pooled from 5 immunized mice, samples were added 
to the first well at 1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody 
(Ab) titres were determined by calculating the reciprocal titre of the last well in which signal 
could be detected above background (OD485-10nm 0.3). 
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6.2  IgG subclasses induced by Immunization with PspA 
fusion vaccines 
Similarly to PATH 1 figure 6-1, intranasal immunization with PspA-PLY results in 
an IgG1/2b anti-PspA response (figure 6-3). 
 
 
Figure 6-3 PATH 3.  
IgG subsets were determined in terminal serum samples from MF1 mice immunized 
intranasally with either PspA-PLY or PspA-Δ6PLY (following schedule detailed in table 2-13).  
Anti-PspA antibodies were assessed by ELISA (Southern Biotech antibody clonotyping kit).  
Serum samples were pooled from 5 immunized mice, samples were added to the first well at 
1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody (Ab) titres were 
determined by calculating the reciprocal titre of the last well in which signal could be 
detected above background (OD485-10nm 0.3). 
 
When administered subcutaneously the antibody response to PspA-Δ6PLY is 
restored, however, the response to PspA-PLY is diminished in comparison to 
intranasal immunization and is dominated by an IgG2b phenotype (figure 6-4).  
The IgG3 subset is produced with this administration route but only in response 
to PspA-PLY.  In the PATH 3 and 4 studies the IgG1 subset is produced in 
response to PspA-PLY only when given intranasally, yet is produced in response 
to both vaccines when given subcutaneously (albeit at greatly reduced titres).   
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Figure 6-4 PATH 4.  
IgG subsets were determined in terminal serum samples from MF1 mice immunized 
subcutaneously with either PspA-PLY or PspA-Δ6PLY (following protocol detailed in table 2-
13).  Anti-PspA antibodies were assessed by ELISA (Southern Biotech antibody clonotyping 
kit).  Serum samples were pooled from 5 immunized mice, samples were added to the first 
well at 1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody (Ab) titres 
were determined by calculating the reciprocal titre of the last well in which signal could be 
detected above background (OD485-10nm 0.3). 
 
 
6.3  IgG subclasses induced by Immunization with PspC 
fusion vaccines 
When PspC was used as a fusion antigen in PATH 5 anti-PspC IgG1, IgG2a and 
IgG2b titres were produced equally in response to PspC-PLY, there was no 
response to PspC-Δ6PLY (figure 6-5).  There was a notable increase in anti-PLY 
antibodies in response to PspC-PLY and they were predominantly of the IgG2b 
subset, this could potentially indicate that PspC itself has some adjuvant 
activity. 
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Figure 6-5 PATH 5.  
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
intranasally with either PspC-PLY or PspC-Δ6PLY (following schedule detailed in table 2-13).  
Both anti-PspC (A) and anti-PLY (B) antibodies were assessed by ELISA (Southern Biotech 
antibody clonotyping kit).  Serum samples were pooled from 5 immunized mice, samples 
were added to the first well at 1:50 dilution and serially diluted 1:5 vertically down the plate.  
Antibody (Ab) titres were determined by calculating the reciprocal titre of the last well in 
which signal could be detected above background (OD485-10nm 0.3). 
 
In contrast to intranasal administration, when PspC-PLY is given subcutaneously 
the antibody response is predominantly composed of IgG1 (figure 6-6).  The anti-
PspC response to PspC-@6PLY is absent when either administration route is used.  
Interestingly, an anti-PLY response is generated to both vaccines when given 
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subcutaneously; similarly to PATH 5 the response is predominantly composed of 
IgG2b, however, the response is around 25-fold lower when the subcutaneous 
route is used (titres of 30000 compared to 750,000 approx.)
 
Figure 6-6 PATH 6. 
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
subcutaneously with either PspC-PLY or PspC-Δ6PLY (following schedule detailed in table 
2-13).  Both anti-PspC (A) and anti-PLY (B) antibodies were assessed by ELISA (Southern 
Biotech antibody clonotyping kit).  Serum samples were pooled from 5 immunized mice, 
samples were added to the first well at 1:50 dilution and serially diluted 1:5 vertically down 
the plate.  Antibody (Ab) titres were determined by calculating the reciprocal titre of the last 
well in which signal could be detected above background (OD485-10nm 0.3). 
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6.4  IgG subclasses induced by Immunization with PhtD 
fusion vaccines 
Intranasal immunization with PhtD-PLY and PhtD-Δ6PLY results in an antibody 
response composed of IgG1 and IgG2a (a subset not dominant in any other PATH 
group) (figure 6-7).  In fact IgG2a is the dominant IgG subset in mice immunized 
intranasally with PhtD-PLY.  There is no anti-PLY IgG response towards either 
vaccine when given intranasally.  
 
Figure 6-7 PATH 7. 
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
intranasally with either PhtD-PLY or PhtD-Δ6PLY (following schedule detailed in table 2-13).  
Both anti-PhtD (A) and anti-PLY (B) antibodies were assessed by ELISA (Southern Biotech 
antibody clonotyping kit).  Serum samples were pooled from 5 immunized mice, samples 
were added to the first well at 1:50 dilution and serially diluted 1:5 vertically down the plate.  
Antibody (Ab) titres were determined by calculating the reciprocal titre of the last well in 
which signal could be detected above background (OD485-10nm 0.3). 
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As previously seen subcutaneous immunization with PLY and Δ6PLY fusions 
results in lower IgG titres compared to intranasal immunization, this is also true 
in PATH 8 (figure 6-8).  Additionally the IgG subset profile is now predominantly 
composed of IgG1.  Finally, subcutaneous immunization with PhtD-Δ6PLY does 
generate anti-PLY antibodies, IgG2a is the least prevalent subset and IgG2b is 
the most prevalent, IgG1 and IgG3 are produced at similar concentrations. 
 
Figure 6-8 PATH 8. 
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
subcutaneously with either PhtD-PLY or PhtD-Δ6PLY (following schedule detailed in table 2-
13).  Both anti-PhtD (A) and anti-PLY (B) antibodies were assessed by ELISA (Southern 
Biotech antibody clonotyping kit).  Serum samples were pooled from 5 immunized mice, 
samples were added to the first well at 1:50 dilution and serially diluted 1:5 vertically down 
the plate.  Antibody (Ab) titres were determined by calculating the reciprocal titre of the last 
well in which signal could be detected above background (OD485-10nm 0.3). 
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6.5  IgG subclasses induced by Immunization with a 10x 
mix of PsaA/PspA/PspC/PhtD –Δ6PLY fusion vaccines 
Following the assessment of single antigen fusion vaccines PATH 9 and 10 
experiments were carried out to test the efficacy of the four fusion vaccines in 
combination using Δ6PLY only as the adjuvant.  The terminal immune sera from 
these experiments were tested for IgG subsets to determine how the antigen 
combinations influence immune phenotype.  Additionally, the PLY only condition 
in both experimental groups gives insight into the baseline IgG subset response 
to PLY before the addition of other antigens. 
The terminal immune sera was tested for antibody subsets directed against each 
individual fusion antigen and compared to the response generated against single 
antigen vaccines.   
In PATH 9 (figure 6-9) the IgG response to PspA is unchanged compared to the 
single antigen vaccine, IgG1 antibody titres towards the other three antigens 
have all increased.  The anti-PsaA IgG subset also has increased titres of IgG2a 
and greatly reduced IgG2b titres compared to the single antigen vaccine. In the 
case of PhtD the IgG subset pattern has reversed and IgG1 is now the dominant 
subset over IgG2a.  Consistent with previous PATH studies there is little to no 
anti-PLY response generated following intranasal immunization with Δ6PLY 
fusions; in contrast the response generated to PLY alone is strong and composed 
predominantly of IgG2b followed by IgG1. 
 196 
 
 
 197 
 
 
 
 198 
 
 
Figure 6-9 PATH 9. 
IgG subsets were determined in terminal serum samples from MF1 mice immunized 
intranasally with a mix of PsaA-Δ6PLY, PspA-Δ6PLY, PspC-Δ6PLY and PhtD-Δ6PLY 
(following schedule detailed in table 2-13).  Antibodies raised against PsaA (A), PspA (B), 
PspC (C), PhtD (D) PLY (E) antibodies were assessed.  In addition, PATH 9 included MF1 
mice immunized with PLY only, anti-PLY IgG subsets in this group were also assessed (E). 
Antibody titres were assessed by ELISA (Southern Biotech antibody clonotyping kit).  
Serum samples were pooled from 5 immunized mice, samples were added to the first well at 
1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody (Ab) titres were 
determined by calculating the reciprocal titre of the last well in which signal could be 
detected above background (OD485-10nm 0.3). 
 
The antibody response generated towards fusion antigens in PATH 10 (figure 6-
10) is greatly reduced compared to PATH 9 and IgG1 is the dominant IgG subset 
in all conditions.  The antibody response to PLY only is now composed of IgG2a 
and IgG3 with a lower titre of IgG1. 
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Figure 6-10 PATH 10. 
 IgG subsets were determined in terminal serum samples from MF1 mice immunized 
subcutaneously with a mix of PsaA-Δ6PLY, PspA-Δ6PLY, PspC-Δ6PLY and PhtD-Δ6PLY 
(following schedule detailed in table 2-13).  Antibodies raised against PsaA (A), PspA (B), 
PspC (C), PhtD (D) PLY (E) antibodies were assessed.  In addition, PATH 10 included 5 MF1 
mice immunized with PLY only, anti-PLY IgG subsets in this group were also assessed (E).  
Antibody titres were assessed by ELISA (Southern Biotech antibody clonotyping kit).  
Serum samples were pooled from 5 immunized mice, samples were added to the first well at 
1:50 dilution and serially diluted 1:5 vertically down the plate.  Antibody (Ab) titres were 
determined by calculating the reciprocal titre of the last well in which signal could be 
detected above background (OD485-10nm 0.3). 
 
6.6 Discussion 
It appears that the fused antigen plays a significant role in determining the 
phenotype of the antibody response generated against PLY and Δ6PLY fusion 
vaccines.  Analysis of IgG subtypes in PATH serum samples has revealed that the 
magnitude of antibody response is not only determined by lytic activity (IL-1β 
etc.) but also by administration route as subcutaneous immunization resulted in 
consistently lower antibody titres compared to intranasal immunization, this is 
fortuitous as the fusion vaccines are intended to be administered intranasally 
should they be deemed suitable and effective for human use.  IgG3 appears to 
be more prevalent where vaccines are administered subcutaneously compared to 
intranasally, this trend may be a reflection of the resident cell types in both 
locales and therefore the cytokine milieu induced in response to PLY.  The 
cytokines induced during initial, innate responses to fusion vaccines will 
ultimately instruct the phenotype of the adaptive response for example, as INF-γ 
induces the IgG3 subclass and is a signature cytokine of Th1-type response it is 
likely that subcutaneously immunization promotes a Th1 response more strongly 
compared to intranasal immunization. The comparison of immunization with PLY 
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only between subcutaneous and intranasal administration has revealed that 
while subcutaneous immunization results in predominant IgG3 (Th1 induced) and 
IgG2b (Th2 induced) subsets, immunization intranasally induced IgG1 and IgG2b 
(both Th2 induced) subsets.  In a study of children with recurrent pneumococcal 
respiratory infections IgG2b was shown to be a protective subclass (Sorensen et 
al., 1996).  A study of protection in immunized mice using various Fc receptor 
transgenic animals suggested a protective role for Ig1 but not IgG3 (Saeland et 
al., 2003).  Taken together these studies suggest that the IgG3 subset is not 
essential for protection and that its absence following intranasal immunization is 
not detrimental. 
Although there is a general trend towards IgG1 predominance and IgG2b 
production in most groups each PATH antigen has a unique IgG subset 
phenotype, this suggests that there is antigenic immunodominance within the 
fusion vaccines.  This is best demonstrated in PATH 9 and PATH 10 (figures 6-9 
and 6-10), in both groups the highest antibody titre is IgG1 directed against 
PhtD, and in addition specific IgG1 against the other antigens has increased 
suggesting that PhtD is influencing the IgG subset phenotype.  There is evidence 
to suggests that PhtD in itself may be a potent adjuvant (Ma, 2012). The 
pneumococcal virulence factors all have their own immunogenic properties 
therefore it is not surprising that they influence the immune phenotype when 
used as vaccine antigens.  Interestingly, as shown in figure 5-15 even an 
innocuous antigen such as eGFP has some influence over the IgG subset 
phenotype; given that eGFP is not immunogenic it would be expected that 
intranasal immunization with e-PLY would result in the same IgG subsets as PLY 
given intranasally (figure 6-9), however this is not the case, IgG2b is reduced in 
response to e-PLY and IgG2a in increased.  Finally, anti-PLY antibodies are rarely 
generated against PLY/Δ6PLY fusion vaccines; this could indicate another 
virulence property of PLY.  It is possible that the adjuvant activity of PLY has 
arisen and been conserved through an ability to promote adaptive immune 
responses to antigens other than itself. 
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7. Final Discussion 
7.1  The Interaction of PLY with Toll-like Receptors 
The work presented in this thesis has contributed to our understanding of 
interactions between PLY and the host immune response.  In particular the 
interaction between TLR4 and PLY has been confirmed and attributed to a 
specific region of the toxin (domains 1-3).  Previously, TLR4-dependent 
responses to PLY had been treated sceptically, a particular criticism being that 
purified PLY was likely contaminated by LPS.  However, analysis of LPS content 
and the use of appropriate vehicle controls have bolstered the argument that 
the interaction between TLR4 and PLY is genuine.   
In addition evidence has been presented that could suggest another TLR binding 
site.  The THP-1 reporter cell line indicated TLR activity in response to 
treatment with both D123PLY and D4PLY (figures 3-9 and 3-11).  There was no 
evidence of TLR4 binding in response to D4 suggesting that a different TLR could 
be involved (figure 3-10).   
The importance of TLR4 in the adjuvant activity of PLY was explored primarily 
by assessing its role in cytokine and chemokine production (section 6.2).  The 
role of TLR4 in PLY-based vaccines has previously been studied in a mouse model 
of immunization, however, there were no statistical differences between    
TLR4-/- and genetic background control mice (Ma, 2012).  This would suggest 
that TLR4 is not essential for the adjuvant activity of PLY, however, (as will be 
discussed in more detail) TLR4 though not essential for adjuvant activity may 
still play a role in the immune response to PLY-fusion vaccines. 
7.2  The Production of KC, IL-6 and IL-1β and Their 
Potential Role(s) in the Adjuvant Activity of PLY 
The list of cytokines and chemokines that could potentially be involved in the 
adjuvant activity of PLY and therefore would be of interest to measure by ELISA 
is prohibitively long.  Therefore, KC, IL-6 and IL-1β were chosen as candidates 
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for initial assessment either because they had already been shown to be 
produced in response to PLY and/or had been shown to have a role in protection 
from pneumococcal infection or disease.  Ideally, the production of additional 
cytokines/chemokines identified by gene expression analysis (noted in section 
7.5) would have been explored; however there was not sufficient time to do 
this. 
7.2.1 IL-1 beta 
IL-1-β was chosen as a candidate cytokine because it has previously been shown 
to be involved in pneumococcal infection/protection (Shoma et al., 2008).  
Additionally its production is tightly regulated by a two-step process (1) TLR 
ligation resulting in pro-IL-1β production, and (2) activation of the NLRP3 
inflammasome, a platform for caspase-1 activation and subsequent cleavage of 
pro-IL-1β into its active form; this made it an ideal candidate for examining the 
TLR4 binding capability of PLY. 
The IL-1β hypothesis was based on two observations about PLY - (1) PLY is 
thought to interact with TLR4 and (2) PLY forms pores in cell membranes causing 
ion flux (which in theory would activate the NLRP3 inflammasome).  Therefore 
the initial IL-1β hypothesis was simple, if PLY can provide both signal 1 and 2 in 
the same cell IL-1β will be produced, Δ6PLY (being non-lytic) would not activate 
the NLRP3 inflammasome, IL-1β would not be produced, and that this could be 
the biological basis for reduced antibody titres in response to Δ6PLY compared 
to PLY.  However, while testing of this hypothesis has shown that although the 
theory is essentially correct, the mechanism of PLY-dependent IL-1β production 
is far more complex than initially thought.  The production of IL-1β in response 
to PLY was completely dependent on NLRP3 activation (figure 5-1), however, the 
role of TLR4 was more complex.  When BMDM from outbred MF1 mice were 
treated with PLY alone IL-1β was not present in the supernatants (figure 3-13), 
however, when TLR4 was removed from the treatment model, either by blocking 
TLR4 signalling with VIPER or using TLR4-/- BMDM IL-1β was present in cell 
supernatants (figures 5-7 and 5-8).  This suggest two new hypotheses –  
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1) TLR4 has a suppressive effect on IL-1β production or secretion when PLY 
alone is used to treat BMDM. 
2) In the absence of TLR4 the presence of IL-1β in cell supernatants would 
suggest transcription of pro-IL-1β is mediated by another, as yet 
unidentified TLR binding site in PLY. 
 
Finally, an additional mechanism for IL-1β production was observed, where TLR4 
is present (MF1 mice) it is possible for PLY to induce IL-1β production without 
the need for an exogenous TLR ligand if treatment is performed in the presence 
of complement sufficient sera (figures 5-2 and 5-3).  Complement activation has 
been shown to synergize with TLR ligation to enhance or induce cytokine 
secretion, particularly IL-1β (Fang et al., 2009; Zhang et al., 2007).  If TLR4 is in 
some way suppressing IL-1β production it is possible that simultaneous 
complement activation provides the inflammatory stimulus required to overcome 
this and induce IL-1β production.  It is unclear at this stage which complement 
components are involved in this mechanism, the anaphylotoxins C3a and C5a 
have been implicated in previous studies of complement – TLR synergy, however, 
as there is still residual IL-1β produced in the absence of C3 it would seem that 
components that precede C3 in the classical complement cascade are involved.  
It is not surprising that the relationship between PLY, TLR4 and IL-1β has been 
difficult to elucidate in the past given this new model of activation.  Proving 
that PLY was capable of inducing IL-1β production without the need for 
exogenous TLR ligands was essential before investigating the role of IL1β in 
adjuvant activity.   
 
7.2.2 IL-6 
As stated in chapter three, no IL-6 was found in the supernatants of PLY treated 
BMDM, it is possible that PLY-dependent IL-6 production is suppressed in a 
similar manner to IL-1β, although the presence of complement had no effect on 
its production (data not shown).  Additionally, in a previous study of cytokines 
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present in BALF following instillation of PLY into mouse lungs, IL-6 was present 
at significant concentrations (Kirkham, 2006).  Clearly IL-6 is produced in 
response to PLY; it may be that IL-6 production is favoured under in vivo 
conditions and/or that it is a late response and was not observed at the time 
points analysed. 
IL-6 has been shown to be induced by and have a protective effect during 
pneumococcal infection (Antunes et al., 2002; van der Poll et al., 1997).  It is 
also required (in combination with TGFβ) for induction of Th17 cells which are 
involved in protection from pneumococcal infection.  Therefore it will be 
important to further investigate the production of IL-6 in response to PLY, 
particularly which cells under what circumstances produce IL-6 and what effect 
this has on adjuvant activity and final immune phenotype. 
7.2.3 KC  
KC is a potent neutrophil chemoattractant and has been shown to be present in 
high concentrations in BALF following instillation of PLY into mouse lungs 
(Kirkham, 2006).  High concentrations of KC were also produced by BMDM 
treated with PLY (figure 3-15).  When analysing the production of KC in response 
to PLY treatment D4PLY did not induce production of this chemokine; KC 
production was primarily mediated by D123PLY (although PLY and Δ6PLY induced 
KC at greater concentrations) and was at least partially TLR4-dependent.   
The attraction of neutrophils could be an important feature of PLY 
adjuvanticity; the role of neutrophils in antigen presentation is increasingly 
recognized as they have been shown to both influence the level of antigen 
presentation and in some circumstances present antigen themselves (Culshaw et 
al., 2008; Yang et al., 2010).   
7.2.4 The Role of Complement in Cytokine Production and 
Adjuvant Activity 
In vitro the presence of complement was found to be essential for IL-1β 
production, however, it did not appear to have a role in adjuvant activity as 
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there was no difference in antibody response between C3-/- and C57BL6 mice.  
The number of variables in this immunization study was limited by the number of 
available transgenic animals and so only e-Δ6PLY immunizations were 
performed.  Therefore this was not a study of the role of complement-enhanced 
IL-1β in adjuvant activity but a study of the role of complement C3 itself in 
adjuvant activity.  Further investigation of the role of complement activation 
should be pursued, particularly since complement C3 gene expression was 
upregulated in initial expression studies of PLY treated BMDM (appendix 5), this 
would provide a source of peripheral complement and could sustain and 
‘inflammatory focus’ at the site of inoculation. 
7.3 Binding of PLY Variants to Host Cells and Interactions 
with the Cell Cytoskeleton 
The binding of PLY to host cells via cholesterol and subsequent formation of 
pores is well understood and is clearly an important feature of adjuvanticity.  
PLY has been shown to bind RAW 264.7 cells as rapidly as 5 seconds after 
introduction in vitro, however, there is a lag time of up to 30 minutes before 
signs of cell death (such as rounding) are obvious (figure 4-1).  The sensitivity of 
different cell types to PLY-mediated lysis and death varied, in particular mature 
macrophages were highly resistant to PLY-mediated lysis compared to cell lines 
of a monocytic lineage (table 3-2), potentially due to active membrane repair 
through endocytosis of pores.  This highlighted the need to be aware of 
differences in lytic activity in different cells when creating new models, 
particularly if the BMDM model is repeated in bone marrow derived dendritic 
cells (BMDC). As described in section 2.9.2 it was decided that consistency in the 
number of PLY monomers would be adhered to (rather than percentage lysis), 
this will be more useful if these studies are repeated in other cell types as it will 
allow direct comparison of responses to non-lytic and truncation mutants 
between cell types. 
The HaloTag® system was a useful platform for analysis of both binding to host 
cells using microscopy and analysis of subsequent interactions with host proteins 
by pull-down.  Unexpectedly, all PLY variants were found to bind to host cells 
and each had a unique binding pattern; D123PLY had a striking binding pattern 
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and was observed in aggregates covering large areas of the cell surface (figures 
4-6 and 4-21).  This was a previously unknown feature of D123PLY, although 
biding of domains 1-3 of LLO has previously been reported (Dubail et al., 2001).  
Both PLY and Δ6PLY were observed inside the cells indicating a specific uptake 
mechanism (figures 4-3 and 4-5); this is unsurprising as the proteins must enter 
the cell at some point in order for antigen processing and presentation to occur.  
There was some evidence that D123PLY could be mediating antigen uptake, 
however this will need further confirmation. 
Finally, D123PLY and D4PLY had dramatically different binding patterns to full-
length PLY and Δ6PLY.  In a previous study using the in vivo model described in 
this thesis, the truncation mutants e-D123PLY and e-D4PLY did not possess 
adjuvant activity (Ma, 2012).  This suggests that the truncation mutants behave 
very differently to the full-length proteins and that adjuvant activity must 
derive from a combination of attributes from both domains.   While the 
truncations mutants were useful for identifying TLR binding sites and other 
biological responses (such as KC production) they may not be reflective of the 
behaviour of the whole molecule. 
7.4  Characteristics of Final Immune Phenotype following 
Immunization with PLY/Δ6PLY Fusion Vaccines 
The difference in magnitude of antibody response between PLY and Δ6PLY based 
fusion vaccines has been demonstrated to be due to differential IL-1β 
production, caused by lack of NLRP3 activation by Δ6PLY (figures 5-12 and 5-13).  
This was found to affect antibody magnitude alone, the IgG subclasses present 
following immunization with either e-PLY or e-Δ6PLY were identical (figure 5-15) 
indicating that lytic activity (and IL-1β) did not influence antibody phenotype 
(IgG1<IgG2a<IgG2b).  Data collected thus far from the PATH project show that 
protection is still observed using Δ6PLY-based fusion vaccines (unpublished data) 
therefore while IL-1β induces increased antibody production this may not be an 
important indicator of protection.   As mentioned in chapter 1 Th17 based 
immunity is thought to be essential for preventing pneumococcal colonization, 
whereas humoral immunity is required for protection from invasive disease.  In 
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future phenotyping of antigen specific T-cells following immunization with e-PLY 
or e-Δ6PLY should be performed to discover whether Th17 cells are induced and 
if so are they equally induced by PLY and Δ6PLY based vaccines. 
The use of PATH proteins demonstrated that IgG subclass is influenced by fusion 
antigens (chapter 6).  Since IgG1 and IgG2b are known to be protective 
subclasses it may be important to modify fusion mix vaccines to preferentially 
induce this IgG phenotype.   Interestingly, even eGFP had a modest effect on 
antibody phenotype compared to PLY alone (IgG2b decreased IgG2a increased).  
The cytokines thought to influence this type antibody subclass pattern are in 
fact in competition, for instance IL-4 induces IgG1 but inhibits IgG2a and IFNγ 
induces IgG2a but inhibits IgG1, IgG2b is induced by TGFβ and this also induces 
IgA production (a key feature of PLY/Δ6PLY-based vaccines).  So the final 
antibody phenotype is probably influenced by a delicate balance of these three 
cytokines and this could explain why the antibody phenotype differs based on 
the fusion antigen.  
7.5 Gene expression analysis 
An analysis of gene expression in BMDM treated with PLY and its derivatives was 
undertaken using gene profiler arrays (SABiosciences), unfortunately it was not 
possible to perform biological replicates before submission of this thesis and so 
there are substantial limitations in the interpretation of this data.  However, the 
data may be of future use for informing hypotheses and some of the data 
corroborates with both data presented in this thesis and in the literature, as 
such the data have been included as an appendix (appendix 5).  Analysis of gene 
expression in response to vaccine adjuvants CpG, PCEP, Alum and MF59 has 
identified a cluster of genes that are differentially regulated and are referred to 
as ‘core response genes’ (Awate et al., 2012; Mosca et al., 2008).  This study has 
identified upregulation of these core genes in response to PLY and Δ6PLY, 
although few were upregulated in response to the truncation mutants D123PLY 
and D4PLY (tables 7-1 and 7-2), this is consistent with previous work that 
demonstrates adjuvant activity in full-length PLY derivatives only (Ma, 2012). 
Tables 7-1 and 7-2 show the regulation of gene expression of cytokines and 
chemokines by PLY and its derivatives that are thought to be part of a ‘core 
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response’ to adjuvants.  The cytokines and chemokine upregulated in response 
to PLY are all involved at some stage in early immune responses.  In combination 
the cytokine and chemokines induced by PLY would induce an early pro-
inflammatory response, inducing migration and activation of cytokine milieu 
mediating cells such as macrophages, sustaining this response by inducing 
monocyte migration and attracting key antigen presenting cells such as DC.  One 
chemokine that was not included in the RT2 PCR panels is KC, as shown 
previously (chapter 3) KC is produced in large concentrations in response to PLY 
treatment and so it is likely that there is an influx of neutrophils to the site of 
PLY administration, there is also up-regulation of CXCL-3 (MIP-2β) (appendix 5, 
table 2) in response to all PLY variants, this is a potent neutrophil 
chemoattractant (Nakagawa et al., 1994) and possibly also involved in PLY-
mediated neutrophil recruitment. 
 
Table 7-1 Regulation of adjuvant core response genes following PLY treatment 
Cytokine Function Is Gene Upregulated in Response to PLY 
Derivative? 
  PLY Δ6PLY D123PLY D4PLY 
IL-6 Induction of acute phase 
proteins, stimulates T- 
and B-cell growth.  
Y Y Y N 
IL-12a 
(p35) 
Both components form 
the IL-12 heterodimer 
responsible for inducing 
IFN gamma and 
promoting Th-1 type 
responses. 
Y Y N N 
IL-12 b 
(p40) 
Y Y Y Y 
IL-1 beta Y Y Y Y 
TNF Induces local 
inflammatory response. 
Y Y N N 
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Table 7-2 Regulation of Adjuvant Core Response genes Following PLY treatment. 
 
Chemokine Function/Cells 
Attracted 
Is Gene Upregulated in Response to PLY 
Derivative? 
  PLY Δ6PLY D123PLY D4PLY 
CCL2 
(MCP-1) 
Monocytes, memory T-
cells and DCs. 
Y N N N 
CCL5 
(RANTES) 
Eosinophils, monocytes, 
NK and T cells and DCs. 
Y Y N N 
CCL12 Attracts eosinophils, 
monocytes and 
lymphocytes. 
Y Y Y Y 
 
As previously mentioned, D123PLY and D4PLY have been investigated as 
adjuvants but did not possess notable adjuvant activity, it was thought that this 
study could isolate and assign properties from the separate domains to the 
adjuvant activity of the full-length protein.  However, the gene expression 
profiles of D123PLY and D4PLY were broadly similar with some exceptions such 
as IL-6 (a core response gene) which is upregulated in response to D123PLY but 
not D4PLY. 
The profile of gene expression in response to LPS did differ in some respects to 
the profiles of BMDM treated with PLY or its derivatives; of the 58 genes 
described in appendix 5, the fold-regulation of 17 genes was different in LPS 
treated BMDM compared to PLY treated BMDM.  It is unlikely that the gene 
expression profiles seen in response to PLY and its derivatives are influenced by 
LPS contamination as the similarities in profiles would be more extensive.  The 
similarities that are seen between the expression profiles could be an indication 
of a common interaction(s) with the host, for example TLR4 ligation, thought to 
be responsible for LPS-induced production of IL-12, IFNγ, TNF-α and IL-1β. 
This study has highlighted genes that could be essential to adjuvant activity in 
PLY-based vaccines and forms a basis for further study.  Importantly, the 
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changes in gene expression in BMDM treated with PLY and its derivatives should 
be verified by individual RT-PCR of biological replicates.  
213 
 
7.6 Future work 
The data presented in this thesis have elaborated on our understanding of 
interactions between PLY and host cells, in particular the relationship between 
TLR4 and PLY has been confirmed and has revealed a complex mechanism of 
PLY-dependent IL-1β production.  This in turn has explained why Δ6PLY-based 
vaccines induce a lower magnitude of antibody response than PLY-based 
vaccines.  However, this work does not put forward a conclusive mechanism of 
adjuvant activity.  Given the breadth of immune responses shown to be induced 
by PLY and its derivatives it is unlikely that one single mechanism is responsible 
for adjuvant activity.  This thesis has however highlighted several avenues of 
investigation and should this work be continued it should include the following 
studies: 
 
• The gene expression analysis presented in appendix 5 must be validated 
by individual RT-PCR of selected genes. 
• Determine whether there are additional TLR binding sites within PLY.  The 
HEK293/SEAP reporter cells could be used to screen for TLR activity, if 
additional TLR binding sites are discovered what role do they play in 
cytokine/chemokine production and subsequent adjuvant activity? 
•  The final immune phenotype following immunization with PLY/Δ6PLY-
based vaccines must be fully characterized, not only will this be useful in 
understanding the optimum immune phenotype for pneumococcal 
protection but will also shed light on the conditions present at the site of 
inoculation (cytokine milieu, chemoattraction etc.) that are conducive to 
adjuvant activity. 
• Further analysis of the role of complement in the immune response to 
PLY.  Particularly, which components of the classical activation pathway 
are involved in licensing IL-1β production, this could be tested using 
Quidel’s depleted sera in the BMDM treatment model.  Also, is 
complement required in vivo for an increased response to PLY based 
vaccines over Δ6-PLY based vaccines?   
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• Characterize gene expression and cytokine/chemokine production in a 
TLR4-/- BMDM and BMDC PLY treatment model, there is some evidence to 
suggest that DC respond differently to PLY compared to macrophages.  
Additionally, as DC are the most efficient APC studies of antigen uptake 
and processing would be more appropriate in this cell type. 
• In vivo tracking of PLY following immunization could be useful in 
determining if there is a depot-effect following PLY immunization, this 
could also help to establish a time line and identify the cells that initially 
come into contact with PLY-based vaccines. 
• Determine why PLY variants have such different binding patterns.  
Discover whether D123PLY binds to a specific receptor that causes 
aggregation on the cell surface, additionally, use cholesterol-depletion to 
determine whether the binding pattern observed for D4PLY is due to 
cholesterol distribution or is caused by D4PLY binding a specific 
receptor/host protein. 
• Visualise the interaction between PLY/Δ6PLY/D123PLY and TLR4, could 
analyse colocalization using eGFP tagged version of PLY and its derivatives 
and staining TLR4 using fluorescent conjugate antibodies.  This would 
however depend on levels of TLR4 expression, if expression is low it could 
be difficult to visualise. 
 
7.7 Conferences/presentations 
Some of the work presented in this thesis has also been presented at national 
and international conferences as follows: 
• SULSA symposium – St. Andrews University 2010 – presented poster 
“Investigating the Adjuvant Activity of Pneumolysin.” 
• SGM Nottingham – University of Nottingham 2010 – presented poster 
“Investigating the Adjuvant Activity of Pneumolysin.” Same title as above 
but different poster. 
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• SULSA symposium – University of Glasgow 2011 – presented poster and oral 
presentation both titled “Pneumolysin: Host Responses and Adjuvant 
Activity.” 
• SULSA symposium – University of Edinburgh 2012 – presented poster 
“Investigating Interactions between Pneumolysin and Host cells using 
HaloTag® technology.” 
• SGM Warwick – University of Warwick 2012 – presented poster 
“Investigating Protein: Protein Interactions between Pneumolysin and 
Mammalian Cells.” 
• Europneumo - Instituto de Salud Carlos II, Madrid 2013 – oral presentation 
“The Role of Complement in the Adjuvant Activity of Pneumolysin.”
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Appendices 
Appendix 1 – Buffer recipes 
 
 1 X PBS 10 x PBS 
NaCl 8g 80g 
KCL 0.2g 2g 
NaH2PO4 1.82g 18.2g 
KH2PO4 0.24g 2.4g 
Make up to 1L with sterile dH2O, pH 7.2-7.4 
 
Mammalian cell lysis buffer 
50mM Tris-HCL 0.6g 
5mM EDTA 0.19g 
150mM NaCl 0.87g 
1% IGEPAL-CA630 1ml 
EDTA-free Protease inhibitor cocktail 
(Roche) 
1 tablet per 100ml 
Make up to 100ml in sterile dH2O, pH7.4.  Autoclave. 
 
 Resolving Gel 
(10mls, 10%) 
Stacking Gel 
(10mls, 4%) 
Acrylamide/bis-acrylamide 
(30% solution) 
3.3mls 1.33mls 
1.5M Tris-HCL, pH 8.8 2.5mls - 
0.5M Tris-HCL, pH 6.8 - 2.5mls 
10% (w/v) SDS 100µl 100µl 
dH2O 4.05mls 6.05mls 
Ammonium persulphate 
10% (w/v) 
100µl 100μl 
TEMED 10µl 10µl 
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Sample buffer (5x) Running Buffer 
(10x) 
Destain Coomassie Stain 
0.6ml 0.5M Tris, pH 
6.8                                   
30g Tris-base 500ml dH2O 0.5g Coomassie Blue 
R-250 
5mls 50% glycerol 144g glycine 400ml methanol 500ml destain 
2.0mls 10% SDS 10g SDS 100ml Acetic acid  
1ml 1% 
Bromophenol blue 
Make up to 1L using 
sterile water 
  
0.9mls H2O    
 
 
Transfer buffer Tris NaCl pH 7.4 Developer 
25mM Tris base (3.03g) Tris base (1.2g) 30mg 4-chloro-1-napthol 
192mM Glycine (14.4g) NaCl (8.7g) 10ml methanol 
20% Methanol (200ml) Make up to 1L with dH2O 40ml Tris NaCl pH 7.4 
Make up to 1L with dH2O Adjust pH with conc. HCL 30µl H2O2 
Chilled to 4°C - - 
 
 
 
Nickel Solution NAC Elution Buffer 
pH 7.4 
AEC Start Buffer 
pH 8.0 
AEC Elution Buffer 
pH 8.0 
0.2M Nickel 0.5M NaCl 20mM Tris base 20mM Tris base 
500ml dH2O 0.5M Imadizole Make up to 1L in 
sterile dH2O 
1.0M NaCl 
- Make up to 1L in 
sterile PBS 
- Make up to 1L in 
sterile dH2O 
 
 
General Actin Buffer (A-
buffer) pH 8.0 
Actin Polymerization 
Buffer (APB) (10X) 
General F-actin Buffer (F-
buffer) 
5mM Tris-HCL 500mM KCL APB diluted 1/10 in GAB 
0.2mM CaCl2 20mM MgCl2  
0.2mM ATP* 10mM ATP*  
0.5mM DTT* -  
*Add immediately before 
use 
*add 1mM before use or 
freeze aliquots at -70°C 
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Appendix 2 – Table of Properties of PLY and its Derivatives (mol. 
weight etc.) 
 
 PLY O6PLY D123PLY D4PLY 
length (aa) 509 507 306 115 
Molecular 
weight (kDa) 
57 57 40 13.5 
Molar 
extinction 
CoEfficient 
69910 69960 44120 8370 
Molecular 
extinction 
CoEfficient 
0.8142 0.810726 0.94377 1.5535 
1µg=?nMol 17.561 17.563 25.02 74.24 
 
 
Appendix 3 – Concentration of HaloTagged proteins in Halo lysates 
 
 
Protein Approximate Concentration (μg/ml) 
Halo-PLY 1321 
Halo-Δ6PLY 1448 
Halo-D123PLY 2099 
Halo-Δ6D123PLY 2079 
Halo-D4PLY 2487 
Halo-eGFP 1538 
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Appendix 4 – Sequence alignment of Tubulin β-5 chain from Bos 
taurus and Mus musculus 
 
 
1 MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGTYHGDSDLQLDRISVYYNEATGGKYV 60 Q2KJD0 TBB5_BOVIN 
1 MREIVHIQAGQCGNQIGAKFWEVISDEHGIDPTGTYHGDSDLQLDRISVYYNEATGGKYV 60 P99024 TBB5_MOUSE 
************************************************************ 
61 PRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVV 120 Q2KJD0 TBB5_BOVIN 
61 PRAILVDLEPGTMDSVRSGPFGQIFRPDNFVFGQSGAGNNWAKGHYTEGAELVDSVLDVV 120 P99024 TBB5_MOUSE 
************************************************************ 
121 RKEAESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVVPSPKVSDTVV 180 Q2KJD0 TBB5_BOVIN 
121 RKEAESCDCLQGFQLTHSLGGGTGSGMGTLLISKIREEYPDRIMNTFSVVPSPKVSDTVV 180 P99024 TBB5_MOUSE 
************************************************************ 
181 EPYNATLSVHQLVENTDETYCIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCL 240 Q2KJD0 TBB5_BOVIN 
181 EPYNATLSVHQLVENTDETYCIDNEALYDICFRTLKLTTPTYGDLNHLVSATMSGVTTCL 240 P99024 TBB5_MOUSE 
************************************************************ 
241 RFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQVFDAKNMM 300 Q2KJD0 TBB5_BOVIN 
241 RFPGQLNADLRKLAVNMVPFPRLHFFMPGFAPLTSRGSQQYRALTVPELTQQVFDAKNMM 300 P99024 TBB5_MOUSE 
************************************************************ 
301 AACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRG 360 Q2KJD0 TBB5_BOVIN 
301 AACDPRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVCDIPPRG 360 P99024 TBB5_MOUSE 
************************************************************ 
361 LKMAVTFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVS 420 Q2KJD0 TBB5_BOVIN 
361 LKMAVTFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESNMNDLVS 420 P99024 TBB5_MOUSE 
************************ 
421 EYQQYQDATAEEEEDFGEEAEEEA 444 Q2KJD0 TBB5_BOVIN 
421 EYQQYQDATAEEEEDFGEEAEEEA 444 P99024 TBB5_MOUSE 
 
Appendix 5 - Analysis of BMDM Gene Expression in Response to 
Treatment with PLY and its Derivatives 
To identify host responses that are involved in the adjuvant activity of PLY an 
analysis of gene expression using RT2 PCR profiler arrays (SABiosciences) was 
performed.  Using RNA obtained from BMDM treated with LPS, PLY or its 
derivatives the expression of genes involved in inflammatory and antibacterial 
responses was measured compared to RNA from untreated BMDM.  The profiler 
arrays used were – PAMM-011 (inflammatory cytokine and chemokine response 
genes) and PAMM-148 (antibacterial response genes).  Previously, PLY-dependent 
gene expression has been analysed in the THP-1 cell line using PLY-/- 
pneumococci and isogenic controls (Rogers et al., 2003).  However, expression in 
response to purified proteins has not previously been performed; in addition this 
study included the non-lytic and truncation derivates @6PLY, D123PLY and D4PLY 
and used primary cells rather than cell lines to create a less artificial model.   
Unfortunately, it was not possible to verify the gene expression analysis by 
individual RT-PCR.  RT-PCR primers had been selected to verify the expression of 
IL-10, C3, IL-1β, TNF-alpha and GAPDH, however, at the time of submitting this 
thesis the order had not been fulfilled.   
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Below tables show fold regulation of genes considered to be statistically 
significant compared to internal controls. 
Table 1 Regulation of Cytokine Genes in BMDM treated with LPS or PLY and its Derivatives. 
Symbol Description Fold-change Up, Down (-) or Unchanged (X) Compared to 
Untreated BMDM 
   LPS PLY @6PLY D123PLY D4PLY 
IL10 Interleukin 10 24 8.5 X 4.7 4.1 
1L12a Interleukin 12 
alpha 
105.4 18 2 X X 
IL12b Interleukin 12 beta 885.3 77.7 10 3.3 3.6 
IL13ra1 Interleukin 13 
receptor, alpha 1 
6.5 2.4 3.2 X X 
IL15 Interleukin 15 10.7 X X X X 
IL16 Interleukin 16 -5 -4 X X X 
IL18 Interleukin 18 15.5 X X X X 
IL1a Interleukin 1 alpha 1640.3 3061.4 77.7 12.8 16.6 
IL1b Interleukin 1 beta 1112.6 604 26 4.4 3.8 
IL1R2 Interleukin 1 
receptor type 2 
-1.0 1.0 1.2 4.6 4.5 
IL1f6 Interleukin 1 
family, member 6 
3 X X 17 14 
IL1f8 Interleukin 1 
family, member 8 
X X X 6.8 6.5 
IL2rg Interleukin 2 
receptor, gamma 
chain 
3.4 2.1 2 X X 
IL6 Interleukin 6 1082.3 98.4 7.6 2.6 X 
IL6ra Interleukin 
receptor alpha 
-6 -3.7 X X X 
IL6st Interleukin signal 
transducer 
-4 X X 5.5 5.6 
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Tnf Tumour necrosis 
factor 
32 14.8 5.5 X X 
Tnfrsf1b TNF receptor 
superfamily, 
member 1 beta 
5.5 3.1 X -2.2 -2.5 
 
Table 2 Regulation of Chemokine Genes in BMDM treated with LPS or PLY and its Derivatives. 
 
Symbol Description Fold-change Up, Down (-) or Unchanged (X) Compared to 
Untreated BMDM 
  LPS PLY @6PLY D123PLY D4PLY 
CCL12 Chemokine (C-C 
motif) ligand 12 
369.6 10.5 4.5 3.5 2.7 
CCL17 Chemokine (C-C 
motif) ligand 17 
11.5 12.6 x 4.6 5.2 
CCL2 Chemokine (C-C 
motif) ligand 2 
27.9 5 x x x 
CCL22 Chemokine (C-C 
motif) ligand 22 
39 13.5 x x x 
CCL3 Chemokine (C-C 
motif) ligand 3 
113 78 4.5 x x 
CCL4 Chemokine (C-C 
motif) ligand 4 
250.7 118.6 7.5 3.8 3.6 
CCL5 Chemokine (C-C 
motif) ligand 7 
1105 83.8 10 x x 
CCL7 Chemokine (C-C 
motif) ligand 5 
101 5.2 x x x 
CCL8 Chemokine (C-C 
motif) ligand 8 
42 x x x x 
CCL9 Chemokine (C-C 
motif) ligand 9 
6.1 10.3 x x x 
CCR1 Chemokine (C-C 
motif) receptor 1 
2.5 3.5 x x x 
CCR2 Chemokine (C-C 
motif) receptor 2 
-10.2 -8.7 x x x 
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CCR9 Chemokine (C-C 
motif) receptor 9 
5 3.5 x 2.9 2.2 
CX3CL1 Chemokine (C-X3-C 
motif) ligand 1 
2.2 x x 22.8 21.4 
CXCL1 Chemokine (C-X-C 
motif) ligand 1 
96.3 144 11.9 4.9 4.7 
  LPS PLY O6PLY D123PLY D4PLY 
CXCL3 Chemokine (C-X-C 
motif) ligand 3 
270.6 2778 21.4 4.5 2.5 
CXCL10 Chemokine (C-X-C 
motif) ligand 10 
814.6 28.2 18.6 3 2.2 
CXCL11 Chemokine (C-X-C 
motif) ligand 11 
47.5 x x x x 
CXCL5 Chemokine (C-X-C 
motif) ligand 5 
3.2 61.8 x 2.9 2.5 
CXCL9 Chemokine (C-X-C 
motif) ligand 9 
474.4 2.9 4.3 7.5 8 
 
Table 3 Regulation of Inflammatory Receptor Genes in BMDM treated with LPS or PLY and its 
Derivatives. 
Symbol Description Fold-change Up, Down (-) or Unchanged (X) Compared to 
Untreated BMDM 
  LPS PLY @6PLY D123PLY D4PLY 
Cd14 CD14 antigen 5 7.6 2 x x 
Nod1 Nucleotide-
binding 
oligomerization 
domain 
containing 1 
 
2.6 x x 2.6 2.9 
Nod2 Nucleotide-
binding 
oligomerization 
domain 
containing 2 
4.1 3.1 x 2.4 2.9 
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Ticam1 Toll-like 
receptor adaptor 
molecule 1 
 
-5.4 x -15 -8 -9.6 
Tlr1 Toll-like 
receptor 1 
3.4 x x x x 
Tlr2 Toll-like 
receptor 2 
3.2 4.9 x x x 
Tlr4 Toll-like 
receptor 4 
-4.3 x x x x 
 
Table 4 Regulation of Genes responsible for signal transduction and cytokine production in 
BMDM treated with LPS or PLY and its Derivatives. 
Symbol Description Fold-change Up, Down (-) or Unchanged (X) Compared to 
Untreated BMDM 
  LPS PLY @6PLY D123PLY D4PLY 
Casp1 Caspase-1 5 x x x x 
Irak1 Interleukin-1 
receptor-
associated 
kinase 1 
 
-5.1 -2.2 x x x 
Irak3 Interleukin-1 
receptor-
associated 
kinase 3 
 
6 4.7 x x x 
Irf5 Interferon 
regulatory 
factor 5 
 
-3.2 x -3.4 -2.6 -2.9 
Irf7 Interferon 
regulatory 
factor 7 
 
20.3 2.7 x -2.4 -3.2 
Mapk3 Mitogen-
activated 
protein 
kinase 3 
-4.9 -2.7 -2.0 x -2.1 
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Nfkb1 Nuclear 
factor of 
kappa light 
polypeptide 
gene 
enhancer in 
B-cells 1, 
p105 
 
3 3.7 x x x 
Nfkbia Nuclear 
factor of 
kappa light 
polypeptide 
gene 
enhancer in 
B-cells 
inhibitor, 
alpha 
 
7.2 4.3 3.5 2 2 
 
Table 5 Regulation of Genes encoding Proinflammatory Mediators in BMDM treated with LPS 
or PLY and its Derivatives.  
Symbol Description Fold-change Up, Down (-) or Unchanged (X) Compared to 
Untreated BMDM 
  LPS PLY @6PLY D123PLY D4PLY 
C3 Complement 
component 
C3 
31.5 4.6 4 x x 
Ltb Lymphotoxin 
b 
2 x x 5.5 5.1 
Ctsg Cathepsin G -16.7 x -9.1 -2.9 -6.6 
Lcn2 Lipocalin 2 39.7 5 -2.2 -2.6 -3.1 
Lyz2 Lysozyme 2 -4 -2 -3.2 x x 
Zbp1 Z-DNA 
binding 
protein 1 
36.5 6.6 4.4 x x 
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